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Abstract 
Aim: This research project explored the relationship between borderline personality disorder, 
difficult to treat depression and treatment outcome. Method: The study used data collected in the 
course of the Tavistock Adult Depression Study (TADS). The TADS was a randomised 
controlled trial comparing Long Term Psychodynamic Psychotherapy (LTPP) to Treatment as 
Usual (TAU) for 129 patients whose depression has not been successfully treated by at least two 
previous interventions. The author of this project took part in rating all patients with the Shedler-
Westen Assessment Profile (SWAP-II) – a 200-item personality measure – at the beginning and 
end of treatment. Statistical analysis explored the relationship between patients’ borderline 
personality scores at the beginning and end of treatment, and their progress in treatment in terms 
of decrease in depression severity, and psychological distress, and increase in general 
functioning. In addition, changes in borderline personality features were also explored in relation 
to changes on the three main outcome measures. The author included the rest of the SWAP-II 
personality scales in the analysis, too, as the SWAP-II generates an overall personality profile. 
Results: Only a small number of patients reached cut-off scores for borderline personality 
disorder or features. When the SWAP-II borderline scale was entered in analysis as a continuous 
variable, no significant link was found between borderline personality scores at the beginning of 
treatment, and treatment outcome. The way borderline features changed in the course of 
treatment, however, was significantly related to the outcome measures. This was particularly the 
case for SWAP-II items indicating insecure attachment and affect dysregulation. In addition, 
patients in the LTPP group who presented with borderline personality features or disorder at the 
end of treatment were more likely to still experience severe or very severe depression at the end 
of therapy. 
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“Words are instruments that people are free to adapt to 
any use, provided they make clear their intentions.” 
Claude Lévi-Strauss 
This thesis is about treatment-resistant depression, borderline personality disorder and treatment 
outcome, and the link between the three. A neat and succinct introduction might start by 
providing a definition of each of these three terms, before launching into exploring if and how 
they are connected. Yet, as argued by the French anthropologist Claude Lévi-Strauss above, 
people use language as means to their varied goals.  
The reason d’être of mental health practice and research is, as many would agree, to alleviate 
human suffering and provide support to those presenting with difficulties that stop them from 
living a fulfilling life. In order to devise and implement effective interventions in a climate of 
growing population and demand, and shrinking resources, clinicians and researchers need to go 
beyond the level of the individual narratives of their patients, and gain deeper knowledge about 
trends and patterns, processes and mechanisms, so that they can make reliable predictions on a 
bigger scale and ensure quality of services. A common language, allowing a multitude of 
patients and professionals to develop such body of knowledge, is inevitably needed for purposes 
of communication and sharing meaning. Such language is, however, the product of multiple and 
ever-evolving social and political processes, professional discourses and conflicting allegiances 
(McPherson & Armstrong, 2006). Furthermore, it is often tainted by interests and priorities 
different to what is, or at least should be, at the core of mental health practices – helping those in 
need of help (Horwitz, 2012). 
In the first section of this chapter the author will present the main concepts related to depression 
and its treatment in mental health research and practice today. Whilst a detailed genealogy of all 
terms used in this thesis is far beyond its purpose and scope, the author considers it incumbent 
upon her to signpost the reader to the most relevant contradictions and debates related to 
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conceptualising depression and its treatment. Only after the broader setting is thus introduced, 
the lens can zoom in, in order to examine the definition and treatment of “treatment-resistant 
depression”, linking it to “borderline personality disorder features” and introducing the aims of 
the current research at the end of the chapter.  
1.1. Major Depression – Current Definitions and Debates 
The World Health Organisation estimates that globally 350 million people of all ages suffer from 
depression (World Health Organization, 2015). Furthermore, it is estimated that 50% of those 
experiencing depression do not receive treatment for it, and that many people are misdiagnosed. 
Depression has been predicted to become the second largest cause for disability worldwide by 
2020 (Murray & Lopez, 1997). 
1.1.1. Major depressive disorder – definition 
The psychiatric communities in Western societies (Europe and the USA) have adopted two main 
mental disorders classification and diagnostic manuals, both of which are updated periodically. 
These are the International Classification of Diseases (ICD), currently in its 10
th
 Edition (World 
Health Organization, 1992) and the Diagnostic and Statistical Manual of Mental Disorders 
(DSM), currently in its 5
th
 Edition (APA, 2013).  
The term “major depression” was first introduced in the 3rd edition of the DSM (Spitzer, 1989), 
and has been in use in all subsequent editions of the Manual, but has not been adopted by the 
ICD. It has been argued that the DSM has been more accessible to psychiatric communities in 
the USA and beyond, than the ICD, due to the APA’s greater budget allowing for lager-scale 
production, dissemination and training in the use of the manual (McPherson & Armstrong, 
2006). The term “major depression” has thus become widely accepted and used by mental health 
professionals, and has guided the clinical management of huge numbers of patients, and the 
creation of successive policies and guidelines in the field (e.g. National Collaborating Centre for 
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Mental Health (Great Britain) & Royal College of Psychiatrists, 2010). 
The DSM-5 classifies Major Depressive Disorder (MDD) as the presence of five or more of a list 
of nine groups of symptoms, for a duration of at least two weeks, where a change to previous 
functioning is observed, the symptoms cause the individual significant distress and/or 
impairment of functioning, and the symptoms are not attributable to other psychiatric disorders, 
substance misuse or another medical condition (APA, 2013). In addition, for MDD to be 
diagnosed, the person should not have history of mania or hypomania, and, if significant loss 
such as a bereavement is experienced, the symptoms should be of an intensity beyond “the 
normal response to a significant loss” (APA, 2013, p. 161). The 12-month prevalence of MDD in 
adults has been estimated to be approximately 7% in the United States (ibid) and 6.9% in Europe 
(Bschor, Bauer, & Adli, 2014). 
1.1.2. Current MDD debates and criticisms 
Key points of criticism of the DSM MDD diagnostic criteria are the seemingly arbitrary number 
of symptoms and their duration required to obtain diagnosis, and the lack of lifetime diagnostic 
stability of MDD (Demyttenaere, Van Oudenhove, & De Fruyt, 2005). In one study, for 
example, where 431 patients with an MDD diagnosis were followed for a period of up to 12 
years, weekly analysis of their symptoms revealed a significant fluctuation of severity and 
duration of symptoms over time; furthermore, 23% of patients who were followed-up for at least 
two years were never symptom-free for more than a week, which suggests a marked MDD 
chronicity in the sample (Judd et al., 1998a). 
Another critical argument highlights that, unlike medicine, where classification relies to a large 
extent on observable physical characteristics, psychiatry has to elicit and interpret patterns of 
symptoms for the purposes of deriving a classification; this renders all functional diagnoses 
(including MDD) “as problematic or mythological” (Pilgrim & Bentall, 1999). Despite attempts 
for standardisation through the use of standardised tools and interview schedules, significant 
Borderline-dysregulated personality and Treatment -resistant Depression  
 
16 
diagnostic heterogeneity is still evident among patients given the diagnosis of MDD (McPherson 
& Armstrong, 2006).  
Moreover, the APA has been criticised for not acknowledging the role that social processes, 
mental health policies, advancements in the production of psychiatric drugs and power struggles 
between disciplines within the mental health field play in the development of its classification 
system (McPherson & Armstrong, 2006; Parker, 2000, 2005). Horwitz (2012), for example, 
points at a 600% increase in spending on anti-depressant medication in the 1990s in the USA and 
a $7 billion annual expenditure by the year 2000. In his compelling book “The loss of sadness: 
how psychiatry transformed normal sadness into depressive disorder’ (ibid), the author argues 
that there has been a deliberate medicalisation of “normal sadness” (conceptualtised a reaction to 
one’s life circumstances), which served the interests of large pharaceuptical companies: 
“antidepressant medications such as Prozac, Paxil, Zoloft, and Effexor, are now among the 
largest selling prescription drugs of any sort” (Horwitz, 2012, p. 4). 
Voicing similar concerns, the British Psychological Society (BPS), published a guideline 
document on the use of language in relation to functional psychiatric diagnosis, encouraging 
psychologists to avoid the use of diagnostic labels, and suggesting alternative descriptions 
instead (Division of Clinical Psychology Beyond Functional Psychiatric Diagnosis Committee, 
2015). More specifically, the document suggests that terms like “emotional distress” and “severe 
mental distress” replace the use of “mental illness”, and “low mood” and “miserty” replace the 
term “depressive disorder”. The BPS Division of Clinical Psychology argues that these changes 
are neccessiated by a “growing body of evidence suggesting that the experiences described in 
functional diagnostic terms may be better understood as a response to psychological factors such 
as loss, trauma, poverty, inequality, unemployment, discrimitation, and other social, relational 
and societal factors” (ibid, p.1). Another BPS document, issued in response to the publication of 
the DSM-5, goes as far as stating that both mental health service users and the general public are 
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negatively affected by the ongoing medicalisation of what can be thought of as a natural 
response to human experiences (British Psychological Society, 2011).  
Another central criticism of the MDD diagnostic label is that it does not meet criteria for 
diagnostic validity and utility (Parker, 2005). Parker critiques the diagnostic criteria for creating 
a profile of high severity, whilst the descriptive criteria are seen as too broad and potentially 
leading to placing the inclusion bar too low. This is seen as compromising the clinicians’ ability 
to make valid treatment response predictions on an individual level. Furthermore, Parker argues 
that “unless the classificatory system is underpinned by a valid explanatory model for the 
disparate depressive disorders, that system will be intrinsically flawed” (p.469). 
The current debates about the validity and utility of MDD as a diagnostic category have 
important treatment implications, and are therefore relevant to the subject of treatment 
resistance. Parker (2005), for example, argues that the “non-specificity” of the MDD diagnosis 
leads to non-specificity in treatment options. Indeed, randomised controlled trials (RCTs) 
literature on the efficacy of various interventions has shown an overall improvement rate of 50-
55%, which is also considered to be a possible over-estimate, as RCTs have been criticised for 
typically including patients who are on the less severe spectrum of the disorder and are more 
likely to remit spontaneously (ibid). The risk of unremitting depression in MDD populations has 
been reported to be as high as 29% (Keller et al., 1984) and the introduction of various 
treatments over the last few decades has been reported to have had little impact on the 
prevalence of chronic major depression (Scott, 1988). Parker (2005) warns against the danger of 
treating clinicians “fitting” the patient into the mode of therapy that the clinician is most familiar 
with.  
Further understanding of treatment-resistance through advanced subtyping of depression has 
therefore been argued to be instrumental in the continuous improvement of treatment choice and 
delivery (Akiskal & McKinney, 1973). 
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The author of this thesis considers the criticisms outlined above to be of key importance to the 
ongoing conceptualisation and treatment of what is currently described as “major depressive 
disorder”; the reader will therefore be reminded of these on-going debates throughout the thesis. 
Yet, the author will continue to use the diagnostic terms “MDD” and “personality disorder” in 
this writing, as this has been the language adopted by the Tavistock Adut Depression Study 
(TADS), of which the current research formed part. 
1.2. Treatment-resistant Depression 
1.2.1. Definition 
In light of the MDD ongoing debates presented above, it is not surprising that the definition of 
“treatment-resistant depression” (TRD) has also been marked by ongoing inconsistencies and 
lack of validation (Berlim & Turecki, 2007). Although a full review of the development and use 
of the term is beyond the scope of this chapter, the author considers it important to mark what 
appears to be common in current definitions of TRD across authors, where the main variations 
lie, and what the resulting limitations and controversies are. The latter, in particular, have 
important treatment implications.  
It appears that most, if not all, authors agree that for a patient to be labelled as “treatment-
resistant”, there has to be a preceding failed treatment attempt. Furthermore, this treatment, 
typically with anti-depressant medication, needs to have been administered at an adequate dose 
and for an adequate duration of time, and the patient must have complied with the prescription 
(Berlim & Turecki, 2007; Fava, 2003; Trivedi, Nieuwsma, & Williams, 2011). It is here that 
variations in TRD definitions begin, with authors presenting different ideas about what 
constitutes “adequate” treatment; how many previous failed treatment attempts are needed before 
TRD is diagnosed; and what is considered an “adequate treatment response”. Some authors 
consider a reduction of >50% of baseline depressive symptoms as significant improvement 
(Sackeim, 2001), whilst others suggest that TRD lies on a continuum, from “absolute” to 
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“partial” resistance (Berlim & Turecki, 2007) or partial response (Fava, 2003). A few authors 
warn against the more liberal definition of treatment response (e.g. >50% symptom reduction), 
and insist that a patient should be considered as treatment-resistant unless a full remission is 
achieved following treatment, for any residual symptoms have been shown to be a strong 
predictor of further relapse into depression and possible chronicity (Fava, 2003; Sackeim, 2001).  
There are two further major problems with the above definitions: first, non-pharmacological 
treatments are largely neglected in the literature; second, treatment “success” is operationalised 
as a reduction of the number of observed or reported symptoms of depression. If “depression” is 
thought of as “misery”, “sadness” or “unhappiness”, “deserving of help and intervention” 
(British Psychological Society, 2011; Division of Clinical Psychology Beyond Functional 
Psychiatric Diagnosis Committee, 2015), the use of medication as a main (and often sole) line of 
treatment becomes hugely questionable. The treatment “failure”, could therefore be easily 
attributed to the treatment (i.e. medication) not being the right type of intervention needed, as 
opposed to the condition (i.e. sadness, misety) being “resistant” to the “right” treatment. 
Furthermore, TRD definitions also pay little, if any, attention to the “embodied conscious 
experience” of sadness (Parnas, Sass, & Zahavi, 2013). Parnas et al. (ibid) critique the exclusive 
focus of symptoms in psychiatry, for they are devoid of “intrinsic sense or mening” (p.275), 
whilst attempting to capture and describe a subjective human experience. TRD definitions and 
the related literature generally fail to make any references to personal experiences and meaning 
of depression, and how those might change as a result of a person being subjected to numerous 
unsuccessful pharmacological interventions. 
Some further limitations of the current TRD definitions include: the evident heterogeneity of 
those considere to have TRD; the confusion of TRD with “pseudo-resistance”, defined as 
resistance due to initial misdiagnosis or the delivery of inadequate treatment;  and the blurred 
line between TRD and chronic depression (Bschor et al., 2014; Greden, Riba, & McInnis, 2011; 
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Scott, 1988). 
Heterogeneity and chronicity pose particular challenges to treatment, as clinicians are left with 
little insight into what might work for a particular patient, labelled as treatment-resistant. Indeed, 
TRD indicates only what had not worked in the past (e.g. a particular class of anti-depressant) 
but reveals virtually nothing about subgroup characteristics and differences on the basis of which 
to justify treatment choice (Fava, 2003). Likewise, there is no clear distinction between chronic 
depression (e.g. MDD that has persisted for 2 or more years (Scott, 1988)) and TRD – a problem 
which some have addressed by offering further sub-classifications, such as “non-chronic TRD” 
and “chronic TRD” (ibid). The DSM-5 (APA, 2013) had, however, merged chronic depression 
and dysthymia into the label of “characterological or chronic minor depression”. These 
differences in classification pose a major challenge to clinical interventions, as depression has 
been manifested to change its course and severity over periods of time (Judd et al., 1998a). It 
might therefore appear that whether one is given a label of “dysthymia”, “chronic”, 
“characterological” or “treatment-resistant” depression might be more dependent on the time one 
is psychiatrically assessed, rather than on the individual’s actual history of depression and the 
underlying subjective experiences. Such an approach might perpetuate, rather than alleviate 
TRD. 
The current thesis uses the TRD definition adopted by the TADS (Fonagy et al., 2015), as it uses 
the RCT’s data. The TADS considered patients to be “treatment-resistant” if they met current 
DSM-IV MDD diagnostic criteria (APA, 1994), with a minimum two-year duration of the 
current depressive episode at the time of assessment. In addition, patients had to score a 
minimum of 14 on the Hamilton Depression Rating Scale (Hamilton, 1960) and have history of 
at least two previously unsuccessful treatments, at least one of which had been with 
antidepressant medication. 
The TADS results will be considered in more detail in the following section of this chapter, 
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which reviews current treatments for TRD and their efficacy. 
1.2.2. Treatment 
1.2.2.1. Pharmacological interventions  
Antidepressant medication generally remains the first line of treatment for MDD, both in terms 
of guidelines recommendations (National Collaborating Centre for Mental Health (Great Britain) 
& Royal College of Psychiatrists, 2010), as well as in actual clinical practice in primary care in 
the UK (McPherson & Armstrong, 2012). This has been despite ongoing critical reviews of 
medication’s actual benefits (Kirsch, 2014) and claims that the medical profession has to a large 
degree “pathologised sadness” (Speed, Moncrieff, & Rapley, 2014). 
A number of reviews of the effectiveness of antidepressants in treating TRD have been published 
(e.g. Berlim & Turecki, 2007; Greden et al., 2011). It is beyond the scope of this thesis to present 
a summary of their findings. However, it is important to note that these publications focus 
predominantly on three main areas: what is considered an “effective treatment”, what factors 
(patient-, treatment-specific and other) are related to treatment outcome, and what treatment 
alternatives are recommended, when a patient does not respond to an antidepressant. Longer 
courses of pharmacological treatment, labelled as “maintenance” treatment, as well as treatment 
augmentation or substitution with another class anti-depressant appear to be common 
recommendations. However, these approaches have been criticised for lacking compelling 
empirical support and validation (Berlim & Turecki, 2007 in the case of prologued treatment;  
Bschor et al., 2014, in the case of medicaion substitution). Furthermore, some authors go as far 
as recommending a “life-time approach” to pharmacological treatment (Greden et al., 2011) , 
whilst significantly downplaying the short- and long-term side-effects of anti-depressants and the 
impact of those on patients’ functioning and overall quality of life (Trivedi et al., 2011). To 
name a few, these are known to include weight gain, insomnia and disruptions in sexual 
functioning (N. H. S. Choices, 2015). Pharmacogenetic testing (looking into how the individual 
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metabolises medication and what side-effects are likely to develop) is recommended for all 
patients diagnosed with MDD, not just those deemed “treatment-resistant” (Greden et al., 2011), 
but it is unclear to what extent this is adopted in routine clinical practice.  
Thase (2013) reported a general estimate of 50% remission rate, following treatment with 
antidepressants. It does appear, however, that for a large proportion of patients, pharmacological 
treatments remain ineffective, which necessitates the exploration of alternative treatment options, 
such as psychological interventions.  
1.2.2.2. Psychological therapies 
Talking therapies have been recommended as a second line of treatment for TRD (Bschor et al., 
2014; Rush et al., 2006), despite a number of studies having reported similar overall treatment 
effectiveness for medication and psychological interventions. Bschor et al. (2014), for example, 
concluded that all interventions appear to lead to clinically significant improvements in roughly 
half of the patients, and that medication and psychotherapy should be given equal weighting in 
the treatment of TRD.  The observed dominance of medication is attributed by some authors to 
funding being more readily available for pharmaceutical trials (Thase, 2013; Trivedi et al., 
2011). Furthermore, carrying out well-designed RCTs is considered methodologically more 
difficult for psychotherapies, because there is no “placebo” condition in therapy and larger-scale 
studies are therefore less feasible, leading to limited statistical power and less likelihood that true 
differences between conditions are detected (Thase, 2013). 
The results of a number of studies on the effectiveness of psychologcial interventions for TRD 
have nonetheless been published in the last couple of decades. These have focused mainly on 
Cognitive, Behavioural and Cognitive-Behavioural Therapy, as well as Interpersonal Therapy. 
 
 
Borderline-dysregulated personality and Treatment -resistant Depression  
 
23 
1.2.2.2.1.Cognitive-behavioural therapy (CBT), Interpersonal therapy (ITP) and 
Behavioural Therapy  
A systematic review of the existing literature on the effectiveness of psychological treatments for 
TRD was carried out by McPherson et al. (2005) and included five controlled and eight 
uncontrolled clinical trials. TRD was defined as failure to respond to at least one course of 
antidepressant treatment and MDD severity of HDRS score >14. All but one study examined the 
effectiveness of CBT, as compared to either medication, being on a waiting list or using self-help 
materials. One trial looked at the effectiveness of psychoeducation as an intervention for TRD. A 
significant decrease in depressive symptoms was reported in two of the controlled and five of the 
uncontrolled trials. However, the authors pointed at a number of definition- and methodology 
limitations in these studies, and concluded that there is an urgent need for more well-designed 
trials testing the effectiveness of various psychological therapies for TRD. 
Trivedi et al. (2011) carried out a systematic review of Randomised Controlled Trials looking at 
the effectiveness of CBT, IPT and/or behavioural therapy for TRD. TRD was defined as failure 
to achieve remission or remitting only partially, following treatment with antidepressant 
medication for six or more weeks. The authors were interested in treatment in primary care 
settings and therefore applied stringent exclusion criteria. This led to only 13 articles, 
representing 6 trials, being included in the review. The majority (78%) of the total number of 
participants (592) came from only two trials. All but one trial studied Cognitive Therapy (CT) 
(the exception was Dialectical Behavioural Therapy) and the number of sessions was 12-16, with 
one trial offering 23 sessions. The average depression severity at baseline in the studies varied. It 
was below 14 on the Hamilton Depression Rating Scale (Hamilton, 1960) in three of the trials 
and between 16.2 and 17.8 for the other three. Finally, the review excluded studies where 
patients presented with any other psychiatric conditions “unlikely to be treated by primary care 
clinicians (e.g. suicidal ideation, severe substance abuse)” (p.644). The results of the review 
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were mixed, with some studies reporting similar benefits of psychological interventions, 
compared to medication (e.g. CT in the STAR*D trial, Rush et al., 2006). One study reported 
lithium augmentation to be superior to CT, whilst another study concluded that CT was superior 
to medication.  
This review has a number of limitations. First, the sample of participants across the studies could 
be considered as “diagnostically clean”, due to the stringent exclusion criteria. Second, although 
participants were followed-up for 8 weeks to 2 years, little information was provided on the 
extent to which treatment benefits were sustained over longer follow-up periods. Finally, no 
reference was made to the aetiology of depression in the population included. The importance of 
a thorough assessment and formulation in the treatment of major depression has been highlighted 
as key to effective treatment planning and delivery (Wakefield, 1998). 
Bschor et al. (2014) carried out a review of the existing literature on treating chronic and 
treatment-resistant depression. The authors recommend a systematic, step-wise approach to 
diagnosis and treatment and argued that following a “scientifically grounded treatment 
algorithm” (p.772) yields better outcomes than providing treatments based on clinical 
judgement. Yet, in the proposed algorithm psychological therapies were presented right at the 
bottom of what would appear a treatment hierarchy. Furthermore, the authors themselves noted 
that psychotherapy appears to yield more sustained longer-term benefits for the patients and 
improves compliance with medication. The authors gave very brief summaries of the main 
psychotherapeutic approaches (CBT, IPT, psychodynamic psychotherapy, and CBASP), and 
provided no reference to trials looking at these therapies’ effectiveness in treating TRD. 
Furthermore, it is unclear if the authors used the term “chronic depression” interchangeably with 
TRD.  
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1.2.2.2.2. Psychodynamic psychotherapy for TRD 
Far fewer studies appear to have been conducted on the effectiveness of psychodynamic 
psychotherapy for TRD. The author carried out a systematic search of the following databases on 
16
th
 January 2016: PsycINFO, Education Source, ERIC, PEP Archive, SocINDEX, Psychology 
and Behavioral Sciences Collection, eBook Collection (EBSCOhost), PsycARTICLES, 
PsycBOOKS, MEDLINE, Health Business Elite, and CINAHL, using the key phrases 
"psychodynamic therapy", OR "psychodynamic psychotherapy", OR "psychoanalytic therapy", 
OR "psychoanalytic psychotherapy" to denote the treatment modality, and "treatment resistant 
depression" OR "treatment refractory depression" to specify TRD. This search yielded 13 results, 
but after their titles and abstracts were screened, only two publications were deemed to be 
relevant (actually looking at the effectiveness of psychodynamic psychotherapy for TRD): 
Abbas (2006) and Fonagy et al. (2015). Each is reviewed below. 
Abbass (2006) reported significant symptomatic and functional improvements in patients with 
TRD, who had completed a course of Intensive Short-Term Dynamic Psychotherapy. This 
treatment was described by the author as focusing on helping patients tolerate difficult emotions, 
by placing emphasis on affect or cognition, followed by supporting the patient in processing 
emotional experiences linked to past or current events and interpersonal relationships. The 
author did not comment on the similarities and differences of this intervention with other 
psychodynamic approaches. The study was not controlled and there were only 10 patients in the 
sample, with the treatment delivered by one clinician. Significant improvements in TRD were 
reported, as measured through both self-report and clinician-rated measures. Based on post-
treatment HDRS scores, 8 of the 10 patients are reported to have remitted. No information was 
provided on the follow-up period. The author reported that all of the patients presented with 
complex difficulties at the start of treatment (personality disorders, HDRS mean score of 22.6 
indicating severe depression, and major interpersonal problems). He concluded that “The 
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observation that depression and interpersonal problems improved simultaneously suggests that 
personality changes may be necessary in the TRD for depression to lift” (p.452).  
It is surprising that the only other study on psychodynamic psychotherapy for TRD was not 
published until 2015, particularly given that a meta-analysis by Driessen et al. (2010) concluded 
that short-term psychodynamic psychotherapy appears to be an effective treatment for major 
depression, with its benefits sustained over 3-, 6- and 12-month follow-up periods. No studies on 
the efficacy of longer-term psychodynamic therapy (LTPT) for major depression have been 
carried out prior to the Tavistock Adult Depression Study (Fonagy et al., 2015), although Luyten 
& Blatt (2012) reported the results of an RCT comparing LTPT to brief psychodynamic therapy 
(BPT) and solution-focused therapy (SFT) for mood and anxiety disorders, where LTPT was 
initially inferior to BPT, but demonstrated superior results to both BPT and SFT in the third year 
of the follow-up period.  
The Tavistock Adult Depression Study (TADS) (Fonagy et al., 2015) was carried out in response 
to these gaps in the evidence base for TRD. It was a pragmatic randomised controlled trial, 
where patients were allocated either to 18-month weekly psychodynamic psychotherapy or to 
Treatment as Usual (TAU). The methodology of the TADS will be presented in detail in the 
methods chapter of this thesis, as the current project forms part of the TADS and uses its data. 
For the purposes of the current review of treatments for TRD, it is sufficient to say that few of 
the participants achieved full remission at the end of treatment (9.4% in the treatment condition 
and 6.5% in the control group), and only some achieved partial remission (32.1% and 23.9% 
respectively). The differences between the two conditions at 18 months were not statistically 
significant. Significant between-group differences emerged, however, at 24-months of the 
follow-up period with 30% of the treatment group participants sustaining partial remission, 
compared to only 4.4% of the TAU group, indicating that long-term psychodynamic 
psychotherapy can lead to long-term improvements in some of the patients considered as 
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“treatment-resistant”. It remains unclear, however, what differentiates those who benefitted 
(albeit partially) from the LTPP treatment, from those who did not. 
1.2.2.3 TRD psychological interventions - conclusion 
As evidenced in the psychological therapies reviews presented above, significant variations in 
the definition of TRD make the comparison of trials difficult (Gaynes et al. 2011). Furthermore, 
studies of the effectiveness of psychological (and pharmacological) interventions tend to use 
predominantly the HDRS (Hamilton, 1960) and the Beck Depression Inventory (Beck, Steer, & 
Brown, 1996) as outcome measures. These two measures focus solely on depressive symptoms 
and provide no information about the individuals’ quality of life or global functioning. 
Furthremore, TRD appears to comprise a heterogeneous group of individuals with likely varying 
depressive aetiologies and comorbidities. It is therefore not surprising that all available 
treatments (psychological and other) appear to fare similarly overall, as it is unlikely that one 
size would fit all. Wijeratne & Sachdev (2008) indeed argued that “treatment resistance may be 
more usefully conceived within the context of well-defined cohorts such as patients with specific 
subtypes of depression” (p.751). Some of the factors that might assist in such further refinement 
of definition and classification, are presented next.  
1.2.3. Risk factors predicting treatment resistance 
A number of authors have attempted to establish what predicts treatment-resistance. Illness-
specific factors (relating to the MDD history, the nature and severity of symptoms and the 
duration of depressive episodes) and person-specific factors (relating to personal characteristic, 
cognition and personality traits/personality disorder) appear to be most often referred to in the 
literature. Overall, these investigations have remained largely medical and diagnosis-driven, 
which is a major limitation to understanding what contributes to the recurrent and persistent 
experiences of depression, as outlined earlier in this chapter. 
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1.2.3.1. Depression-specific factors 
The number of previous depressive episodes was linked by a few authors to rapid treatment 
relapse and chronicity (e.g. Judd et al., 1998b; Kessing, Andersen, Mortensen, & Bolwig, 1998). 
One study estimated that a history of three or more previous major depression episodes is 
associated with 70-80% likelihood of relapse (Segal, Pearson, & Thase, 2003). Kessing et al. 
(1998) concluded that the higher the number of episodes, the shorter the time to recurrence, and 
that severe unipolar depressive disorder is recurrent and progressive in nature, despite the effect 
of treatment. 
In addition, both the length of pervious major depressive episodes (Scott, 1988) and the duration 
of the current episode (Sackeim, 2001) have been found to be predictive of chronicity and 
treatment-resistance, respectively. Sackeim (2001) acknowledges, however, that subjecting the 
patient to an ineffective treatment for a prolonged period of time might actively contribute to the 
duration of the depressive episode and therefore might be precipitating “treatment-resistance”.  
Partial-recovery and sub-syndromal depressive symptoms were also found to be reliable 
predictors of rapid relapse into MDD, even when adequate treatment had been delivered (Scott, 
1988; Judd et al., 1998b; Rush, Thase, & Dubé, 2003). Rush et al. (2003) suggest that 
temperament and personality disorder might predispose individuals to incomplete recovery and 
that the link between MDD and personality should therefore be investigated further. 
1.2.3.2. Personality traits – neuroticism 
Howland & Thase (2005) stated that there are two main ways of classifying personality: 
categorically (in line with the DSM Axis II clusters) and in terms of traits and temperaments, 
which lie on a continuum “and span normal and pathological populations, differing only by a 
matter of degree of severity” (p.158-159). Neuroticism is one such trait. It is defined as “a 
tendency to respond to distress in emotional, anxious and somatic ways” (p.159). 
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Kay, Garside, Beamish, & Roy, (1969), Hirschfeld, Klerman, Andreasen, Clayton, & Keller 
(1986) and Segal et al. (2003) all link neuroticism to MDD chronicity and treatment resistance, 
whilst also highlighting hypotheses that the prolonged experience of major depression might 
exaggerate certain personality traits, including neuroticism. It is therefore recommended by these 
authors that personality assessments are ideally carried out pre-morbidly (i.e. before the patient 
becomes depressed, or during an episode of remission). Kay et al. (1969) and Scott (1988) 
emphasise the importance of premorbid personality assessment in the formulation of prognosis 
and the choice and course of treatment, but consider such assessments problematic, not least 
because depression and personality traits are thought to interact, making causal relationships 
difficult to ascertain. Personality appears to play an important role in treatment chronicity and 
resistance, however, despite these conceptual challenges.  
The remaining part of this chapter will focus on the link between personality disorders in 
general, and borderline personality disorder, in particular, and treatment-resistant depression, as 
well as on the potential implications that this has for treatment. 
1.3. Depression and Personality Disorders 
The relationship between depression and personality has been most widely studied in terms of 
the links between the different personality disorders and depressive illness. A review of the 
literature on depression and personality disorders is beyond the scope of this thesis. The author 
will therefore give a brief summary of what is known about the prevalence of personality 
disorders in treatment-resistant depression and the implications that the former are thought to 
have for the treatment of the latter. The author will then examine more closely the literature on 
borderline personality disorder (BPD) and TRD. BPD is chosen as the focus of this thesis, as it 
has been reported to be commonly diagnosed in outpatient and forensic psychiatric settings, and 
to be associated with a number of other psychiatric diagnoses (MDD being one of them), 
incurring significant personal and social costs (Bateman & Fonagy, 2016).  The thesis’s research 
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questions, which address the links between BPD, TRD and treatment outcome, will be presened 
at the end of the chapter.  
The reader is again reminded of the limitations of psychiatric diagnosis, this time in relation to 
the term “personality disorder”; the BPS recommends the use of terms like “complex trauma” or 
“relationship or attachment difficulties”, instead (Division of Clinical Psychology Beyond 
Functional Psychiatric Diagnosis Committee, 2015). The link between personality disorder and 
trauma will be explored in more detail later in this chapter. The author continues to use the term 
“personality disorder”, however, as this was the language adopted by the TADS. 
1.3.1 Treatment-resistant depression and personality disorders – prevalence, 
comorbidity and treatment implications 
A number of research studies have reported high comorbidity rates of depression and personality 
disorders (PD) (Farmer & Nelson-Gray, 1990; Keown, Holloway, & Kuipers, 2002; Rao, 2003). 
A review by Hirschfeld (1999) found that comorbidity of PD across the different types of 
depression ranges from 41% to 81%. Shea & Yen (2005) provided an overview of existing 
theories, but focused more broadly on the role of personality traits, in addition to personality 
disorders, in relation to depression. The authors concluded that there is not a single theoretical 
model that could explain the complex links between depression and personality in general. 
Petersen et al. (2002) found no differences in the prevalence of PD in a sample of TRD patients 
compared to non-TRD patients. In fact, more patients in the latter group initially appeared to 
meet criteria for Obsessive Compulsive personality disorder, but this difference became 
statistically insignificant after adjustments were made in statistical analysis. The authors pointed 
at the large body of literature that indicates that poor response to treatment of depression is 
associated with “personality dysfunctions” (expressed in shorter periods of remission, poorer 
social support, and earlier age of depression onset). Yet, they also argued that the exact role of 
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personality disturbance in treatment-resistant depression has been difficult to study, because of 
TRD being historically poorly defined by clinicians and researchers. 
Howland & Thase (2005) argued that the link between TRD and personality is not simply one of 
co-morbidity, but rather a reciprocal and interactive one, where stress is likely to be also linked 
to and have an impact on both. The authors presented several different ways of conceptualising 
the relationship between depression and personality: the two have common causes; personality is 
an early manifestation of depression; personality predisposes one to depression; personality 
influences the expression/course of depression; personality features are amplified in the course 
of depression and can therefore be seen as the effect of depression. Furthermore, the authors 
reported mixed findings in terms of the impact of personality on antidepressant treatment 
outcome, but a few studies have been carried out to address this issue. Moreover, there have 
been very few studies looking at personality implications for psychotherapy treatment outcome 
in chronic depression (none reported for TRD). The authors nonetheless concluded that 
personality difficulties and disorder have negative impact on treatment, although treatment 
(medication and psychotherapy) has also been found to improve personality functioning in 
depressed individuals in some studies. The authors pointed at the importance of comprehensive 
initial assessment in chronic and refractory depression, which makes use of both the patient and 
collateral sources in order to build up a formulation and gather information about possible 
personality pathology. When Axis II comorbidity is clearly established a wide range of treatment 
options (medication and/or therapy) should be considered (ibid). 
1.3.2. Psychoanalytic conceptualisation of depression, its links to personality and the 
related treatment implications 
The DSM-5 (APA, 2013) is a classification and diagnostic tool which, at least in theory, has 
been designed as a-theoretical. This means that each disorder listed in the Manual is described in 
terms of its presenting symptoms but with no reference to its aetiology.  
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The aetiology of depression is conceptualised differently by psychiatry and psychoanalysis (Bell, 
2010). Psychiatry, argues Bell (2010), makes a clear distinction between personality and mental 
illness and between normal and abnormal (as expressed through the DSM’s definition of Axis I 
and Axis II disorders and the categorical approach to diagnosis). More specifically, personality 
difficulties, or disorders, are thought to be associated with enduring, long-term dysfunctions 
across a number of life domains, and therefore are considered to require long-term treatment. 
Mental illnesses, like depression, however, are seen as episodic, and therefore susceptible to 
localised, shorter-term treatments. Different disorders are then seen as co-morbid, and, as 
presented earlier in this chapter, the implications of such comorbidities for treatment outcome 
are studied empirically in RCTs. 
Psychoanalytic theories, conversely, view mental illness as lodged into personality development, 
under the stress of external and internal conditions. Symptoms are viewed as “the outer 
expression of deeper [personality] structures” (Bell, 2010, p. 148). The term co-morbidity does 
not exist, consequently, as disorders like depression are understood and treated through an 
understanding of how the person functions as whole. 
Furthermore, psychoanalysis takes a dimensional, rather than categorical view with regards to 
what is “normal” and what is “abnormal”:  
“Disorder manifests aspects of mental life which at a different developmental phase 
might have been normal. Although we never completely lose earlier ways of 
functioning, when these more archaic forms come to dominate mental life they become 
the basis of psychopathology.” (Bell, 2010, p. 146) 
The concept of depression was first explored by Freud, as the concept of melancholia in his 
seminal paper Mourning and Melancholia (Freud, 1917). There, he argued that the loss of 
important objects (e.g. a loved person, one’s country, liberty or an idea) leads the person to 
experience a range of complex feelings, including sadness and internally directed anger 
Borderline-dysregulated personality and Treatment -resistant Depression  
 
33 
(expressed through self-denigration, for example). According to Freud, loss is an inevitable part 
of life. When the person navigates successfully through the process of loss, they are thought to 
have “mourned” the lost object, or in other words to have “fully relinquished” what has been 
lost, which in turn leads to a resolution of the painful feelings and to developmental progress. 
When this process is arrested, however, the individual is left in a state of melancholia, which 
Freud described as characterised by: 
“(…) a profoundly painful dejection, cessation of interest in the outside world, loss of 
the capacity to love, inhibition of all activity, and a lowering of the self-regarding 
feelings to a degree that finds utterance in self-reproaches and self-revilings, and 
culminates in a delusional expectation of punishment.” (Freud, 1917, p. 244) 
Freud further made links between melancholia and personality (he used the word “character” to 
denote this), by hypothesizing that melancholia was marked by an identification with the lost 
object and a narcissistic object-choice, as well by narcissistic regression. It is important to note 
that the term “narcissism” was not used in the same way as what psychiatry today classifies as 
narcissistic personality disorder. The scope of this thesis does not allow for a detailed analysis of 
Freud’s theory on melancholia, but it suffices to say that Freud, for the first time, tried to link the 
experience of real or perceived loss, to depressive states and the structure of the personality as 
understood through object-identification, object-choice and the nature of regression into earlier 
modes of psychic functioning. 
Freud, in that sense, established the psychoanalytic tradition of viewing depression, and mental 
illnesses in general, not as what the person “has” (in terms of symptoms and complaints), but as 
who he or she is, “his or her way of being in the world”, with the current problems being “woven 
into the fabric of their lives” (Shedler, 2010).  
Psychoanalytic authors since Freud have criticised the symptom-based approach to diagnosing 
and treating depression and the lack of attention paid to the overall personality an individual 
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experiencing depression. Parker (2005), for example, argued that the term “major depression” 
aims at having a “cachet value”, whilst circumscribing a set of different conditions, 
homogenising them and thus misconstruing the individual patient’s experiences and treatment 
needs. He pointed to the importance of linking the different depression subtypes to “predisposing 
personality style and clinical phenotype” (p.472).  
In line with Parker’s (2005) critique, recent psychoanalytic writings on depression stress the 
importance of focusing on the individual’s internal experience of depression, such as the 
“feelings of loss and of being abandoned and unloved, on the one hand, and feelings of 
worthlessness, failure, and guilt on the other” (Blatt, 2015, p. 131). Furthermore, it is suggested 
that depression can be further understood in relation to two main dimensions: the “quality of 
interpersonal relatedness” (e.g. feelings of being unloved, abandoned, and uncared for by others) 
and the “experiences of self-definition” (e.g. feeling worthless and a failure) (ibid). These two 
dimensions are further labelled as “anaclitic” (or “dependent”) and “introjective” (or “self-
critical”), respectively. Blatt (2015) argues that the expression of either is determined by a 
heterogeneous group of early life experiences, leading to different symptomatic manifestations 
and therefore to different responsiveness to treatments. For example, those individuals who 
present as predominantly anaclitic, are thought to be more dependent on others for support, and 
to be very fearful of losing important others, which in turn leads them to be more submissive and 
placating. Suicidality and substance misuse are thought to be an attempt to elicit others’ support, 
within an anxious-avoidant attachment context, as opposed to a serious intent to harm or kill 
oneself (i.e. the individual’s strategies to elicit interpersonal support are limited to eliciting care 
through, for example, self-harming, whilst they do not indent to actually end their life). 
Individuals who are more introjected, on the other hand, are thought to be highly-critical of self 
and others and therefore rejecting of support and generally more hostile in their interpersonal 
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interactions. The differences between these two dimensions are argued to be of huge relevance to 
the treatment of depression. Blatt (ibid) concluded that: 
“(…) significant differences in sustained therapeutic change might occur, in a variety of 
treatment interventions, as a function of interaction between differences in patients’ pre-
treatment personality organisation and aspects of the treatment process, especially the 
quality of the therapeutic relationship. Including a differentiation among patients in 
research designs and data analytic strategies could provide a fuller understanding of the 
processes that lead to sustained therapeutic change.” (p.138). 
The TADS LTPP Manual (Taylor, 2003) maintained the general psychoanalytic view of 
depression by postulating that all types of depression “involve needs and dependency, 
separation, loss, and disappointment, and internally directed aggression, arising in relation to 
these important primary object-relation wishes” (p. 4). Taylor further argued that in ‘treatment 
resistant’ depression the more destructive parts of the personality have taken over the healthy, 
functioning parts of the self, through a complex constellation of factors, which operate 
“powerfully to keep the individual concerned in a state of chronicity in a way that is not the case 
in ‘ordinary’, self-limiting depressions”. 
Long-term psychoanalytic psychotherapy for depression is thus not primarily aimed at 
alleviating symptoms, although the symptoms might be the focus of conversation between the 
therapist and patient in the initial stages of the treatment. Rather, the therapist attempts to 
support the patient in gradually changing key aspects of his/her personal functioning, aspects 
“often connected with developmentally early experiences of loss, to reduce an underlying 
depressive diathesis” (ibid). Of note, different aspects of the personality are considered to be in 
constant interaction both with the external environment, as well as with one another (Taylor, 
2003). Furthermore, object relations, personality structure and the experience of symptoms are 
all regarded as “dimensional rather than categorical, and dynamic rather than static in nature”. 
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(Taylor, 2003, p. 28). This point is of particular importance to the subject of the current project 
and will be considered in more detail in the discussion chapter of the thesis. 
The LTPP approach to depression and the way it is intrinsically liked to personality appears 
further in line with Parker's (2000) argument for linking, what is in DSM terms, Axis I and Axis 
II conditions, in order to obtain a more refined classification of different types of depression. The 
author discusses the role that clinical observation has to play in identifying clinical patterns, or 
clinical “syndromes”. This is demonstrated through examples from existing studies, where 
participants’ experiences of depression and the way in which the condition is manifested are 
qualitatively different, based on the person’s personality characteristics, as well as on the 
presence of other Axis I conditions, such as anxiety. The author further argues that temperament 
is likely to play an important role in the expression of depressive symptoms. He does not 
comment on the link between personality and past life experiences, such as one’s early 
attachment relationships, however. 
In conclusion, the experience of loss, and feelings of abandonment, loneliness, worthlessness and 
self-criticism appear to be central features of depression in the psychoanalytic literature. These 
features are in fact not dissimilar to the more symptom-focused DSM conceptualisation. What 
distinguishes psychoanalytic theories from psychiatric ones, however, is the importance that 
personality plays in understanding any mental illness, depression included, as symptoms are seen 
as the expression of deeper psychic structures. Exploring and understanding the personality 
structure in theory, as well as in the consulting room, is therefore seen as an integral part of 
facilitating treatment management and good treatment outcome. 
1.4. Borderline Personality Disorder and Treatment-resistant Depression 
This section will present a summary of the psychiatric and psychoanalytic conceptualisation of 
borderline personality disorder, followed by a discussion of how this relates to depression and 
treatment outcome. 
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1.4.1. Definition 
1.4.1.1. DSM-5 definition 
The DSM-5 defines personality disorder as: 
“… an enduring pattern of inner experience and behaviour that deviates markedly from 
the expectations of the individual’s culture, is pervasive and inflexible, has an onset in 
adolescence or early adulthood, is stable over time, and leads to distress or impairment.” 
(APA, 2013, p. 645) 
Furthermore, this enduring pattern needs to manifest itself in at least two of the following areas: 
cognition, affectivity, interpersonal functioning, impulse control. In terms of diagnosing 
personality disorder, the DSM-5 recommends that the diagnosing clinician carries out a number 
of interviews with the patient, spread over time and focusing on the individual’s functioning 
across different situations, as well as gathering information from “other informants” (ibid). This 
is contrasted to the assessment and diagnosis of “more transient mental states”, such as anxiety 
or depressive disorders (APA, 2013, p.647).  
The main diagnostic features of borderline personality disorder (BPD), as described in the DSM-
5, include instability of self-image and interpersonal relationships, as well as unstable affect and 
marked impulsivity. Nine BPD criteria are listed in the manual, at least five of which need to be 
met in order for a diagnosis to be justified. In summary, the criteria are: efforts to avoid real or 
imagined abandonment; unstable and intense interpersonal relationships, marked by an 
oscillation between denigrating or idealising others; unstable self-image/sense of self; 
impulsivity that leads to risk to oneself; recurrent suicidal or self-harm behaviour or threats; 
affective instability; chronic feelings of emptiness; inappropriate, intense anger, and difficulties 
managing it; transient dissociation and paranoid ideation, triggered by stress.  
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The DSM-5 further highlights that individuals diagnosed with BPD are highly sensitive to 
environmental circumstances and experience intense fear of abandonment and strong reaction 
(e.g. panic, anger) to endings, even when those had been planned in advance. Furthermore, new 
relationships (with a care-giver or an intimate partner) tend to follow a pattern of initial 
idealisation and high hopes, followed by disillusionment and denigration in the face of perceived 
abandonment and expected punishment. The individual’s self-image is described as likewise 
unstable, with shifting values, interests and goals. Strong feelings of not-existing are linked to 
lack of supportive relationships and it is argued that individuals diagnosed with BPD struggle 
particularly in unstructured activities (e.g. work or school situations). 
Suicidality is considered a particular feature of BPD and the Manual quotes an 8-10% completed 
suicide rate in individuals diagnosed with BPD. Self-harm and attempted suicide are argued to 
be common reasons for borderline patients to come in contact with health care services. Co-
occurring depressive disorder is considered to increase the risk of premature death due to 
suicide. 
Finally, the Manual lists “features” that are associated with BPD diagnosis, but not included in 
the main diagnostic criteria. These are: sabotaging oneself before the attainment of an important 
goal (e.g. completing a degree or staying in a supportive relationship); physical handicaps 
resulting from risk-taking and suicidal behaviours; recurrent occupational, educational and 
interpersonal disturbances and losses; early life history of neglect, abuse and parental loss; high 
comorbidity with other disorders such as mood, substance misuse and eating disorders, as well as 
post-traumatic stress disorder. 
Of note, the Manual states that whilst considered to be stable and enduring over time, some 
personality disorders, such as anti-social and borderline personality disorders, tend to remit or 
become less expressed as the individual advances in age and might therefore be more difficult to 
identify in later life. Borderline personality disorder in particular is considered as most acutely 
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expressed during early adulthood, with individuals arguably becoming more settled in their 
vocational and interpersonal functioning during the third and fourth decade of life.  
The DSM-5 acknowledges the high rates of personality disorders’ comorbidity, pointing at the 
poor discriminant validity of its classification system, and in response discusses an alternative 
model for personality disorders, which places the degree of impairment in functioning and the 
presence of specific personality traits at the core of making a diagnosis. The alternative criteria 
for BPD, in particular, include an impairment in two of the following four areas: identity, self-
direction, empathy, and intimacy; and the presence of at least four of the following seven 
personality traits: emotional liability, anxiousness, separation insecurity, depressivity, 
impulsivity, risk taking, and hostility. Depressivity, which bears particular relevance to this 
thesis’ subject, is described as: “Frequent feelings of being down, miserable, and/or hopeless; 
difficulty recovering from such moods; pessimism about the future; pervasive shame; feelings of 
inferior self-worth; thoughts of suicide and suicidal behaviour” (APA, 2013, p. 767). 
As with other mental disorders described in the DSM-5, no reference is made to aetiology or 
treatment implications. Trauma is only mentioned briefly in terms of higher rates of 
victimisation and parental loss in early life for those diagnosed with BPD, as specified above. 
This latter point will be returned to later in this chapter, as well as in the discussion chapter of 
this thesis.   
1.4.1.2. Psychoanalytic definitions 
Psychoanalytic theorists define personality disorders as marked by “chronic, long-standing 
patterns of responding to distress, which are often limited in variability and rigidly applied 
regardless of appropriateness of context” (Meehan & Levy, 2015, p. 313).  
Clarkin, Fonagy, Levy, & Bateman (2015) define borderline personality disorder as “(…) a 
chronic, serious disorder involving suicidal and self-destructive behaviour, affective liability and 
Borderline-dysregulated personality and Treatment -resistant Depression  
 
40 
dysregulation, intense interpersonal conflict, and incoherent internal representations of self and 
others” (p.353). 
The term “borderline” was first used in 1938 by the psychoanalyst Adolph Stern when he 
described patients, whom he considered to be neither neurotic, nor psychotic, but fell somewhere 
“in-between” these two categories and thus posed a significant challenge to treatment (Stern, 
1938). Stern did not consider psychoanalysis a recommended treatment for this group of patients 
in general, unless they presented with what he called “neurotic” symptoms, such as depression 
and/or anxiety (ibid). He argues that a psychoanalytic treatment was not a suitable intervention 
for the more psychotic parts of these patients’ personalities. 
Since Stern, the “borderline patient” and issues related to the classification, diagnosis and 
treatment of borderline personality, have been the subject of many theoretical writings in the 
psychoanalytic world. These include, to name but a few, Helene Deutsch (Deutsch, 1942), 
Robert Kinght (Knight, 1953), Donald Winnicott (Winnicott, 1969), Andre Green (Andre Green, 
1977), Otto Kernberg (Kernberg, 1978), and Judy Gamelgaard (Gammelgaard, 2010). The sheer 
volume of these works would not allow for a synthesis of their ideas here, but the interested 
reader is guided to collections which attempt to accomplish this task (e.g. Hartocollis, 1977; 
Stone, 1986).  
For the purpose of the current thesis, the author has chosen some key points from the past and 
current psychoanalytic ideas about the “borderline patient”, which are presented next. 
“Ego weakness” and the use of primitive defences such as denial, splitting and 
projection/projective identification, have been described as central borderline personality 
characteristics by Green (1977) and Kernberg (1978). Kernberg (1975, 1978) described 
borderline patients as lacking integration in representations of self and others, leading to the 
reliance on more primitive psychic defences, such as splitting between “good” and “bad”, as well 
as identity diffusion, and difficulties with reality-testing. Positive and negative aspects of the self 
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and others cannot thus be integrated as part of a coherent whole. This in turn compromises the 
ability of the developing mind in early childhood to differentiate between self and other, inside 
and outside, somatic and psychic, fantasy and reality (Green, 1977).  
Attachment theorists, starting with John Bowlby (Bowlby, 1975) and more recently Levy and 
Blatt (1999), as referred to in Meehan & Levy (2015), made links between anxious-avoidant and 
anxious-preoccupied attachment patterns of relating, and personality difficulties and disorder. 
Early attachment relationships (i.e. to the primary caregiver), and the process of mirroring in 
early life,  have been hypothesised as key to the development of a stable sense of self, regulation 
of affect and the capacity for relatedness (e.g. Lyons-Ruth & Jacobvitz, 2008; Target, 2015).  
Clarkin et al. (2015) further linked the lack of a stable and integrated sense of self to severe 
disruptions in the interpersonal relationships of borderline patients, which research has found to 
be marked by “disagreements, confusion, hostility, emptiness, and ambivalence” (p.356). The 
authors also listed impulsivity and negative affect, which includes experiences of depression, 
anxiety, anger and irritability, as the other two main features of borderline personality disorder. 
The emotional experiences, in particular, are marked by instability and fluctuations that are 
linked to environmental stimuli. 
Finally, the ability to perceive and understand one’s own and others’ mental states and their link 
to behaviour, was coined as “the capacity to mentalize” (Fonagy, Gergely, Jurist, & Target, 
2002). Deficits in mentalizing have been linked to early disruptions in the relationship between 
the child and the care-giver, and have been identified as particularly prevalent in people 
diagnosed with borderline personality disorder (ibid). 
1.4.2. The role of trauma and early adversity 
In her book “Trauma and Recovery” Judith Herman (1997) draws attention to the complex 
psychological processes that take place in the context of repeated trauma, and the impact trauma 
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has on the development of the personality. Throughout the book she comments on humans’ 
innate need to relate to others. This can both protect an individual psychologically during 
traumatic experiences (e.g. the development of camaraderie in war context; of a “buddy” 
relationship in concentration camps) or can perpetuate the individual staying in an abusive 
relationship where the person who perpetrates the abuse is also the only person available to 
provide support, closeness and guidance. Furthermore, she points at the close link between 
trauma and depression: 
“These staggering psychological losses can result in a tenacious state of depression. 
Protracted depression is the most common finding in virtually all clinical studies of 
chronically traumatized people. Every aspect of the experience of prolonged trauma works 
to aggravate depressive symptoms” (Herman, 1997, p. 94). 
Herman (ibid) further links experiences of abuse, particularly during childhood, to disrupted 
early attachments, which – as noted above – have been known to be characteristic of many 
patients diagnosed with BPD. She describes how for abused children, caregivers, who in any 
non-abusive parent-child relationship, are the source of protection, care and comfort, become a 
source of grave danger, too. In order to protect the attachment relationship with the parent or 
care-giver, the child develops a belief that he/she is causing the abuse, and a related sense of 
inner badness. This, Herman argues, allows the child to preserve some sense of hope, power and 
control – if only the child can become better, the abuse will stop. It is not difficult to the 
understand how a distorted representation of self- and others results, and how very little of what 
Bion (2003) describes as the “container” function of the parent – to process raw affect and reflect 
it back to the child in a more manageable form – can take place, in order to facilitate the young 
mind’s development of the capacity for thought. 
The experience of trauma, single or multiple, does not in itself lead to a borderline personality 
organisation. A number of authors have written, however, about the links between the two. 
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Green (1977), for example, linked a precocious and therefore fragile ego development to the 
experiences of early trauma, which he stated is often observed with borderline patients, and carry 
along the threat of object loss. Feelings of inner badness, fragmented representations of self- and 
other, and deficits in thinking and mentalizing, are all characteristic of patients diagnosed with 
BPD and, as just described, can be traced to experiences of early and often repeated abuse. 
More recent studies point at the link between abuse and borderline pathology, too. Clarkin et al. 
(2015), for example, are in agreement about attachment disruptions being “robust predictors of 
later BPD pathology”, and link such disruptions to prospective studies of abused and neglected 
children. They argue, however, that the experience of early neglect, more than sexual and 
physical abuse, is predictive of borderline personality pathology in adult life.  
Fonagy & Luyten (2016), in their comprehensive conceptualisation of the development of BPD, 
further point at the multifaceted links between early life experiences in general, and trauma, 
abuse and neglect in particular, and the development of BDP. More specifically, the authors 
consider the negative impat that early life adversity, especially as expressed through emotional 
neglect, has on the development of the “full mentalizing capacities” of the individual (ibid). The 
theory proposed, suggests that a child develops the ability to think about and understand its own 
mind, and the mind of others, in the context of a relationship with a care-giver who is attuned 
and responsive to its needs and emotional experiences. A care-giver who is abusive and/or 
neglectful creates an environment where the child learns, as an adaptive manuver, to suppress, or 
dissociate from its emotional experiences, and/or elicit contingent care-giver responses through 
extreme behaviours (e.g. aggression, self-harm). Difficulties with regulating one’s emotions have 
been found to also ensue from abusive and neglectful early life relationships. These attachment 
patterns are replicated in later-life relationships and situations, but in a less adaptive, or even 
harmul ways. For example, those idividuals diagnosed with borderline-personality disorder, are 
thought to experience more extreme negative affects, particularly under stress, which leads to an 
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activation of their attachment relationships (i.e. they experience a stronger need to seek closeness 
to and support by others); at the same time the very experience of heightened affect 
compromises their ability to accurately perceive their own and others’ subjective worlds, which 
leaves them vulnerable to further interpersonal difficulties and stress. Fonagy & Luyten (2016) 
further link developmental (particularly attachment) theories to recent neuroscience research and 
the development of BPD. A comprehensive summary of their model is beyond the scope of this 
chapter, but the reader is encouraged to refer to the original text. 
The link between early adversity, borderline personality and depression is likely to be even more 
complex, but this does not mean that these different factors should not be thought about and 
investigated both in clinical work, as well as in research. This point will therefore be returned to 
again in the following chapters of this thesis. 
1.4.3. A prototype approach to describing and diagnosing borderline personality 
disorder  
The two approaches to assessing and diagnosing borderline personality disorder, described 
above, each have their strengths and limitations. More specifically, the psychiatric approach has 
been argued to enable communication by providing common language for mental health 
professionals and patients, and to be well-fitted for the purposes of research and defining discrete 
population groups. Its main disadvantages have been argued to include poor reliability and 
validity, and limited usefulness in guiding management or treatment (McLean, 2016). Moncrieff 
(2007) further argues that psychiatric diagnosis, compared to a more detailed formulation of 
one’s individual difficulties and their context, predict treatment response poorly. 
The psychoanalytic approach, on the other hand, has been argued to be a better guide to 
intervention, due to its narrative nature, which allows for encompassing greater clinical 
complexity. The psychoanalytic assessment, however, is also critiqued for providing 
poorershared language between professionals and lay people; it is also considered lacking 
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indicators of severity or dimension of the “disorder” in question (McLean, 2016). 
A prototype-approach to personality disorders has been suggested as superior to the current 
DSM classification by a number of authors (e.g. PDM Task Force, 2006; Shedler, 2015; Westen 
& Shedler, 1999a; Westen, Shedler, Bradley, & DeFife, 2012). A personality “prototype” is 
considered to be a distinct pattern of “thinking, feeling, behaving, and relating to others” 
(Meehan & Levy, 2015). 
Jonathan Shedler and Drew Westen introduced a prototype-based approach to assessing 
personality disorder, which they argued combines the strengths of a quantitative approach to 
assessment and classification, whilst harnessing clinical judgement and experience (Shedler, 
2015; Shedler & Westen, 2010; Westen & Shedler, 1999a, 1999c). The Shedler-Westen 
Assessment Procedure (SWAP) will be presented and discussed in more detail in the method 
chapter of this thesis, as the tool was used as one of the main measures in the current research 
project. 
Shedler & Westen (2007) describe a borderline-dysregulated personality disorder prototype, 
which they argue to be parallel to the DSM borderline personality disorder construct. The 
borderline-dysregulated PD is assessed through the SWAP tool and consists of a list of 24 
descriptive statements. These are organised under seven sub-groupings as follows: affect 
dysregulation, splitting, projective identification, identity diffusion, insecure attachment, self-
harm, and chaotic life-style (Shedler, 2015). These sub-headings of the borderline-dysregulated 
descriptive items appear to capture and combine some of the key aspects of borderline 
personality disorder described by psychiatry, psychoanalysis and attachment theory, as 
summarised earlier in this chapter. Shedler & Westen (2007) argued that their approach to 
assessing and categorising personality disorders allowed for the description of “complex 
intrapsychic processes” (p.154), like splitting and projective identification, in addition to listing 
more easily observable patterns of behaviour and relating to self and others (e.g. self-harm, 
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unstable relationships). 
Appendix A presents the full list of the SWAP-II 24 items considered to encapsulate the 
borderline-dysregulated personality disorder profile in its pure form. Appendix B presents the 
narrative description of the borderline-dysregulated personality (Westen et al., 2012). 
1.4.3.1. Personality “disorder” vs. personality “features”  
The DSM-5 (APA, 2013) differentiates between personality disorders, in general, and 
personality traits or features. Features are described as separate parts of the personality disorders 
criteria, such as “dependency” or “insensitivity”. The manual states that personality disorder 
should be diagnosed only when its features originate in adolescence or early adulthood, are 
persistent over time and lead to significant impartment in the individual’s functioning.  
Meehan & Levy (2015) point at psychodynamic theories taking a continuum approach to 
personality conceptualisation. Individuals on the healthy end of the personality spectrum are 
characterised by using a wide range of defence and coping strategies in response to stressors, 
which in turn enables them to form and maintain stable, mutual and intimate relationships with 
others. Higher personality pathology, in turn, is marked by difficulties in functioning in one or 
more areas of life. The pervasiveness of such difficulties across different areas (e.g. 
occupational, interpersonal) is what distinguishes those with personality disorder features from 
those with more severe pathology – or personality disorder. 
Westen, Shedler, & Bradley (2006) took a similar approach to distinguishing between 
personality disorder and personality disorder features, as measured by the SWAP. More 
specifically, an assessed patient’s personality is compared in the SWAP to each of the 
personality disorders’ prototypes in their “pure” form. If the degree of match between the 
patient’s presentation and the specific PD prototype is very high, the patient is considered to 
“exemplify” the disorder or, in high but not perfect match, to “have” the disorder. If there is a 
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“significant” match, the patient is considered to present with “significant features” of the 
disorder. The meaning of “features” vs. “disorder” in the SWAP and how this is measured will 
be discussed in further detail in the method chapter of this thesis. 
Researchers and clinicians have now long argued that personality traits should be measured on a 
continuum, as opposed to categorically (Johnson & Bornstein, 1991; Perry, 1993; Shedler & 
Westen, 2007). It is therefore likely that there would be a group of people who fall on the BPD 
spectrum without meeting the diagnostic criteria for BPD (Blagov, Bradley, & Westen, 2007). 
Such individuals might be more likely to seek treatment for other co-exsisting problems, such as 
depression. It is not clear at present how BPD features might affect the treatment and outcome of 
depression for that group, especially for people who have never been formally diagnosed with a 
personality disorder (or would not meet the criteria for such diagnosis). It is even more unclear 
what might be of therapeutic benefit for those individuals, who also fall under the umbrella of 
“treatment resistant depression”.  
1.4.4. Conceptualisation of the Links Between Depression, BPD and the Related 
Treatment Implications 
The DSM-5 notes that “Borderline personality disorder often co-occurs with depressive or 
bipolar disorders, and when criteria for both are met, both may be diagnosed” (p.666). Bateman 
and Fonagy (2001) argue, however, that “depression in borderline personality disorder is an 
indication of affect dysregulation rather than part of an affective disorder” (p.41). This view is 
also supported by Trull, Stepp, and Solhan (2006), who conceptualise BPD as “primarily 
characterized by disturbances in emotional regulation, impulse control and identity” (p.299).  
The affect disturbance is thought to be expressed by emotional shifts (in response to 
environmental stimuli) “between different types of negative affect (e.g. anger, depression, 
anxiety)” (ibid). 
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These different theoretical standpoints pose the question of whether borderline personality 
disorder and depression should be viewed as separate “comorbid conditions”, or whether the two 
are underpinned by common intra- and interpersonal processes and experiences. This question is 
a very important one when treatment planning and delivery is considered. As already stated 
earlier in this chapter, the answer depends, at least to an extent, on the theoretical framework 
within which it is answered (e.g. psychiatric vs. psychoanalytic). 
Furthermore, the National Collaborating Centre for Mental Health guidelines for treating BPD 
and those for treating depression differ in the treatments they recommend. For example, a 
combination of anti-depressant medication and Cognitive Behavioural Therapy 
(CBT)/Interpersonal Therapy (IPT) is recommended for those with moderate to severe 
depression (National Collaborating Centre for Mental Health (Great Britain) & Royal College of 
Psychiatrists, 2010), whilst the recommendation for BPD is for a minimum of three months of 
(ideally) twice-weekly therapy and no use of medication for unstable mood, where the latter is 
considered as part of the BPD presentation (National Collaborating Centre for Mental Health 
(UK), 2009). There is also no clear guidance currently for what course of treatment to follow 
when both disorders are present. Furthermore, current personality diagnostic tools (e.g. the DSM 
Structured Clinical Interview, SCID) have been criticized for their poor validity and reliability, 
as well as for placing individuals into categories, rather than on a spectrum with regards to their 
personality traits (Clark, Livesley, & Morey, 1997; Westen & Shedler, 1999b, 1999c).  
When depression and borderline personality features (particularly in the absence of a personality 
disorder diagnosis) are not taken into consideration by the clinician from the intervention onset 
and as part of the initial formulation, it could be argued that the clinician remains blind to 
potential therapeutic obstacles. It is insufficient to attend to the depressive symptoms alone. 
Furthermore, there are implications for the therapeutic relationship and treatment duration. For 
example, Gabbard & Simonsen (2007) explored the link between childhood trauma, BPD and 
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the implications for treatment of depression and suggested that “neurobiological changes may 
account for some of the difficulty in treating patients who are comorbid for BPD and depression” 
(p.168). The authors further postulated that BPD patients might ascribe (wrongly) negative 
intentions/misreading facial expressions to others, including the therapist and therefore might 
experience the clinician as a “bad object” in the transference, which in turn creates significant 
obstacles to building a therapeutic alliance. This latter point is supported by recent research, 
presented by Fonagy & Luyten (2016), where patients with a BPD diagnosis have been found to 
ascribe negative emotions and intent to others’ factial expressions that are in reality “neutral”. It 
is easy to understand how this might pose challenges to fostering a positive therapeutic 
relationship, in turn. 
Gabbard & Simonsen (2007) further argued that patients with BPD and depression need to be in 
treatment for at least 12 months in order for therapist and patient to allow time for the 
therapeutic alliance to develop. Following a case example, the authors stated that “treating the 
depression alone without a psychotherapeutic treatment specifically tailored to BPD was simply 
not sufficient” (p.171). Furthermore, the process of learning for individuals with BPD diagnosis 
and history of trauma was argued to take longer, despite the person accumulating new evidence 
and insight. This was linked to neurobiological changes associated with repeated exposure to 
trauma (also noted in Fonagy & Luyten (2016)). The treatment approach should therefore be 
tailored to take into consideration the impact of trauma. The longer time needed in treatment was 
also related by the authors to research showing that procedural or implicit memories need more 
time to alter (e.g. via multiple repetition of new experiences). Gabbard and colleagues (ibid) 
finally stressed the importance of nonetheless maintaining hope with this patient group, as they 
believe that change is possible.  
The idea that treatments for patients with BPD diagnosis should be altered is not new. A number 
of authors over the past few decades have suggested different modifications and new treatment 
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approaches in order to respond to these patients’ presentation and the challenges it creats for the 
therapeutic relationship (Clarkin, Fonagy, & Gabbard, 2010; Clarkin et al., 2015; Knight, 1953; 
Milner, 2010; Winnicott, 1969). Winnicott (1969), for example, argued that “borderline patients” 
can engage very skilfully in analysis by inviting the analyst to collude with their “false” neurotic 
self and thus to never engage with the more psychotic parts of the personality. He linked this to 
the “borderline patient” not being able to experience the transference as a transitional space - the 
analyst as a representation of the mother, but rather analyst is the mother in the patient’s mind.  
More recently, manualised treatment packages have been developed for patients with borderline 
personality disorder, and these new, “tailored” therapies have been tested through Randomised 
Controlled Trials and subsequently included in national guidelines in the UK (National 
Collaborating Centre for Mental Health (UK), 2009). Three main examples of such treatment 
approaches are Mentalization-Based Therapy (MBT) (Bateman & Fonagy, 2006, 2013; Daubney 
& Bateman, 2015), Dialectical Behavioural Therapy (DBT) (Linehan, 2014), and Transference-
focused Psychotherapy (TFP) (Arntz et al., 2015; Kernberg, 2016; Yeomans, Clarkin & 
Kernberg, 2015). Despite the theoretical differences that underpin them, all three types of 
treatments are characterised by a relatively focused approach (the therapist being more active 
and guiding), compared to other “talking therapies” such as psychodynamic psychotherapy, as 
well as by the higher intensity of treatment engagement – for example, typically a combination 
of individual and group work, as well as other structured activities within a therapeutic 
community (DBT) or day centre setting (MBT). Patients who have not been formally diagnosed 
with borderline personality disorder do not typically “qualify” for the receipt of MBT, DBT or 
TFP. 
The question thus remains of what the treatment implications are for those individuals who 
might present to services with depression, when there is also a degree of personality difficulties, 
too, which could be described as, for example, borderline personality features. In such cases 
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there seems to be a risk of clinicians and researchers labelling patients as “treatment-resistant” 
when it is the mental health professionals’ failure to develop a more sophisticated formulation of 
the patient’s presenting difficulties, and to offer treatment in accordance with this initial 
formulation.  
1.5. Rationale and Aims of the Current Study 
1.5.1. Rationale 
Treatment-resistant depression is experienced by a heterogeneous group of individuals and no 
single aetiological conceptualtisation has been proposed to date. The high comorbidity of 
depression and personality disorders in general, and depression and borderline personality 
disorder in particular, suggests that for at least some individuals experiencing persistant 
depression, intra- and interpersonal difficulties may be linked to the experiences of low mood. 
There is little research, however, that explores the link between borderline personality features 
and treatment-resistant depression. It is therefore not known what the prevalence of BPD is 
amongst individuals who experience difficult to treat depression, neither is there any empirical 
data on the impact that such comorbidity might have on treatment outcome.  
Having a clearer idea about the potential impact that borderline personality disorder or borderline 
personality features might have on treatment outcome is likely to have important implications for 
a number of reasons.  
First, healthcare professionals might consider more carefully what type of intevention they offer. 
For example, treatments recommended for major depression in general, such as CBT, might be 
counter-indicated for people with a borderline personality profile; or the same intervention might 
be offered, but with a different duration and in combination with another intervention (e.g. 
medication and psychotherapy).  
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Second, offering better tailored treatments to people who experience depression in the context of 
a BPD diagnosis might reduce the likelihood of these individuals being labelled “treatment 
resistant”. This in itself shifts the “responsibility” for improvement from the person to the type of 
support offered, as it demonstrates that not all interventions work for all patients experiencing 
depression, and interventions need to be more carefully matched to the overall presentation of 
the individual and their idiosyncrasies.  
Finally, a focus on borderline features, as opposed to borderline disorder and the relation of the 
former to treatment outcome in difficult-to-treat depression is likely to aid the tailoring of 
interventions, as it shifts clinical decision-making from a categorical diagnostic approach which 
focuses on symptoms and comorbidities, to a conceptualisation that seeks to understand 
depressive experiences in the context of personality organisation and functioning. 
1.5.2. Aim 
The main aim of this research project is to test initial hypotheses about the link between 
borderline personality features and treatment outcomes of difficult-to-treat depression. In order 
to achieve this aim, the research will focus on the following research questions: 
1. Do high scores on a measure for borderline personality disorder at baseline predict 
treatment outcomes amongst patients with treatment-resistant depression who have been 
randomly allocated to either Treatment as Usual (TAU) or to Long-term (18-month) 
Psychodynamic Psychotherapy (LTPP)? 
2. Are changes in borderline personality organisation in the course of therapy related to 
changes in depression and treatment outcome? 
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2. Method 
2.1. Epistemology 
Critical-realism postulates that there is a “reality” existing independently of the process of 
observation, whilst each observation and attempt to make sense of this reality is a form of social 
practice. This includes science and social science. Consequently, the study of the social world is 
constructed through language, meaning and concepts (Danermark, 2002). Pilgrim & Bentall 
(1999) further state that “our theories of reality, and the methodological priorities we deploy to 
investigate it” are also a form of social construction (p.262). 
“Conceptual abstraction” is the process of isolating aspects of certain events or phenomena in the 
social world in order to study the underlying generative mechanisms (Danermark, 2002). 
Furthermore, Danermark (ibid) argues that “abstraction” is necessary, for it allows us to 
differentiate an object or groups of objects from everything else. 
The current project uses theoretical concepts from the fields of psychology, psychiatry and 
psychoanalysis. “Borderline personality disorder and features” and “treatment-resistant 
depression” can be considered such conceptual abstractions as they refer to specific 
characteristics and subjective states that can be attributed to an individual. The researcher aims to 
link these two concepts in order to build hypotheses about the inter- and intrapersonal processes 
in operation for those experiencing difficult to treat depression. These hypotheses can in turn be 
tested further and hopefully used to inform the design of more effective treatments for 
depression. 
At the same time, the reader is reminded of some of the limitations of psychiatric diagnosis and 
language, which have been noted in the Introduction chapter. Psychiatry as a discipline has been 
subjected to very different pressures over the last century: from needing to “prove” itself as 
being “a science” in its own right in the second half of the 20th century, to more recently being 
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criticised for: its focus on individual “pathology” (as opposed to context), having a technological 
(as opposed to ethical) stance to clinical practice, and for using coercive practices more often 
than collaborating with patients in a reciprocal manner (Bracken & Thomas, 2001). 
The author of this thesis is aware that by chosing to use psychiatric terms (such as “BPD” and 
“TRD”) she is inadvertanlty adopting psychiatry’s position in relation to the experiences of low 
mood and interpersonal difficulties. At the same time, an attempt is being made throughout this 
thesis to remain attuned of the ongoing conceptual and clinical debates in the field of mental 
health, and to thus sustain a more critical and reflective position. The discussion chapter of this 
thesis will give a closer consideration to the limitations of the concepts of “borderline personality 
features” and “treatment resistant depression”. 
A central aim of the research, as outlined in the previous chapter, is to establish whether 
borderline personality features at the start of an intervention are in any way associated with its 
outcome, and whether changes in borderline features are associated with changes in depression 
and treatment outcome. The issue of studying causality has been discussed from an 
epistemological point of view by a number of philosophers. David Hume, for example, stated 
that “causation” is not something that exists “out there” in the world but is something that we, as 
human species, add in order to “make sense” of impressions we perceive from the world around 
us (Hume & Millican, 2007). Danemark (2002) does not dismiss causal relationships as purely 
constructed, but warns against confusing co-variance for a causal relationship. Moreover, she 
states that: 
“(…) a causal statement does not deal with regularities between distinct objects and events 
(cause and effect), but with what an object is and the things it can do by virtue of its nature. 
This also entails that objects have the causal powers and liabilities they have, 
independently of any specific pattern of events. The mechanism is not only existent when 
A leads to B, but also when A does not lead to B; this is a cardinal point in critical realist 
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causal analysis, and has far-reaching consequences for social scientific explanations” 
(Danermark, 2002, p. 55). 
The researcher aims to adopt a similar stance to studying borderline personality features and how 
they link to treatment outcome in patients with difficult-to-treat depression.  Engaging in a 
therapeutic interaction and addressing one’s difficult emotional and relational experiences is 
thought of as a multi-layered and multi-determined social phenomenon and the current project is 
but making a humble attempt to bring into light some of the operating processes in the name of 
better future treatment provision. 
2.2. Design and Participants 
In order to meet the aims specified above, the current research project used patient data already 
available as part of a Randomised Control Trial – The Tavistock Adult Depression Study 
(TADS). The TADS compared the effectiveness of 18-month psychoanalytic psychotherapy to 
treatment as usual (TAU) for treatment-resistant depression (TRD) (Fonagy et al., 2015; Taylor 
et al., 2012). TRD was defined by its duration (a minimum of two years), the number of 
unsuccessful previous treatments (a minimum of two, at least one of which was with anti-
depressant medication), and the severity of depressive symptoms. 
The TADS’s study protocol was registered with the International Randomized Control Trial 
Number Register (ISRCTN40586372) (Fonagy et al., 2015). 
A summary of the TADS method and participants is presented next in this chapter, followed by 
information about the specific data used for the purposes of the current study, the measures used 
both directly and indirectly by the researcher, and the procedure adopted in assessing personality 
features and testing their relationship with treatment outcome.   
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The TADS study protocol (Taylor et al., 2012) and the TADS outcome paper (Fonagy et al., 
2015) both use the term “patient” when referring to the study participants. The current project 
also adopts this term, in order to avoid confusion. 
2.2.1. Ethical approval and participant consent 
The TADS was granted full ethical approval by the Institutional Review Board of the NHS West 
Midlands Research Ethics Committee (Appendix C). This approval included secondary data 
analyses by the TADS research team. The current project did not involve any additional contact 
with the TADS patients . It was therefore not deemed necessary to apply for another NHS Ethics 
Approval, as data that have already been collected during the original RCT were used for the 
purposes of the project. The project was, however, granted ethical approval by the University of 
Essex (Appendix D). 
Participants in the TADS RCT had not given their consent explicitly for their data to be used for 
the purposes of the current research project. They had, however, given their written consent for 
the data collected in the course of the trail to be used by the TADS research team for the 
purposes of secondary analyses past the treatment and follow-up phases (Appendix E). The 
researcher joined the TADS team on an honorary contract for the duration of her work on the 
current project (Appendix F). Additional consent was therefore not sought from the TADS 
participants. Ethical considerations related to this will be discussed in more detail in a later 
section of this chapter. 
2.2.2. Recruitment 
The recruitment for the TADS trial took place between 2002 and 2009, through General 
Practitioners (GPs) working in Primary Care Trusts (PCTs) in Central and North London (Taylor 
et al., 2012). 425 GPs had been approached, 119 out of whom had subsequently agreed to refer 
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patients to the trial (ibid). Taylor et al. (2012) do not specify the reasons the rest of the GPs gave 
for not referring their patients to the TADS. 
In total 308 patients were screened for eligibility (Fonagy et al., 2015). The TADS inclusion 
criteria (Fonagy et al., 2015; Taylor et al., 2012) were: 
 Age 18-65 
 Current DSM-IV diagnosis of major depressive disorder as assessed by the Structured 
Clinical Interview for DSM-IV Axis I disorders (SCID-I) (First, Gibbon, Spitzer, & 
Williams, 1996) 
 The current depressive episode having lasted for at least two years  
 A minimum score of 14 on the 17-item Hamilton Depression Rating Scale (HDRS-17) 
(Hamilton, 1960), as well as a minimum score of 21 on the Beck Depression Inventory II 
(BDI-II) (Beck et al., 1996) 
 At least two previous unsuccessful treatment attempts, at least one of which was with 
anti-depressants. No time-frame was specified for this criterion. 
The exclusion criteria, were: 
 Having received psychodynamic psychotherapy in the past two years 
 Meeting the DSM-IV criteria for psychotic or Bipolar I disorder (currently, or in the last 
five years) 
 Having been in psychiatric treatment for substance dependence in the last two years 
 Having moderate or severe learning disability 
 Evidence of organic brain disorder 
The current study did not include any additional inclusion and exclusion criteria. For a more 
detailed description of the recruitment process and procedures, refer to Fonagy et al. (2015) and 
Taylor et al. (2012). 
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2.2.3. TADS eligibility screening and baseline assessment 
Patients referred by their GP and considered to meet the eligibility criteria were invited for the 
initial SCID-I interview at the Adult Service of the Tavistock & Portman National Health 
Service (NHS) Foundation Trust, London (Fonagy et al., 2015). Figure 1 summarises this stage 
of the screening process, based on the information provided by Fonagy and colleagues (ibid).  
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Figure 1 
TADS Patients’ Pre-randomisation Screening 
 
A statistical analysis compared the demographic characteristics of those who refused to take 
further part to those who remained in the trial, and no significant differences between the two 
groups were reported (Fonagy et al., 2015).  
A total of 129 patients were randomly allocated either to an 18-month course of weekly 
psychoanalytic psychotherapy, provided at the Tavistock Centre, London, or to treatment as 
usual, which was managed by the referring practitioner. The follow-up period for all patients was 
two years. Fonagy et al. (2015) reported that the randomisation was carried out offsite by an 
independent statistician. The randomisation procedure balanced for gender, depression severity 
and medication (on or off) (ibid). 
All patients had to complete a range of assessments, at baseline and every three months during 
treatment. Measures were completed at the end of treatment too, and every six months during 
follow-up. The author of this thesis was not involved in the collection of any of these data. The 
list of measures and a very brief description of each are summarised in Table 1 overleaf. More 
235 patients invited 
for SCID-I interview 
106 screened out 
24 did not attend 
intreview 
14 did not want to 
take part in further 
assessment 
20 refused to be 
randomised into 
treatment 
27 did not meet 
eligibility criteria 
21 screened out for 
reasons unspecified 
129 screened as 
elligible and agreed 
to take part in trial 
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detailed information about the measures used in the current study is provided later in this 
chapter. The current study uses available data on all 129 patients who took part in the TADS. 
Table 1  
Measures Used in the TADS Trial 
Measure Authors Brief summary of measure 
Hamilton Depression Rating Scale (HDRS) Hamilton, 1967 Clinician-rated measure for depression 
Beck Depression Inventory (BDI)  Beck et al., 1996 Self-report measure for depression 
Clinical Outcomes in Routine Evaluation 
(CORE) 
(Evans et al., 2000) 
Self-report measure of general 
psychological distress 
Global Assessment of Functioning (GAF) APA, 1994 
Clinician-rated measure of general 
functioning 
Persons Relating to Others Questionnaire – 
Version 2 (PROQ2) 
Birtchnell, 1999 Self-report measure of object relations 
Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q-les Q) 
Endicott, Nee, 
Harrison, & 
Blumenthal, 1993 
Self-report measure of quality of life 
specifically developed for people with 
depression 
Client Service Receipt Interview (CSRI) 
Beecham & Knapp, 
1992 
Clinician-rated interview for collecting 
data on service utilization and 
calculating comprehensive costs 
The Structured Clinical Interview for DSM-IV 
(SCID-I) 
First et al., 1996 
Clinician-rated interview of Axis-I 
diagnoses 
Shedler-Westen Assessment Procedure 
(SWAP-II) 
Westen, Waller, 
Blagov, Shedler, & 
Bradley, 2007 
Clinician-rated measure of personality 
disorders and “personality health” 
Private Theories Interview  
Ginner, Werbart, 
Lavander, & 
Sahlberg, 2001 
Semi-structured interview eliciting 
information on patient theories about 
their problems’ formation, 
pathogenesis and cure, as well as 
theories of change 
 
2.2.4. TADS baseline characteristics 
Table 2 presents a summary of the baseline demographic and clinical characteristics for the 129 
patients randomised in the study. 
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Table 2 
TADS Patients’ Baseline Characteristics (Fonagy et al., 2015) 
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2.2.5. Treatments 
The following section describes the nature of each of the two TADS  treatments . 
2.2.5.1. Long-term psychoanalytic psychotherapy (LTPP) for treatment-resistant 
depression 
The main characteristics and guiding principles of long-term psychodynamic psychotherapy 
were discussed in the introduction chapter. This section is concerned specifically with the 18-
month psychoanalytic psychotherapy that formed one of the two treatment arms in the Tavistock 
Adult Depression Study.  
Sixty-seven patients were randomised to the LTPP arm of the study, which consisted of 60 
sessions (each 50-minutes long) with a clinician accredited by the British Psychoanalytic 
Council  (Fonagy et al., 2015; Taylor, 2015). Once-weekly psychotherapy, time-limited to up to 
two years, is considered “standard treatment” at the Tavistock and Portman NHS Foundation 
Trust, where publicly-funded interventions are provided (Taylor, 2015). There were 22 treating 
clinicians in the LTPP arm of the study, and their average length of clinical experience was 
17.45 years (Fonagy et al., 2015). 
Taylor (2015; 2003) authored a Treatment Manual specifically written for the purposes of the 
TADS. The Manual is described by Taylor (2003) as a “description of the psychoanalytic way of 
working” (p.4), rather than a prescriptive document that lists specific procedures that should be 
followed rigidly. Furthermore, it highlights the necessity for each therapist’s individual approach 
to each individual patient, and the importance of the use of clinical judgement by the therapist. 
The Manual had therefore been developed primarily in order to enable treatment adherence 
evaluations to take place, rather than to instruct the psychodynamic therapists what to do in their 
work with the patients (ibid) or to constitute psychoanalytic training in itself (Taylor, 2015). 
Treatment adherence was indeed assessed as part of the TADS, through the use of the 100-item 
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Psychotherapy Process Q-sort (Jones, 2000), and a high correlation (82.2%) was reported with 
the psychodynamic prototype of the measure (Fonagy et al., 2015). 
2.2.5.2. Treatment as usual (TAU) 
The treatment of the patients in the the TAU group was managed in Primary Care by the 
referring clinician (the GP) (Fonagy et al., 2015). The National Collaborating Centre for Mental 
Health in the UK has published a specific guidance which recommends evidence-based 
interventions for individuals diagnosed with depression (National Collaborating Centre for 
Mental Health (Great Britain) & Royal College of Psychiatrists, 2010). The treatments 
recommended by this guideline are anti-depressant medication as first line of treatment, followed 
by Cognitive Behavioural Therapy (CBT) or Interpersonal Therapy (IPT). Long-term 
psychoanalytic psychotherapy is not included in the guideline.  
Patients randomised to the TAU group were therefore not in receipt of LTPP. Likewise, those in 
the LTPP group were not offered any of the psychological interventions recommended by the the 
National Collaborating Centre for Mental Health (ibid). However, 82% in the LTPP group and 
80.7% of patients were in receipt of anti-depressants prior to randomisation, and the average 
number of medications per patient was 2.1 and 2 for each of the two groups respectively (Fonagy 
et al., 2015). 
2.2.6. Study attrition 
The attrition rates for the LTPP group and the TAU group were similar – 24% and 26% 
respectively (this included attrition during the two-year follow-up period). Figure 2 (Fonagy et 
al., 2015) provides details of the drop-out numbers for each group and at each stage of the study. 
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Figure 2  
TADS Treatment Allocation and Attrition Rates (adapted from Fonagy et al., 2015) 
 
  129 entered into trial 
67 allocated to LTPP group 62 allocated to control group 
Treatment period (18 months) 
 
10 drop-outs 
 8 withdrawn 
 2 lost contact 
7 terminated LTPP early but 
continued assessment 
 
Treatment period (18 months) 
 
8 drop-outs 
 6 withdrawn 
 1 lost contact 
 1 deceased 
 
Follow-up period (2 years) 
 
6 drop-outs 
 3 withdrawn 
 3 lost contact 
 
Follow-up period (2 years) 
 
8 drop-outs 
 4 withdrawn 
 4 lost contact 
 
51 completed (76%) 
67 included in ITT analysis 
46 completed (74%) 
62 included in ITT analysis 
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2.3. Current Study Procedure 
2.3.1. Retrospective assessment of personality 
As specified at the beginning of this chapter, the author was appointed as an Honorary 
Researcher in the TADS team in March 2014. This provided authorised access to the TADS 
patient data for the initial purpose of carrying out retrospective personality assessments of the 
129 patients who took part in the TADS trial. The personality assessments were carried out by a 
small team of five researchers (two of them were paid and the other three were appointed on 
honorary contracts). The five researchers were supervised by the TADS project coordinator, 
Felicitas Rost. All five researchers attended initial training in the use of the SWAP–II, delivered 
by the TADS project coordinator. The training included practice scoring the of the SWAP–II and 
team discussions about the scoring process.  
The researchers used the Tavistock Psychodynamic Interview (TPI) and the Structured Clinical 
Interview for DSM-IV Axis I Disorders (SCID–I) in order to conduct the retrospective 
personality assessments for all 129 participants, using the Shedler-Westen Assessment Profile II 
(SWAP-II) (Shedler & Westen, 2007). Approximately half of the patients were rated on the 
SWAP–II by two researchers at baseline and at the end of treatment, in order to establish 
acceptable inter-rater reliability. Where this was not achieved, a third rating was obtained for the 
specific patient. The remaining half of the patients were rated by one researcher. The inter-rated 
reliability statistics will be presented in the results chapter.  
The author of this thesis completed 26 SWAP–II ratings at baseline and 20 at the end of 
treatment (including single, double, and triple ratings). This consisted of listening to 
approximately 150 hours of clinical material (SCID-I and TPI interviews), in order to rate 
patients on the SWAP-II. The author also took part in regular team meetings and disussions 
related to the completion of the SWAP-II profiles. 
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Table 3 provides a summary of the TADS SWAP–II rating schedule. 
Table 3 
SWAP – II Rating Schedule 
 Single-rated Double-rated Triple-rated Not rated 
Baseline 64 57 7 1 – not enough data 
End of Treatment 47 52 11 19 – not enough data 
1 withdrawn 
2 DNA 
5 lost contact 
1 deceased 
A brief description of the SCID-I and the TPI is presented next, followed by a more detailed 
description of the SWAP–II. This chapter finishes with a description of the other measures used 
by the researcher for the purposes of the current study. 
2.3.2. Measures used 
2.3.2.1. Structured Clinical Interview for DSM-IV Axis-I disorders  
The Structured Clinical Interview (SCID) (First et al., 1996) is a semi-structured interview, 
designed to assess patients on the five axes of the Diagnostic and Statistical Manual for mental 
disorders, 4
th
 Edition (DSM-IV) (APA, 1994). The SCID-I assesses individuals for Axis-I 
conditions, such as Major Depressive Disorder, Anxiety Disorder and Panic Disorder, to name a 
few.  
The SCID-I’s reliability and validity have  been studied by a number of authors (Lobbestael, 
Leurgans, & Arntz, 2011; Zanarini et al., 2000; Zanarini & Frankenburg, 2001). The Structured 
Clinical Interview for DSM Disorders Official Website (2015) summarises the SCID-I reliability 
Kappa values as reported in “the most comprehensive” published studies to date. These range 
from .35 for Dysthymic Disorder (Zanarini et al., 2000) to 1.0 for Post-Traumatic Stress 
Borderline-dysregulated personality and Treatment -resistant Depression  
 
67 
Disorder (Zanarini & Frankenburg, 2001). The majority of the Kappa values reported in these 
studies are above .70, however, which is considered an indicator for good level of agreement.  
With regards to its validity, the SCID-I has been considered the “gold-standard” in the field of 
psychiatric diagnosis (Shear et al., 2000). At the same time, however, it is recognised that “a 
gold standard for psychiatric diagnoses remains elusive” and the term best estimate diagnosis is 
suggested instead (The Structured Clinical Interview for DSM Disorders Official Website, 
2015). Also known as the “LEAD standard”, the best estimate diagnostic approach is 
longitudinal in nature, and combines structured clinical tools, like the SCID-I, with clinical 
observations, and information gathered from family members and medical records (ibid).  
The SCID-I was initially used during the recruitment and screening stage of the TADS, as 
specified earlier in this chapter. The measure was repeated at the end of treatment for both arms 
of the TADS. The interview was slightly amended to fit the purposes of re-assessment at the end 
of the trial. This included changing some of the language, to acknowledge the follow-up nature 
of the interview, and incorporating the HDRS-17 questions within the SCID-I, in order to avoid 
delivering two separate clinical interviews. The HDRS-17 questions were clearly demarcated in 
the follow-up SCID-I interview schedule. 
2.3.2.2. Tavistock Psychodynamic Interview 
The Tavistock Psychodynamic Interview (TPI) is a semi-structured clinical interview that was 
specifically designed for the purposes of the TADS. Taylor et al. (2012) describe the TPI as a 
tool which “draws on well-validated psychodynamic and attachment-based interviews” (p.7). 
These interviews are the Adult Attachment Interview (Main, Kaplan, & Cassidy, 1985), the 
Quality of Object Relating Scale (Piper, McCallum, & Joyce, 1993) and the Current 
Relationships Interview (Crowell & Owens, 1998). By incorporating aspects of these three 
interviews, the TPI aims to obtain information about the patient’s attachment patterns, as 
established in early life development, as well as the nature of the patient’s current object 
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relations. In addition, the TPI focuses closely on key transitional periods during childhood, 
adolescence and adulthood, and the way in which relationships and events in the patient’s life 
have been cognitively and emotionally processed. The interviewer asks the patient to relay an 
early life memory and a recent dream, as these are believed to provide further insight into the 
patient’s internal representations of self and others. Overall, however, the interview encourages 
the patient to speak freely, and the clinician limits prompting as much as possible (Carlyle, 
2015). The interview does not rely on interpretations or psychodynamic formulations of the 
patient’s difficulties (ibid). 
The TPI was carried out by a trained TADS clinician at baseline, and was repeated two years 
later (six months after treatment completion for the LTPP group). Whilst the initial interview 
sought to arrive at an “independent psychodynamic formulation of the participant’s illness”, the 
end of treatment interview focused on noticing any changes in interpersonal and psychological 
functioning. More specifically, the patient was “asked to comment on their relationships, work, 
physical health, functioning and depression history over the intervening period” (Carlyle, 2015). 
The patient was also invited to comment on the treatment/support they had received, if any. The 
request for a recent dream and a childhood memory was also repeated. The clinician was again 
aiming to provide a free form of narrative, in order to ascertain whether any inter-psychic 
changes had taken place since the first interview was carried out. Examples of such anticipated 
changes are the development of “initiative”, “curiosity”, “sense of self”, “capacity for 
responsibility” and “coherence of self” (ibid). 
All SCID-I and TPI interviews at baseline and end of treatment were audio recorded. The current 
study used the recordings in order to carry out the SWAP-II assessments. The SCID-I and TPI 
combined have an average length of 2-3 hours for each stage of assessment (pre- and post-
treatment). The five researchers who completed the SWAP-II ratings were blind to the type of 
treatment the patient was randomised at baseline (LTPP vs. TAU). Researcher-blinding was not 
Borderline-dysregulated personality and Treatment -resistant Depression  
 
69 
fully possible for the end of treatment interviews, however, as some of the interview material 
contained information about the type of treatment received by the patient. The interview material 
for each patient was randomly allocated to the researchers. Baseline and end-of-treatment 
assessments for the same patient were not carried out by the same researcher.  
2.3.2.3.The Shedler-Westen Assessment Procedure, Second Edition (SWAP-II) 
The Shedler-Westen Assessment Procedure (SWAP) was developed by Professor Drew Westen 
and Dr Jonathan Shedler (Westen & Shedler, 1999b, 1999c). The SWAP-II (Appendix G) is the 
third edition of the SWAP. It is a 200-item personality measurement tool, in which the clinician 
rates the patient, without asking them direct questions, as with other existing Axis II diagnostic 
tools. Rather, “the clinical assessor sorts the [200] statements into eight categories based on the 
degree to which the statements describe the patient, from 7 (highly descriptive) to 0 (not 
descriptive)” (Westen & Shedler, 2007, p. 810). The item distribution is fixed – only a pre-
determined number of statements can go into each rating group (Table 4). 
Table 4 
SWAP-II Item Count per Score (adapted from Blagov et al., 2012) 
Score 0 1 2 3 4 5 6 7 
Frequency 100 22 18 16 14 12 10 8 
This method of assessing personality is known as the Q-sort method (Block, 1961; Westen & 
Shedler, 1999b). For a comprehensive description of the Q-sort method, the interested reader is 
referred to Block’s (1961) original text. 
2.3.2.3.1. SWAP – II development and aims 
Shedler and Westen developed the SWAP-200 with three main aims in mind: to refine the 
existing Axis II personality disorder taxonomy; to suggest an alternative taxonomy for 
classifying personality disorders; and to identify factors and trait dimensions relevant to 
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describing personality (Westen & Shedler, 2007). The authors argued that such new taxonomy 
was necessary for a number of reasons.  
First, they highlighted a number of shortcomings of the existing DSM-IV Axis II classification 
of personality disorders. These included: high comorbidity amongst the 10 personality disorders 
(and hence poor discriminant validity of the classification); discrepancies between the Axis II 
categories and empirical data from cluster and factor analyses; a categorical (present/absent) 
approach to personality disorders, which makes little clinical and empirical sense and neglects 
individuals who do not meet diagnostic thresholds but nonetheless experience persistent and 
enduring personality difficulties; lack of acknowledgment of personality strengths, which might 
counter-indicate personality disorder diagnosis for some individuals; and lack of weighting of 
specific personality traits, which might bear particular relevance to clinical assessment and 
treatment (Westen & Shedler, 1999b).  
Second, Westen and Shedler (ibid) pointed at a number of limitations of the personality disorder 
assessment tools used at present. For example, they argued that whilst all tools rely on either 
self-report or direct questioning of the individual, this is not a reliable way of measuring 
personality processes, as individuals are often unaware of certain personality traits or unwilling 
to disclose those (in the case of narcissism, for example), or both. When this is combined with 
the inherent flaws in the DSM-IV classification of personality disorders, on which the 
assessments are based, a poor validity of these tools results (ibid). Furthermore, a large-scale 
study which asked 1800 experienced psychologists and psychiatrists how they arrive at 
personality disorder diagnosis in clinical practice, concluded that direct questioning of the 
patients is rarely adopted in clinical work, and the preferred approach is making clinical 
inferences based on listening to the patients’ narratives and observing the patients’ behaviours in 
relation to the clinician (Westen, 1997). 
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In order to address these shortcomings, Shedler and Westen developed an alternative assessment 
and classification tool, the SWAP-200. They stated that the 200 personality descriptions were 
derived from multiple sources, including DSM-III and DSM-IV diagnostic criteria, items from 
Axis I which they thought to be relevant to personality functioning, literature from the last 50 
years on normal and pathological personality, research on coping and defensive processes, and a 
number of pilot studies (Westen & Shedler, 2007). Furthermore, the authors claimed that the 
SWAP was edited multiple times and refined in line with further research since its first version. 
The SWAP-II was therefore described as the product of ongoing work that had spanned over 12 
years of clinical consultations and research (ibid). Shedler (2015) described the clinicians who 
had taken part in the SWAP development as coming from various theoretical backgrounds (e.g. 
psychoanalytic, behavioural, etc.), the SWAP thus presenting a shared clinical vocabulary, which 
does not favour a particular school of thought. Of note, however, only 30% of the clinicians 
approached (the total number was not specified in the original publication), agreed to take part in 
one of the studies (Westen, Waller, Shedler, & Blagov, 2014), and no significant demographic 
differences were reported between those who took part and those who did not, it is unclear 
whether the remaining 70% of clinicians would have taken a similar approach to describing 
personality pathology through the SWAP. 
In the development stages of the SWAP, clinicians were asked to use the tool in order to rate 
real-life patients (who were or were not diagnosed with an Axis II personality disorder, but did 
experience enduring personality difficulties), as well as to rate a “typical” patient for each of the 
10 DSM-IV personality disorders: in other words, to describe the personality of a patient 
diagnosed with, for example antisocial personality disorder, in what they believed to be “the 
purest form of the condition” (Westen & Shedler, 1999b). In the same study, clinicians were also 
asked to describe an actual or prototypical healthy, high-functioning patient. In order to avoid an 
artificial inflation of pathology due to the fixed distribution, Westen and Shedler claim to have 
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included a wide range of items, including ones describing personality traits not severe enough to 
warrant Axis II diagnoses, as well as items describing healthy functioning and strengths. A full 
description of the SWAP-200 and SWAP-II development is beyond the scope of this chapter, but 
is available in Westen and Shedler’s original journal articles (Westen & Shedler, 1999b, 1999c, 
2007). 
Last, the SWAP-II arguably attempts to address the schism between clinical practice and 
research by harnessing clinical judgement and inference, and systematising it in a empirical, 
quantifiable way, which allows for reliable diagnoses and predictions to be made, and for 
treatment to be planned in a person-cantered manner (Shedler, 2015). 
2.3.2.3.2. SWAP personality syndromes and personality traits 
The Q-sort method of assessing personality allows for data collected through the SWAP to be 
aggregated and analysed in order to derive personality descriptions of a particular type of patient 
(Westen & Shedler, 1999b). Data collected from the initial SWAP studies were used to derive 
personality clusters/syndromes based on both hypothetical patients who were deemed to meet 
criteria for each of the Axis II diagnoses, as well as on real-life patients, as they were described 
by their treating clinician. Westen & Shedler (1999a; 1999b; 2007) used this data to revise the 
existing PD constructs, as well as to empirically derive alternative personality configurations. 
They ran two main types of statistical analyses in order to meet these objectives: Q-sort analysis, 
which aggregates patients with similar profiles and empirically derives personality syndromes 
(Westen et al., 2012), and trait factor analysis, which derives discrete trait dimensions across the 
set of SWAP items (Westen et al., 2014).  
Westen and Shedler define personality syndromes as: 
“… diagnostic groupings (…) defined by empirically derived prototypes— descriptions that 
represent each diagnostic syndrome in its ideal or pure form (based on all 200 SWAP items). 
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Individual patients are diagnosed dimensionally (on a continuum) based on the degree of 
resemblance or match with the prototype.” (Westen & Shedler, 2007, p. 815) 
This degree of resemblance is statistically calculated as a T score, which has a mean of 50 and a 
standard deviation of 10. The higher the score, the closer the resemblance to the diagnostic 
syndrome in question. A cut-off score of 60 is used for the purposes of categorical diagnosis 
(presence/absence of personality disorder), whereas a score between 55 and 60 is considered 
indicative of significant presence of features of the particular syndrome. 
In their latest large-scale study, which collected SWAP data on 1201 patients, Westen et al. 
(2012) statistically derived 10 diagnostic syndromes: depressive, anxious-avoidant, dependent-
victimised, schizoid-schizotypal, antisocial-psychopathic, narcissistic, paranoid, borderline-
dysregulated, obsessional and hysteric-histrionic. In addition, a personality health syndrome 
(Appendix H) was also derived, denoting the key characteristics of individuals who are highly-
functioning. Each syndrome included between 15 and 24 SWAP items, which statistical analysis 
indicated as correlating highly with the overall profile. Moreover, the analysis also yielded a first 
order hierarchical factor structure, which is depicted in Figure 3 below. 
Figure 3 
Hierarchical Structure of Personality Diagnoses (adapted from Westen et al., 2012) 
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In addition to calculating the T-score, the SWAP allows for a narrative account of the patient to 
be created, which, according to Westen et al. (2012) resembles much more a clinical case 
formulation as observed in routine clinical practice, in contrast to descriptive psychiatry, which 
merely provides lists of symptoms. 
Furthermore, Shedler & Westen (2010) also gave an example of how a change score can be 
calculated on an item level, and a new narrative description arrived at, for items where the 
difference in score was >4. This approach to examining changes in the personality profiles of the 
TADS patients was adopted in the analysis of the data in the current study, and the results will be 
presented in the result chapter to follow.   
The current study focuses on the borderline-dysregulated syndrome, in particular, which is 
described by Shedler & Westen (2007) as closest to the DSM-IV Axis II borderline personality 
disorder. Appendix A provides a list of the 24 SWAP items most descriptive of the borderline-
dysregulated syndrome (Shedler, 2015), whilst Appendix B presented the narrative description 
of the borderline-dysregulated spectrum (Westen et al., 2012). 
2.3.2.3.3. Reliability and validity of the SWAP-II 
Westen & Muderrisoglu (2003, 2006) reported good reliability of the SWAP-200, as measured 
through the inter-rater coefficients between two clinican raters in a sample of 24 outpatients. 
More specifically, in the first publicaiton of their results, the authors repoted an inter-rater 
correlations of r >.80 for the personality syndrome scales. The second publication, based on the 
same sample, reported inter-rater correlation coeficient of r >.88 for the trait dimension scales. 
Marin-Avellan, McGauley, Campbell, & Fonagy (2005a) reported similarly high inter-rater 
reliability (r >.91). In the same study, as well as in a subsequent one, based on a larger sample 
(Marin-Avellan, McGauley, Campbell, & Fonagy, 2005b) a stong predictive valdity was 
reported, as measured by independently-assessed factors, such as the nature of the the index 
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offence committed by the patient and their future violent behaviour. More specifically, individals 
who scored higher on the SWAP-200 antisocial PD scale, were more likely to have committed a 
violent index offence, as well as more likely to engage in violent behaviour on an inpatient ward 
in the 12 months following the assessment. 
Westen, Waller, Blagov, Shedler, & Bradley (2007) reported good validity of the SWAP-II as 
measured by correlations between cross-informants and correlations with independent measures, 
such as self-reported arrest history. In addtion, Westen & Shedler (2007) summarised the results 
of a few studies where results on the SWAP were shown to predict a range of external 
independent criteria, such as suicide attemps, hospitalisaions and adaptive functioning as 
measured by the Global Assessment Functioning index (GAF). 
Blagov, Bi, Shedler, & Westen (2012) addressed some of the main criticisms to the validity and 
reliability of the SWAP-II. For example, they presented counter-arguments to the critique that 
the SWAP-II’s fixed score distribution inflates the T-scores artificially (Block, 2008). For a full 
discussion of the SWAP-II’s reliability and validity, the reader is directed to Blagov et al. 
(2012). 
2.3.2.3.4. SWAP – II ratings using the SCID-I and Tavistock Psychodynamic Interview 
The SWAP-II is typically scored on the basis of information gathered through the Clinical 
Diagnostic Interview (CDI), which was designed specifically for this purpose (Westen & 
Muderrisoglu, 2006). The TADS team did not carry out the CDI, however.  
Lewis (2008) compared the use of the TPI and the SCID-I to the use of the CDI when rating 
participants on the SWAP-II. She concluded that the interviews are similar in their content, 
structure and flow, whilst also highlighting areas of difference. For example, the CDI is designed 
to be delivered by the same clinician, who then rates the individual, using the SWAP-II. This 
allows the assessor to observe the patient and their non-verbal/visual presentation and 
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interactional style – information that is then used to score some of the SWAP items. Lewis 
(2008) used the SWAP-II to retrospectively score a sub-sample of 25 TADS participants and 
concluded that despite the inherent limitations, the use of the TPI and the SCID-I is reliable. She 
based her conclusions on high correlation scores between her SWAP-II and other measures of 
personality for her sample. Carlyle (2015), who developed the TPI, indeed stated that one of the 
interview’s aims was to be “sufficiently free” in order for other existing or future measures to be 
applied to the qualitative data collected by it. Furthermore, she suggested that one type of 
clinical question that might be addressed by the interview subsequently, is whether any “key 
personality or object relation’s indicators” might be linked to specific “outcomes” (ibid). 
An anticipated difficulty in the current research, which is not addressed by either Lewis (2008) 
or the SWAP developers in any of their publications, is the rating of items where there is 
insufficient information. A score of “0” is generally assigned in order to denote an item as “not 
descriptive” for the patient. However, it is not unlikely that in the current study some items 
might well be descriptive of a patient, but for the relevant information to not have been elicited 
by the SCID-I or the TPI. In such case scores of “0” might be better interpreted as “missing 
data”. Furthermore, it is generally recommended that the SWAP-II is scored either following the 
administration of the CDI, or, when this is not practical, after a minimum of six clinical hours 
with the patient (Shedler, 2015; Shedler & Westen, 2007). The deviation from this guideline is 
clearly a limitation in the current study and this will be addressed further in the discussion 
chapter of the thesis.  
2.3.2.3.5. The use of the SWAP II by newly-trained researchers 
The SWAP-II measure was originally developed and tested through the involvement of hundreds 
of experienced clinicians (psychiatrists and psychologists). Its effective use relies significantly 
on “clinical judgement” and expertise. In the current study the measure was used by five junior 
researchers with some clinical experience. One of the researchers (not the author of this thesis) 
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had over 10 years of clinically-relevant experience. Whilst the limited clinical experience of 
some of the researchers might be seen as a potential limitation, both in terms of evaluating the 
SWAP-II ratings’ reliability, as well as ethically, a study looking at the convergence between 
SWAP-II and self-report (PAI) data for antisocial and borderline PD by Bradley, Hilsenroth, 
Guarnaccia, & Westen (2007) used “advanced clinical psychology graduate students” to do the 
SWAP-II assessments and reported good reliability of the measure. In addition, the TADS 
researchers were supervised by another senior researcher, who has been trained in using the 
SWAP-II procedure and who is also in possession of vast experience in administering 
personality assessments for research purposes. This supervisor is also in receipt of ongoing 
support and guidance by one of the SWAP-II primary developers – Dr Shedler.  
2.3.3. Other measures 
2.3.3.1. Structured Clinical Interview for DSM-IV Axis-II disorders – Patient 
Questionnaire (SCID-II-PQ) 
The SCID-II-PQ is a self-rated personality disorders screening tool (First, Gibbon, Spitzer, 
Williams, & Benjamin, 1997). It consists of 119 yes/no items, and is not intended to be used as a 
stand-alone personality disorders measure. Rather, the questionnaire is designed to alert the 
clinician about a possible PD diagnosis, so that the more thorough semi-structured SCID-II 
interview is carried out. The SCID-II interview was not conducted as part of the TADS, but all 
patients were asked to complete the SCID-II-PQ pre- and post-treatment. The SCID-II-PQ alone 
is not a reliable measure of personality pathology, and it is therefore not used as such in the 
current study. The author nonetheless analysed some of the SCID-II-PQ in order to cross-
reference it with results from the SWAP-II. 
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2.3.3.2. The Hamilton Depression Rating Scale (HDRS-17) 
The primary outcome measure in the TADS was the the Hamilton Depression Rating Scale 
(HDRS-17) (Hamilton, 1960). Depression was also measured by the Beck Depression Inventory, 
2
nd
 Edition (Beck et al., 1996), which was treated as a secondary measure (Fonagy et al., 2015). 
The HDRS is a 17-item clinician-rated measure, which covers symptoms such as depression, 
feelings of guilt, suicide and anxiety (Hamilton, 1960) (Appendix I). Some of the items are rated 
on a five-point scale, where a score of “0” denotes an absence of the specific symptom, and a 
score of “4” denotes a high severity of the symptom. Other items are rated on a three-point scale 
(0-2), the rationale for this being that “quantification of the variable is either difficult or 
impossible” (Hamilton, 1960, p. 57). The scale also contains four additional items, which are not 
included in the final scoring. These are diurnal variation, depersonalisation and derealisation, 
paranoid symptoms, and obsessional and compulsive symptoms. Hamilton (1960) justified the 
exclusion of these items from the final score, by arguing that the first one refers to the type of 
depression (not its presence and intensity), and the latter three do not occur frequently enough to 
make a clinical difference. 
Unlike other widely-used measures of depression (e.g. the BDI-II), the HDRS-17 requires the 
rater to be a health-care professional with adequate clinical experience. Hamilton (1960) 
reiterated the importance of the rater’s ability to make accurate clinical judgements, particularly 
for items he considered more difficult to define, such as general somatic symptoms and 
hypochondriasis (ibid). In addition, he recommended that the scale is completed independently 
by two raters, but that the rating is based on the same clinical interview with the patient, where 
the final score of the HDRS is the average of the two raters’ scores.  
The TADS used the measure in its original form, adding items to track increases in sleep, 
appetite and weight (Fonagy et al., 2015) (Appendix J). Each patient was rated by a trained 
interviewer, who was blind to the patient’s treatment allocation, and the interview was 
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subsequently double-rated by another coder, with an inter-rated coefficient of .89 having been 
reported by Fonagy et al. (2015). The following severity categories were used in the TADS: 0-7 
“not depressed”; 8-13 “mild depression”; 14-18 “moderate depression”; 19-22 “severe 
depression”; and ≥ 23 “very severe depression”. Full remission was denoted by HDRS score of 8 
or lower, where as a score of ≤ 12 was considered indicative of partial remission (ibid). 
Trajković et al. (2011) carried out a meta-analysis of studies which had reported HDRS’s 
reliability calculations, and had been published between 1960 and 2008. These included both 
studies designed to test the HDRS’s psychometric properties, and studies of clinical samples 
where the HDRS was one of the employed measures. Trajković et al. (2011) evaluated the 
scale’s reliability by estimating internal consistency, inter-rater reliability and test-retest 
reliability via the meta-analytic method on 409 journal articles. They concluded that overall the 
HDRS is a reliable assessment tool for depression in clinical settings, as it has good internal 
consistency, high inter-rater reliability, and yields similar results when repeated on multiple 
occasions. The authors also highlighted some exceptions to the findings. For example, their 
results suggested that the “loss of insight” scale item has a very low internal consistency, as 
measured through total-item correlations. In addition, inter-rater reliability was found to increase 
significantly the more recent the studies were, suggesting that accumulated experience of using 
the HDRS and better training have improved the scale’s use. Finally, test-retest reliability was 
found to be highest when there was a short period between the two assessment episodes and 
when each assessment was carried out by the same rater. The longer the time period between the 
assessment episodes, the poorer the test-retest reliability. However, Trajković et al. (2011) 
highlighted that a longer time lapse might also be related to changes in symptoms, rather than be 
indicative of a poor test-retest reliability, as such. A more general limitation of this meta-
analysis, as identified by its authors, is that of all publications screened, only 7.4% reported 
reliability coefficients and many of the studies lacked important information (e.g. participants’ 
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characteristics). Thus, the conclusions about the HDRS reliability need to be treated with 
caution, as they refer to a small subsample of the studies that used the scale. 
Bagby, Ryder, Schuller, & Marshall (2004) carried out a review of the psychometric properties 
of the HDRS, including articles published between 1980 and 2003. Seventy articles were 
included in the review and the results were presented in relation to main psychometric criteria: 
reliability, item response and validity. First, the authors reported an overall good internal, inter-
rater and test-retest reliability, when the HDRS total score is considered. When examined on an 
item-level, however, the scale was reported as less reliable. For example, the item “loss of 
insight” was again found to be problem-ridden. There was also a great inter-rater and test-retest 
variation for many of the 17 scale items.  
Second, further criticism was directed towards the weighting of the individual items (some of 
them rated on a 3-point scale, whilst others on a 5-point scale). This, in combination with the 
varying likelihood of ascribing a high/low score to certain items regardless of the severity of 
depression experienced by the patient, was argued to ultimately result in the scale’s weakened 
capacity to detect change (ibid). 
Third, the authors examined five types of validity: content, convergent, discriminant, factorial 
and predictive. Whilst content validity was reported to be good, the HDRS was criticised for not 
being adequately constant with the DSM-IV definition of depression. For example, some 
symptoms, such as “psychotic anxiety” are captured by the HDRS but are not included in the 
DSM diagnostic criteria, whilst “other important features of DSM-IV depression are often buried 
within more complex items and sometimes are not captured [by the HDRS] at all” (Bagby et al., 
2004, p. 2170). This critique was linked to the reported convergent validity, which had been 
found in different studies to be good with all other measures of depression, except for two, one 
of which is the SCID-I. The HDRS discriminant validity was also reported as good overall, but 
only on the total-score level, and less so on an item level. Nonetheless, a number of studies had 
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reported the HDRS to have better discriminant validity than the BDI-II. The authors concluded 
that overall reliability and validity standards appear to be generally met for the HDRS. However, 
they argued that the scale needs to be revised, firstly as it does not match adequately the 
contemporary DSM-IV conceptualisation of depression, and secondly, as it it does not have a 
clearly defined factor structure which has proven to be consistent across populations.  
The current study uses the HDRS as a main outcome measure. This decision was made in part in 
order to maintain consistency with the method of the TADS (where the HDRS was used at the 
primary measure of depression), and partially due to the clinician-rated nature of the HDRS. The 
use of clinical judgement and inference was shown to be a central feature of the SWAP-II, as 
described earlier in this chapter. A clinician-rated measure of depression is thus considered to be 
theoretically consistent with the other main measure used in the current project (the SWAP-II). 
2.3.3.3. Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM) 
The CORE-OM (Appendix K) is a 34-item self-rated generic measure of psychological distress 
(CORE IMS Ltd, 2016). It covers four domains: well-being, social functioning, 
problems/symptoms, and risk (to self and others). The total clinical score is the mean score of all 
rated items, and denotes the individual’s current level of overall psychological difficulties. Items 
are scored on a scale from 0 to 4 (from “not at all” to “most or all of the time”) and refer to the 
week preceding the completion of the questionnaire. The CORE-OM manual specifies cut-off 
scores that differentiate clinical from non-clinical populations. The CORE-OM total cut off score 
for men is 1.19 and for women – 1.29 (CORE System Team, 2016). 
The CORE-OM was introduced as a measure of clinical outcome, in response to criticims of the 
lack of routine evaluation of psychotherapy interventions (Evans et al., 2000). Its developers 
aimed at designing a measure, which was short, easy to understand, and compatible with the 
different schools of therapy (ibid).  
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With regards to its psychometric properties, the CORE-OM was reported to have high internal 
consistency and test-retest reliability, as well as excellent convergent validity against other self-
report measures used in routine practice. This information was based on an initial study of 2000 
participants (counselling/psychotherapy patients and lay-participants), as well as on subsequent 
data from 23 clinical sites in the UK, and a non-clinical sample (Evans et al., 2000, 2002). 
Furthermore, the CORE-OM has been argued to be sensitive to clinical change, and to reliably 
discriminate between clinical and non-clinical populations (ibid). 
A more recent study with over 3000 patients in the UK, also reported good test-retest reliability 
for the CORE-OM and concluded that the tool measures psychological disturbance reliably 
(Barkham, Mullin, Leach, Stiles, & Lucock, 2007).  
The current study used the CORE-OM total score, as a measure of general psychological 
distress. The author decided against using the separate CORE-OM domains (e.g. well-being, or 
social functioning) as recent research has questioned the face validity of the measure’s domains 
and subdomains, and has claimed that the tool is “a large psychological distress scale with 
considerable item redundancy” (Bedford et al., 2010, p. 51).  
2.3.3.4. General Assessment of Functioning (GAF) 
The Global Assessment of Functioning Scale (GAF) (Appendix L) comprises Axis V of the 
DSM-IV (APA, 1994). The measure is clinician-rated and aims at evaluating the patient’s 
overall level of functioning in the psychological, social and occupational domains. The APA 
(1994) states that “the GAF scale may be particularly useful in tracking the clinical progress of 
individuals in global terms, using a single measure” (p.32). “Intended to be a generic, rather than 
a diagnosis-specific” measure (Aas, 2010, p.1), the GAF has been widely adopted internationally 
(ibid). 
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The GAF is divided into 10 categories of functioning, each of which is rated on a 10-point scale. 
The clinician is asked to choose a single value that best describes the patient’s current level of 
functioning. When making this decision, the clinician has to consider both symptom severity, as 
well as functioning. However, to be ascribed to one of the 10 categories, the patient needs to 
match either the symptom or functioning description of the category, and not both, meaning that 
“the final GAF rating always reflects the worse of the two” (p.33). For a more detailed 
description of the GAF rating procedure, please refer to the DSM-IV Manual (APA, 1994). 
The reliability of the GAF has been assessed by a number of authors. Jones, Thornicroft, Coffey, 
& Dunn (1995), for example, evaluated the measure as applied to a sample of 103 outpatients, 
diagnosed with chronic mental health conditions, such as schizophrenia. The authors reported 
satisfactory reliability for all cases. They also assessed the GAF in relation to two other measures 
of clinical need – the level of support a patient requires, and the changes to anti-psychotic 
medication – and concluded that the GAF reflects adequately symptom and functioning severity.  
Another study (Startup, Jackson, & Bendix, 2002), on inpatients with diagnosis of schizophrenia, 
reported excellent GAF inter-rater reliability, at all three measurement time-points (admission, 6- 
and 12-month follow-up). These authors also correlated the GAF scores with scores on two 
symptom measures and one measure of social behaviours, and reported significant results for the 
two follow-up time-points, but not for the point of admission.  
Aas (2010) reviewed the GAF literature and concluded that overall reliability is good, although 
less so in routine clinical settings. Another recent study by Grootenboer et al. (2012) investigated 
the measure’s validity and reliability for over 432 outpatients diagnosed with major depression 
and treated in “normal clinical practice” in the Netherlands. The authors reported weak inter-
rater reliability, and poor discriminant validity. Furthermore, GAF scores were significantly 
correlated with disease severity, as measured by other clinical assessment tools, as well as with 
physical functioning, despite the DSM-IV instructing clinicians to not base their ratings on 
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physical symptomatology. There was also an association between the GAF ratings and a measure 
of social functioning.  
Finally, some authors highlighted the minimal training required for clinicians to be able to 
complete the GAF, which arguably makes it an easy-to-deliver measure in routine clinical 
practice (Jones et al., 1995; Startup et al., 2002). Other authors, however, warned against an 
over-reliance on the GAF as an outcome measure. For example, reviewing the existing GAF 
literature, Moos, Nichol, & Moos (2002), concluded that “GAF ratings tend to be more closely 
associated with diagnoses and psychiatric symptoms than with social and occupational 
functioning” (p.731). Grootenboer et al. (2012) questioned the use of the GAF to determine 
treatment needs and evaluate the quality of services, given the measure’s poor reliability and 
validity (as established by their study). 
It can thus be concluded that the existing GAF literature points at mixed results, with regards to 
the measure’s reliability, validity and applicability in treatment outcome research. This will be 
considered in further detail in the discussion chapter of the thesis. 
2.4. Ethical Considerations 
2.4.1. Confidentiality 
All data has been dealt with, listened to (in the case of audio recordings) and saved in line with 
the National Health Service Information Governance guidelines (Department of Health, 2003). 
2.4.2. Personality disorder diagnosis 
It is not unlikely that at least some of the participants will reach the cut-off scores for a 
personality disorder diagnosis, as measured by the SWAP-II. In such cases it might transpire that 
the particular individual has not been diagnosed before (they might have completed a DSM-
based measurement tool, but not met those sets of criteria), particularly as participants in the 
TADS were referred for the treatment of depression, and not personality disorder. Whereas other 
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outcome and diagnostic tools used in the TADS were employed during the treatment and follow-
up phases, the SWAP-II was carried out retrospectively, after the participants had left the trial. 
Yet, no patients were contacted following the end of the trial, in order to be informed of 
potentially meeting PD diagnostic criteria. This poses the ethical dilemma whether participants 
are entitled to know the outcome of any retrospective assessments, particularly if that might lead 
to a re-formulation of their difficulties or additional or alternative forms of 
interventions/treatments (treatment for personality disorder, in particular).  
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3. Results 
This chapter begins with a summary of the SWAP-II scoring, inter-rater reliability correlations 
and account of the missing values. The chapter then explores more closely the prevalence of the 
different personality disorders, including borderline-dysregulated personality disorder and 
features in the TADS patient group. The results of the statistical analysis performed using SPSS 
version 21, and looking at the relationship between the borderline-dysregulated syndrome and 
treatment outcome is presented next. The chapter finishes with exploring the relationship 
between specific borderline personality characteristics and depression, psychological distress and 
general functioning.  
3.1. SWAP-II Scoring and Calculation of Inter-rater Reliability 
As specified in the method chapter of this thesis, the SWAP adopts a prototype matching 
approach to constructing personality profiles. 
“A diagnostic prototype is a SWAP-200 description of a recognized personality disorder 
or syndrome. It is not a description of an individual person, but rather a richly detailed 
description of a disorder or syndrome in its “ideal” or pure form.” (Shedler, 2009, pp. 5–
6) 
The T-scores, calculated through the SWAP-II algorithm, thus reflect the degree of similarity or 
“match” between the patients’ SWAP-II score and each of the diagnostic prototypes (“the better 
the match, the more applicable the diagnosis”, p.6). The SWAP-II calculates T-scores for the 10 
DSM-IV personality disorders; for the 11 personality syndromes, derived empirically through 
the SWAP-II developers’ research; and for the 16 personality traits. The T-score ranges from 0 
to 100, where 10 points denote one standard deviation. 
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3.1.1. Overall SWAP-II inter-rater reliability and scoring 
The SWAP-II scoring procedure was described in detail in the previous chapter. Figure 4 
reminds the reader of the number of patients whose SWAP-II scores were double- and triple-
rated and summarises the process of inter-rater calculations. All double-ratings were correlated 
to establish inter-rater reliability. In addition to calculating a correlation coefficient, a Intraclass 
Correlation Coefficient (ICC) was calculated by the project co-ordinator (not the author of this 
thesis) using the SPSS data analysis software package. ICC values <.40 are considered to 
indicate “poor” inter-rater agreement, ICC values between .41 and .75 - “fair” inter-rater 
reliability, and values above .75 - “excellent” agreement (Fleiss, 1973; Fleiss, Levin, & Paik, 
2013; Shrout & Fleiss, 1979). These criteria were used when interpreting the SWAP-II ICC 
scores and any cases with poor reliability were rated by a third researcher.  
Figure 4 
ICC Calculation for SWAP-II Double- and Triple Ratings 
 
 
 
 
 
 
 
 
129 patients 
End of treatment SWAP ratings Baseline SWAP ratings 
Double –rated N=57 Triple –rated N=7 Double –rated N=52 
ICC calculated between Rater 1 
and Rater 2. 
ICC calculated between Rater 1 and 2, 
Rater 2 and 3, and Rater 1 and 3. 
The highest correlation was used 
to compute the final ICC score.  
Triple–rated N=11 
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The average ICC coefficient at baseline, based on 64 double- and triple ratings, was calculated to 
be .80, and therefore considered as indicating excellent agreement between the raters. The ICC 
coefficient at 18-months, based on 63 double- and triple ratings was .70, which indicated fair 
agreement. The Spearman-Brown prophecy formula was also used to compare two raters, which 
yielded a corrected ICC and correlation co-efficients for both time-points. The corrected ICC 
coefficient at baseline was .89, and at 18-months it was .83. Appendices Ma and Mb present the 
full list of ICC and Correlation coefficients for all double and triple SWAP-II ratings at baseline 
and end of treatment.  
The SWAP-II scores were calculated via an SPSS syntax sent by Dr Jonathan Shedler to the 
TADS project co-ordinator. In short, this entailed entering the raw SWAP-II scores into the 
algorithm, which calculated a T-score for each of the SWAP-II prototypes and traits. Where 
participants were double-rated, their data was entered in the syntax for each of the ratings, and 
the final scores were averaged, producing a single T-score for each of the prototypes and traits. 
In the case of triple ratings, only the two that had the higher correlation were used, with their 
resulting T-scores averaged in order to produce a final SWAP-II set of scores. 
3.1.2. SWAP-II Borderline-dysregulated items inter-rater reliability 
Inter-rater reliability was calculated not only for the SWAP-II measure as whole, but for each of 
the 200 items at baseline, too. The same statistical procedures were followed, as described 
above, in calculating correlation and ICC coefficients.  
Appendix N presents the ICC and correlation statistics for the borderline-dysregulated 
personality prototype items. The introduction chapter of this thesis presented the full list of the 
items, 24 in total. When the Fleiss’ (1973) criteria were applied, only half of the items (12) 
qualified as having fair or excellent ICC coefficients. The author of this thesis used the initial 
ICC values, as opposed to the corrected ones, as this was considered to be a more conservative 
estimate of inter-rater reliability. 
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Table 5 below presents a list of the items with poor inter-rater agreement, and a list of those with 
fair or excellent one. This information will be used later in the chapter, when borderline-
dysregulated prototype items are linked to treatment outcome. 
Table 5 
SWAP-II Borderline-dysregulated Items’ Inter-rater Reliability 
Poor Inter-rater reliability (r < .40) Fair – Excellent Inter-rater reliability (r > .40) 
Is unable to soothe or comfort him/herself without 
the help of another person (i.e., has difficulty 
regulating own emotions). 
Emotions tend to change rapidly and unpredictably  
Tends to “catastrophize”; is prone to see problems as 
disastrous, unsolvable, etc. 
Emotions tend to spiral out of control, leading to 
extremes of anxiety, sadness, rage, etc. 
When upset, has trouble perceiving both positive and 
negative qualities in the same person at the same time 
(e.g., may see others in black or white terms, shift 
suddenly from seeing someone as caring to seeing 
him/her as malevolent and intentionally hurtful, etc.). 
Tends to become irrational when strong emotions are 
stirred up; may show a significant decline from 
customary level of functioning. 
Manages to elicit in others feelings similar to those 
s/he is experiencing (e.g., when angry, acts in such a 
way as to provoke anger in others; when anxious, 
acts in such a way as to induce anxiety in others). 
Is prone to intense anger, out of proportion to the 
situation at hand (e.g., has rage episodes). 
Tends to draw others into scenarios, or “pull” them 
into roles, that feel alien or unfamiliar (e.g., being 
uncharacteristically insensitive or cruel, feeling like 
the only person in the world who can help, etc.). 
Tends to stir up conflict or animosity between other 
people (e.g., may portray a situation differently to 
different people, leading them to form contradictory 
views or work at cross purposes). 
Lacks a stable sense of who s/he is (e.g., attitudes, 
values, goals, and feelings about self seem unstable 
or ever-changing). 
Tends to be needy or dependent. 
Is prone to painful feelings of emptiness (e.g., may 
feel lost, bereft, abjectly alone even in the presence of 
others, etc.). 
Tends to fear s/he will be rejected or abandoned. 
Appears to fear being alone; may go to great lengths 
to avoid being alone. 
Tends to become attached quickly or intensely; 
develops feelings, expectations, etc. that are not 
warranted by the history or context of the 
relationship. 
Tends to engage in self-mutilating behaviour (e.g., 
self-cutting, self-burning, etc.). 
Tends to feel misunderstood, mistreated, or 
victimized. 
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Tends to make repeated suicidal threats or gestures, 
either as a “cry for help” or as an effort to manipulate 
others. 
Struggles with genuine wishes to kill him/herself. 
Tends to act impulsively (e.g., acts 
without forethought or concern for consequences). 
Relationships tend to be unstable, chaotic, and 
rapidly changing. 
Tend to feel unhappy, depressed or despondent.  Work-life and/or living arrangements tend to be 
chaotic or unstable (e.g., job or housing situation 
seems always temporary, transitional, or ill-defined). 
 
Only SWAP-II borderline-dysregulated items which had a “fair” or “excellent” inter-rater 
agreement were used in the individual item analysis, which will be reported later in this chapter. 
3.2. Missing Values 
3.2.1. SWAP-II 
A SWAP-II profile at baseline was created for all but one TADS participant. As already 
presented in the previous section, 7 patients (11.3%) in the TAU group and 12 patients (17.9%) 
in the LTPP group did not have SWAP-II profiles at the end of treatment. The reasons for this 
were summarised in the methods chapter of this thesis.  
It is unclear what the SWAP-II PD distribution and prevalence would have been, if there was no 
missing data at the end of treatment. The patients who did not have an end-of-treatment SWAP-
II profile completed, might have been very different from those who did have a personality 
profile for that time point.  
To address this issue, the author created two groups in the SPSS data set: of those who had an 
18-months SWAP-II profile completed, and those who did not have a profile completed, and 
compared the mean values for each of the personality syndromes’ T-scores. The means were 
calculated both for the entire TADS sample, as well as for the TAU and LTPP groups separately. 
A difference in the means and standard deviations of 3 points or less was considered not 
clinically significant for further statistical analysis to be carried out. A difference of 4 points or 
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more was considered significant, as the SWAP-II developers consider a >4 change in score to 
denote a clinically meaningful difference (Shedler & Westen, 2010). Only the depressive 
syndrome mean-values in the LTPP group met this criteria, with those who did not have a 
SWAP-II profile completed at 18 months (N=12) having a depressive personality mean value of 
58.42, and those who did have a SWAP-II profile completed at the end of treatment (N=54) – a 
mean value of 63.37.  
An independent t-test confirmed that this difference was statistically significant, too (t (64) = - 
2.67, p < .05): participants, for whom a SWAP-II profile was not completed at the end of 
treatment, scored lower at baseline on the depressive syndrome scale (58.42 ± 1.87), than those 
who had a SWAP-II profile completed at the end of treatment (63.37 ± .77). The difference 
represented a small-sized effect r = .10. The implications of ths difference for interpreting the 
rest of the findings will be addressed in the discussion chapter. 
3.2.2. Hamilton Depression Rating Scale (HDRS-17)  
A number of participants in both the TAU and LTPP groups had missing HDRS-17 values at 18- 
and 42-months. For the TAU group the missing values were 16 (25.8%) at 18 months and 17 
(27.4%) at 42 months. For the LTPP group, 15 people (22.3%) did not have a HDRS-17 score 
reported at 18 months, and 20 people (29.9%) – at 42 months. 
The baseline HDRS-17 mean values of those who completed the measure at 18- and 42- months, 
and those who did not, were compared, through the same statistical procedure employed with the 
SWAP-II missing data. No significant differences were identified. 
3.2.3. Global Assessment of Functioning (GAF) and CORE-OM  
Similar to the HDRS-17 scores, there was a high number of missing values for the other two 
outcome measures used in the current study – the GAF and the CORE-OM. These are 
summarised in Table 6 overleaf.  
Borderline-dysregulated personality and Treatment -resistant Depression  
 
92 
Table 6 
GAF and CORE-OM Missing Values 
Allocation group GAF rating 
at Baseline 
GAF rating 
at 18 
months 
GAF rating 
at 42 
months 
CORE-OM 
at Baseline 
CORE-OM 
at 18 
months 
CORE-OM 
at 42 
months 
TAU N 
Valid 62 44 44 59 38 39 
Missing 0 18(29%) 18(29%) 3(4.8%) 24(38.7%) 23(37.1%) 
LTPP N 
Valid 67 52 47 63 45 42 
Missing 0 15(22.3%) 20(29.9%) 4(6%) 22(32.8%) 25(37.3%) 
 
The GAF and CORE-OM baseline mean values of those participants who did not complete the 
measures at 18- and 42-months were compared to those who competed them. No significant 
differences were found, indicating that the participants whose values were missing at the latter 
two time-points, were not better or worse in terms of their global functioning and psychological 
distress than those for whom data was available throughout. 
Fonagy et al. (2015) reported that “missing values were not a major problem” (p.315) in the 
TADS data analysis, with outcome measures data being available across all time-points for 82% 
of the participants for the primary measures (HRDS-17) and 75% - for the secondary measures 
(GAF and CORE-OM). No significant difference in completion rates was reported between the 
TAU and LTPP groups. 
The author decided to treat missing values by excluding them from any subsequent data 
analyses, as opposed to computing missing values, by, for example, using data available at the 
nearest other time-point when an outcome measure was completed (e.g. at 12- or 15-months). 
This decision was made as it was considered that “borrowing” scores from earlier/later time-
points will complicate and confuse the subsequent interpretation of the results. 
The rest of this chapter presents the results of the different statistical analyses performed in order 
to investigate the relationship between borderline personality, and treatment outcome. The 
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SWAP-II provides both categorical, as well as dimensional data. The analysis of each is reported 
in turn. 
3.3. Personality Disorder Features and Diagnoses 
The introduction and method chapters described some of the current limitations of the DSM-IV 
personality disorders taxonomy. The developers of the SWAP-II claim that the empirically 
derived personality syndromes are an improved alternative to the current Axis-II classification 
(Shedler, 2015; Westen et al., 2012). The author of this thesis decided to therefore use the ten 
SWAP personality syndromes, as a primary measure of personality disorder and the SWAP-II 
“personality health” syndrome, as specified in the methods chapter. 
Graph 1 below presents the categorical prevalence for all 10 SWAP-II personality disorders at 
baseline (TAU N=62, LTPP N=66). The reader is reminded that the SWAP-II cut-off T-score for 
personality disorder is 60. All participants were rated on the SWAP-II at baseline, except for one 
person in the LTPP group, where there was insufficient information for the scoring to be 
completed. 
Graph 1  
SWAP-II Personality Disorders Prevalence at Baseline  
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An independent t-test was carried out, in order to check for significant differences between the 
two groups for each of the SWAP-II personality disorder scales, at baseline, as well as for the 
“personality health” scale. No such differences were identified through the analysis (Appendix 
P). 
Graph 2 displays the personality disorders prevalence for the TAU and LTPP groups at 18 
months (N=55 for both groups). No significant between-group differences were identified at this 
time point, either (Appendix Q). 
Graph 2  
SWAP-II Personality Disorders Prevalence at the End of Treatment (18 months) 
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3.3.1. Borderline-dysregulated prototype 
Graph 3 below presents the categorical distribution for the borderline-dysregulated personality 
prototype for each time-point and allocation group. 
Graph 3 
SWAP-II Borderline-dysregulated Prototype Frequency at Baseline and End of Treatment 
 
 
Of note, although there is no significant difference between the TAU and LTPP group in their 
borderline-dysregulated mean values, the graph above shows that only five people in the TAU 
group met criteria for significant features, and none for borderline-dysregulated personality 
disorder, compared to nine people meeting criteria for features and two for personality disorder 
in the LTPP group at baseline. The categorical distribution was more even between the two 
groups at the end of the treatment period, as shown in the graph. 
Graph 4 presents the borderline personality disorder prevalence, as measured by the SCID-II-PQ. 
A cut-off score of 5 on the BPD sub-scale was used, in order to establish which patients met 
SCID-II-PQ criteria for the disorder (van Alebeek, van der Heijden, Hessels, Thong, & van 
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at baseline and end of treatment, than measured by the SWAP-II (10 patients in the TAU group 
and 14 – in LTPP). The SCID-II-PQ also had much higher missing values than the SWAP at the 
end of treatment (27 in TAU and 30 in LTPP, compared to 7 in TAU and 12 in LTPP for the 
SWAP-II).  
Graph 4 
SCID-II-PQ Borderline Personality Disorder Frequency at Baseline, End of Treatment, and End of Follow-up 
 
3.3.2. SWAP-II personality disorders comorbidity 
The TADS patient group was characterised not only by high prevalence of personality disorder, 
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Graph 5 
SWAP-II Multiple Personality Disorders Prevalence 
 
The average number of personality disorders, as measured by the SWAP-II and SCID-II-PQ, 
was also calculated and is presented in Table 7, together with the total number of cases, and the 
number of missing values. The SCID-II-PQ cut-off scores for each disorder varied, ranging from 
3 to 6 (First et al., 1997).  
Table 7 
Average Number of Personality Disorders, as Measured by the SWAP-II and SCID-II-PQ 
Allocation 
group     
SWAP-II 
Baseline 
SWAP-II End 
of treatment 
SCID-II-PQ 
Baseline 
SCID-II-PQ 
End of 
treatment 
SCID-II-PQ 
End of 
follow-up 
TAU  Mean   1.9 2.13 4.21 3.38 3.52 
 N Valid 62 55 61 34 31 
   Missing 0 7 1 28 31 
LTPP  Mean   1.92 2.07 4.56 3.61 2.89 
 N Valid 66 55 62 36 35 
   Missing 1 12 5 31 32 
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An independent t-test did not identify any significant differences between the two groups (at any 
of the times points, and for neither of the two personality measures). A paired sample t-test did 
not find any significant differences in the number of SWAP-II PDs at the end of treatment, 
compared to baseline, in either group. 
3.4. Borderline-dysregulated Personality as a Categorical Variable 
3.4.1. Cross-tabulation analysis 
The categorical distribution for the borderline-dysregulated syndrome was presented at the 
beginning of this chapter. Graphs 6 and 7 display the HDRS-17’s categorical distribution at 
baseline, end of treatment and follow-up, for each of the treatment groups. 
Graph 6 
HDRS Categorical Distribution in the TAU Group 
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Graph 7 
HDRS Categorical Distribution in the LTPP Group 
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3.4.2. Patients with borderline-dysregulated features or disorder 
As identified at the beginning of this chapter (Graph 3), few participants scored high enough on 
the SWAP-II borderline-dysregulated prototype scale, to be considered as having significant 
borderline features or borderline personality disorder at baseline (TAU N = 5, LTPP N = 11).  
A one-way repeated measures ANOVA with Bonferoni post-hoc tests was conducted to 
determine whether there was a statistically significant difference in HDRS-17, CORE-OM and 
GAF scores in the course of treatment and follow-up for each group. There was an increase of 
the GAF scores in the LTPP group from 43.33 ± 7.737 at baseline to 55.00 ± 8.672 at the end of 
treatment. This increase of 11.667 ± 3.201 [mean ± standard error] points was statistically 
significant (p < .05). No other statistically significant changes in the three outcome measures’ 
scores were identified. 
This suggests that despite their lack of significant improvement of depression and psychological 
distress, patients who scored as having borderline features or disorder at baseline in the LTPP 
group did present with better general functioning after 18 months of therapy. The reader is 
reminded, however, that the GAF is a clinician-rated measure. The implication of this, together 
with some further limitations of the GAF, will be discussed in the final chapter of this thesis. 
The same set of analyses was carried out for those who met borderline features or disorder 
criteria at 18 months (TAU N = 9, LTPP N = 10). No significant changes in the HDRS-17, 
CORE-OM and GAF scores were identified in either group, which suggests that these patients 
did not benefit from the treatment, nor did they deteriorate, based on their scores on the three 
outcome measures. A paired-sample T-test identified, however, a significantly higher SWAP-II 
borderline-dysregulated score at the end of treatment (56.67 ± 1.414), compared to baseline (51 
± 5.326), t (8) = -3.604, p < .05, in the TAU group. 
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These results should be considered with caution due to the low number of patients who met 
borderline-dysregulated features/disorder criteria, making the comparison of mean values less 
reliable in detecting trends and changes.  
Looking at individual scores and change patterns might therefore be more meaningful, despite 
having very limited value in drawing generalisible conclusions. Appendices Qa and Qb present a 
summary of this group of patients’ borderline-dysregulated scores at baseline and at the end of 
treatment, including the calculated borderline and depression change scores. One trend that can 
be observed when the individual cases are studied, is that in both groups some patients change 
categorically from having borderline “features” at baseline to “no features” at the end of 
treatment, whilst others moved from “no features” to “features”. In many of the cases the change 
score was > 5 points (half a Standard Deviation). Likewise, some patients in both groups 
experienced improvement in their depression, whilst others remained as depressed or 
deteriorated. As reported above, however, the mean pre- and post-treatment/post-follow up 
values were not significantly different, which suggests that any further conclusions about trends, 
based on individual case analyses, should be made with caution. 
3.4.2.1. Borderline patients’ full personality profile 
A previous section in this chapter presented the personality disorders prevalence and rates of 
comorbidity in the TADS sample. Like the rest of the TADS patients, those who scored as 
having features or disorder on the borderline-dysregulated scale, also scored above the SWAP-II 
55-point cut-off on at least one more of the prototype scales. Graph 8 presents the full pre-and 
post-treatment personality profile of one of the three LTPP patients, who met criteria for 
borderline-dysregulated disorder. The full personality profiles of the other two LTPP patients, as 
well as of the TAU patient who met criteria for BPD at 18 months, can be found in Appendix R. 
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Graph 8 
Patient 114 SWAP-II Personality Profile 
 
Whilst no generalisable conclusions can be drawn from this data, it illustrates the complexity of 
these patients’ presentation and alerts against thinking about each person only in terms of their 
borderline-dysregulated presentation. It is also interesting that all four patients scored 
significantly higher on the SWAP-II personality health scale at the end of treatment, despite their 
personality difficulties persisting, as captured by the other subscales, at that time point. 
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patients who presented with borderline-dysregulated features. A similar complexity of 
personality presentation, as captured by the SWAP-II scores, was observed there, too. 
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symptoms at the end of treatment and follow-up. Conversely, negative change score values 
indicate deterioration in the patient’s presentation at the end of treatment and 2-year follow-up. 
For the GAF change score, the baseline score was subtracted from the 18- and 42-month scores, 
as an increase in score indicates improvement in general functioning. Like with the HDRS-17 
and CORE-OM change scores, a positive GAF change score thus denotes improvement, and a 
negative one – a deterioration in functioning. 
A number of variables were included in the correlational analyses, as follows: 
 Outcome measures change scores (HDRS-17, GAF and CORE-OM) 
 Borderline-dysregulated disorder scores, as measured by the SWAP-II  
 Participants’ age at baseline 
 Number of attended therapy sessions (for the LTPP group) 
 Number of Axis I disorders at baseline, end of treatment, and follow-up 
Whilst this thesis is primarily concerned with the relationship between the borderline-
dysregulated personality syndrome, as measured by the SWAP-II, and depression, as measured 
by the HRDS-17, the author decided to test whether any of the other above-listed variables have 
a significant relationship with the change scores of the three outcome measures. This decision 
was made because, as discussed in the introduction chapter of this thesis, many authors have 
reported personality disorders to predict poor treatment outcome (e.g. Petersen et al., 2002). The 
same has been argued to be true for multiple Axis-I diagnoses, reflecting clinical complexity and 
consequently – poorer prognosis when only one condition, such as depression, is targeted during 
treatment (e.g. Zimmerman et al., 2014). Finally, the number of attended sessions has also been 
found by some authors to moderate treatment outcome (e.g. Hundt et al., 2014; Roseborough, 
2005). 
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The statistical exploration of the above was undertaken, in order to establish whether any other 
variables, besides the borderline-dysregulated personality syndrome, might interact with 
treatment outcome, and thus might need to be controlled for in the next stages of the data 
analysis.  
All tests of correlation were run using the Pearson correlation statistic, after assumptions of 
normal distribution were tested and established for all variables included in the analyses. Graph 
9 below gives an example of the HDRS-17 histogram (testing normal distribution) at 18 months. 
The same analysis of normality was run for the remaining variables too. 
Graph 9 
HDRS-17 Histogram at 18 months 
 
 
Two - tailed tests were deemed appropriate, as the author could not make an advance prediction 
about the direction of correlations.  
3.5.1.1. Borderline-dysregulated Q-sort correlation with the number of Axis I disorder, 
and the outcome measures  
The SWAP-II borderline-dysregulated Q-factor baseline score, the number of Axis I disorders at 
baseline, 18- and 42-months, and the three outcome measures’ change scores at 18- and 42-
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months were all correlated. The results are presented in Table 8 overleaf. As can be seen, the 
borderline-dysregulated prototype baseline score did not correlate significantly with any of the 
other variables in the TAU group. There was, however, a significant relationship between this 
personality prototype score and the number of Axis I disorders at 18- and 42-months in the LTPP 
group (r = 504, p < .01, and r = .347, p < .05, respectively), which suggests that the more 
patients resembled a borderline personality disorder presentation at baseline, the more Axis I 
disorders they had at the end of treatment and at a 2-year follow-up.  
The number of Axis I diagnoses at baseline was not significantly related to any of the outcome 
variables’ change scores. Higher number of Axis I disorders at the end of treatment was only 
linked to less improvement in general functioning at 42 months in the LTPP group (r = -.312, p 
< .05). Changes in psychological distress (as measured by the CORE-OM) were not significantly 
linked to the number of Axis I disorders or to the SWAP-II borderline-dysregulated prototype 
score. 
In both the TAU and LTPP groups, a higher number of Axis I diagnoses at 42-months were 
related to less improvement in depression at follow-up (but not the end-of-treatment) (r = -.426, 
p < .01, and r = -.491, p < .01, respectively). More Axis I diagnoses at 42 months was also 
linked to less improvement in general functioning (as measured by the GAF) at the end of 
treatment and follow-up in the LTPP group (r = -.368, p < .01, and r = -.494, p < .01, 
respectively).  
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Table 8 Correlation Coefficients between the SWAP-II Borderline-dysregulated Q-factor, Number of Axis-I Disorders, HDRS-17, GAF and CORE-OM 
Allocation 
group 
 
Borderline-
Dysregulated  
Number of 
Axis I 
diagnoses 
at Baseline 
Number of 
Axis I 
diagnoses 
18m  
Number of 
Axis I 
diagnoses 
42m  
HDRS 
Change 
Score 
18m 
HDRS 
Change 
Score     
42m 
GAF 
Change 
Score 
18m  
GAF 
Change 
Score 
42m 
CORE 
Change 
Score 
18m  
CORE 
Change 
Score 
42m 
TAU 
Group 
Borderline-
Dysregulated  
N 
1 
62 
-0.036 
62 
0 
46 
0 
46 
-0.012 
46 
0.007 
45 
0.189 
44 
0.21 
44 
0.005 
35 
-0.048 
36 
 
Number of 
Axis I 
diagnoses 
Baseline 
N 
-0.036 
62 
1 
62 
.675** 
46 
.630** 
46 
-0.081 
46 
-0.022 
45 
0.147 
44 
0.121 
44 
0.018 
35 
-0.037 
36 
 
Number of 
Axis I 
diagnoses 18m  
N 
0 
46 
.675** 
46 
1 
46 
.679** 
39 
-.309* 
44 
-0.232 
38 
-0.074 
43 
0.111 
37 
-0.035 
33 
-0.146 
30 
 
Number of 
Axis I 
diagnoses 42m  
N 
0 
46 
.630** 
46 
.679** 
39 
1 
46 
-0.241 
38 
-.426** 
43 
0.171 
37 
-0.228 
42 
-0.188 
28 
-0.322 
33 
LTPP  
Group 
Borderline-
Dysregulated   
N 
1 
66 
0.175 
66 
.504** 
50 
.347* 
46 
-0.056 
51 
0.054 
46 
-0.079 
51 
0.135 
46 
0.086 
42 
0.084 
42 
 
Number of 
Axis I 
diagnoses at 
Baseline 
N 
0.175 
66 
1 
67 
.680** 
51 
.539** 
46 
-0.047 
52 
-0.192 
47 
-0.254 
52 
-0.11 
47 
0.221 
43 
0.141 
42 
 
Number of 
Axis I 
diagnoses 18m 
N 
.504** 
50 
.680** 
51 
1 
51 
.742** 
44 
-0.265 
51 
-0.249 
44 
-.312* 
51 
-0.119 
45 
-0.035 
42 
-0.091 
40 
 
Number of 
Axis I 
diagnoses 42m 
N 
.347* 
46 
.539** 
46 
.742** 
44 
1 
46 
-0.177 
44 
-.491** 
45 
-.368* 
44 
-.494** 
46 
-0.033 
37 
-0.284 
42 
** Correlation is significant at the 0.01 level (2-tailed); * Correlation is significant at the 0.05 level (2-tailed). 
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3.5.2. The Borderline-dysregulated change score 
Finally, a borderline-dysregulated change score was calculated, too, by subtracting the T-score at 
18-months from the baseline score. A positive change score value thus denotes a decrease on the 
borderline-dysregulated prototype sub-scale, whilst a negative score denotes a score increase (i.e. 
the person resembling more the borderline-dysregulated pure prototype).  
The rationale for calculating the change score was that, as presented in the introduction chapter 
of this thesis, most authors agree that it is difficult to establish a causal link between personality 
disorders and depression, and some have argued that prolonged experiences of depression may 
lead to personality changes, in turn. The author therefore decided to investigate whether changes 
in the borderline-dysregulated prototype score were related to changes in depression, general 
functioning and psychological distress, as well as to the number of Axis I disorders, at the three 
different time-points. These results are presented in Table 9 overleaf. 
With regards to the three outcome measures, in the TAU group a decrease of the borderline-
dysregulated score was related to a decrease in depression at 18-months (r = .324, p < .05), to 
increase in general functioning at 18- and 42-months (r = .438, p < .01; and r = .372, p < .05), 
and to decrease in psychological distress at 18 months (r = .548, p < .01).  
In the LTPP group a lower borderline-dysregulated score was significantly related only to 
decrease in depression at 42-months (r = .319, p < .05). 
In neither of the groups were changes in the borderline-dysregulated score significantly 
associated with the number of Axis I disorders at baseline, end of treatment or end of follow-up. 
A decrease in the borderline-dysregulated score was, however, associated with an increase in the 
personality health Q-factor score, in both groups.  
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Table 9 
Correlation Coefficients between the SWAP-II Borderline-dysregulated and Personality Health Change Scores, and Number of Axis I Disorders, HDRS-17, GAF and CORE-
OM 
Allocation 
group   
Borderline 
Dysregulated 
Change 
Score 
Personality 
Health 
Change 
Score 18m 
HDRS-
17 
Change 
Score at 
18 
months 
HDRS-
17 
Change 
Score at 
42 
months 
GAF 
Change 
Score at 
18 
months 
GAF 
Change 
Score at 
42 months 
CORE-
OM 
Change 
Score at 
18 months 
CORE-
OM 
Change 
Score at 
42 months 
Number of 
Axis I 
diagnoses 
at Baseline 
Number of 
Axis I 
diagnoses 
at 18 
months 
Number of 
Axis I 
diagnoses 
at 42 
months 
TAU 
  
  
  
  
  
Borderline 
Dysregulated 
Change Score 
1 .500** .324* .275 .438** .372* .548** .193 -.053 .011 -.065 
N 55 55 46 45 44 44 34 35 55 45 45 
Personality 
Health 
Change Score  
.500** 1 .108 .163 .153 .149 .260 .010 -.128 .166 -.050 
N 55 55 46 45 44 44 34 35 55 45 45 
LTPP 
  
  
  
  
  
Borderline 
Dysregulated 
Change Score 
1 .454** .224 .319* .131 .239 .306 .287 -.113 -.121 -.145 
N 54 54 50 46 50 46 41 42 54 50 46 
Personality 
Health 
Change Score  
.454** 1 .200 .398** .319* .415** .306 .461** .002 -.069 -.303* 
N  54 54 50 46 50 46 41 42 54 50 46 
**. Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed).
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3.5.3. The personality health change score 
As noted above, increased SWAP-II personality health scores were linked to decreased 
borderline-dysregulated score in both groups (r = .500, p < .01, and r = .454, p < .01, for the 
TAU and LTPP groups respectively). 
In addition, in the LTPP group a higher personality health score at the end of treatment was also 
related to a decrease in depressive symptoms at 42-months (HDRS-17) (r = .398, p < .01), 
increase in general functioning (GAF) and 18- and 42-months (r = .319, p < .05, and r = .415, p 
< .01, respectively), and decrease in psychological distress (CORE-OM) at 42 months (r = .461, 
p < .01). The personality health change score was negatively related to the number of Axis I 
disorders at 42 months, too (r = -.303, p < .05), indicating that the bigger the increase in 
personality heath, the fewer the Axis I diagnoses at follow-up. 
In the TAU group the personality health change score did not correlate significantly with any of 
the outcome measures, or with the number of Axis I disorders at the three time points. 
3.5.4. The rest of the SWAP-II Q-factors change scores  
The SWAP-II was developed as an overall measure of personality, and individuals receive a 
score on all prototype subscales. These scores are subsequently interpreted in relation to one 
another, in order to make clinical sense of the person’s overall presentation. It would therefore 
be artificial and clinically meaningless to explore only the borderline-dysregulated prototype in 
isolation, without considering how it relates to the other personality prototypes.  
Furthermore, it is in the nature of correlational analysis that it tells us little about causation or the 
impact that other variables might have on the outcome measures of interest. More specifically, 
depression might be linked to other personality constellations, which might or might not in turn 
also be related to the borderline-dysregulated prototype. 
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In order to investigate this hypothesis, the author carried out a correlational analysis of the rest of 
the Q-factor prototypes’ change scores and the three outcome measures. The correlation statistics 
are presented in Appendix S. 
There were a number of significant correlations between different SWAP-II prototype change 
scores. For the purposes of the current project, it would suffice to focus on those personality 
prototype change scores that had a statistically significant relationship to the borderline-
dysregulated score and to the three outcome measures’ change scores. This is summarised in 
Table 10. 
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Table 10 
Correlation Coefficients Between the SWAP-II Personality Prototypes’ Change Scores, and the HDRS-17, GAF and 
CORE-OM  
Allocatio
n group   
Borderline 
Dysregulate
d Change 
Score 
Personalit
y Health 
Change 
Score 
HDRS-
17 
Chang
e Score 
18m 
HDRS-
17 
Chang
e Score 
42m 
GAF 
Chang
e Score 
18m  
GAF 
Chang
e Score 
42m 
CORE-
OM 
Chang
e Score 
18m 
CORE-
OM 
Chang
e Score 
42m 
TAU 
  
  
  
  
  
Dependent-
Victimised 
Change 
Score -0.218 -0.055 0.036 -0.11 -0.162 -.372* -0.037 -0.08 
N 55 55 46 45 44 44 34 35 
Paranoid 
Change 
Score  .455** .349** 0.142 0.141 0.083 0.083 0.214 0.112 
N 55 55 46 45 44 44 34 35 
Obsessiona
l Change 
Score -.378** -0.077 -0.24 -0.258 -0.19 -.369* -0.078 0.128 
N 55 55 46 45 44 44 34 35 
LTPP 
  
  
  
  
  
Depressive 
Change 
Score 0.058 0.245 0.119 .357* 0.164 .499** .311* 0.227 
N 54 54 50 46 50 46 41 42 
Anxious 
Avoidant 
Change 
Score  0.041 .471** 0.228 .436** .404** .568** 0.261 .351* 
N  54 54 50 46 50 46 41 42 
Dependent-
Victimised 
Change 
Score  .303* 0.141 0.07 0.255 -0.229 0.063 0.101 0.039 
N  54 54 50 46 50 46 41 42 
Paranoid 
Change 
Score  .439** .458** 0.23 0.115 0.115 -0.019 0.21 0.198 
N  54 54 50 46 50 46 41 42 
Hysteric-
Histrionic 
Change 
Score  0.247 -0.02 -0.013 -0.099 -0.275 -.344* 0.02 -0.085 
N 54 54 50 46 50 46 41 42 
**. Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed). 
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As displayed in table 10, in the TAU group none of the SWAP-II personality prototype change 
scores were significantly related to changes in depression, except for the borderline-dysregulated 
change score (Table 8). Interestingly, patients who scored higher on the dependent-victimised 
and obsessional scales at the end of treatment, compared to their baseline scores, also tended to 
have better general functioning at 42 months (as measured by the GAF). An increase in the 
obsessional personality score was also linked to a decrease in the borderline-dysregulated scores 
at the end of treatment, whereas a decrease in patients’ paranoid score was associated with less 
resemblance with the borderline prototype.  
In the LTPP group lower depressive and anxious-avoidant personality scores were linked to a 
decrease in depression severity and increased general functioning at 42 months. The reader is 
reminded that the borderline-dysregulated change score was significantly related to the HDRS 
change score at 42 months, as well. Decreases in anxious-avoidant personality scores were 
significantly linked to better general functioning at the end of treatment and to less psychological 
distress at the end of follow-up, too. The dependent-victimised and paranoid change scores were 
not related to any of the outcome measures, but a decrease on both scales was associated with a 
decrease on the borderline-dysregulated scale. Finally, patients who presented as more hysteric-
histrionic at the end of treatment also seemed to function better at the end of the follow-up 
period. Both the hysteric-histrionic and the dependent-vicitimised mean scores at 18 months 
were significantly lower than those at baseline, as reported earlier in this chapter. 
An increase in personality health at the end of treatment, as measured by the SWAP-II, was 
associated with a decrease in paranoid features in both groups, and with lower anxious-avoidant 
personality scores in the LTPP group. 
3.5.5. Borderline-dysregulated prototype item analysis 
The results presented in the previous section indicate a significant association between the 
borderline-dysregulated change score and a number of the outcome variables in both groups. In 
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addition, the changes in patients’ degree of resemblance to the borderline-dysregulated 
personality disorder appeared to be linked to other personality changes, including to the patients’ 
“personality health”.  
These results are interesting, given the small number of patients who met the criteria for 
borderline features or disorder. The author therefore decided to analyse the correlations between 
the 12 borderline-dysregulated SWAP-II items which had fair or excellent inter-rater agreement 
(as reported at the beginning of this chapter), and the three outcome measures’ change scores. 
This was calculated both for the borderline items’ scores at baseline, as well as for the borderline 
items’ change scores. 
Tables 11a and 11b present the statistically significant correlations (the rest of the statistics can 
be found in Appendices Ta and Tb). 
The results presented in Table 11a show that only a few of the SWAP-II borderline-dysregulated 
items correlated with the three outcome measures. In the TAU group those were three items 
representing insecure attachment, chaotic life-style and self-harm. More specifically, higher 
scores on the item indicating “unstable, chaotic, and rapidly changing” relationships at baseline 
were associated with less improvement in depression and general functioning at the end of 
treatment. Patients who presented as having urges to kill themselves were also less likely to 
experience a decrease in psychological distress by the end of follow-up. Interestingly, feeling 
more fearful of rejection or abandonment at baseline was associated with a decrease in 
psychological distress at 42 months, as measured by the CORE-OM. 
In the LTPP group higher scores on the item reflecting tendency to stir up conflict or animosity 
in others were linked to patients reporting less psychological distress at the end of follow-up. 
A number of the borderline-dysregulated items’ change scores were associated with treatment 
outcome at 18- and 42-months in both groups (Table 11b). In the TAU group, a decrease in 
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affect dysregulation and insecure attachment and an increase in chaotic relationships were all 
associated with improvement in depression at 42 months. Decreased scores on two further items 
indicating affect dysregulation were associated with better general functioning at 42 months.  
In the LTPP group, a decrease in depression at the end of follow-up was only linked to a 
decrease in affect dysregulation (the person’s tendency to become less rational when 
experiencing strong emotions). A decrease in insecure attachment (feeling misunderstood and 
victimized) was associated with improved general functioning at the end of treatment, and 
decrease in splitting (stirring up conflict and animosity between others) was related to less 
psychological distress at the end of follow-up. 
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Table 11a 
Borderline-dysregulated Baseline Items Correlations with the HDRS-17, GAF and CORE-OM  
Allocation 
group SWAP-II Item Item type 
HDRS-17 
Change Score 
at 18 months 
HDRS-17 
Change Score 
at 42 months 
GAF Change 
Score at 18 
months 
GAF Change 
Score at 42 
months 
CORE 
Change Score 
at 18 months 
CORE 
Change Score 
at 42 months 
TAU 
Tends to fear she/he will be 
rejected or abandoned 
Insecure 
attachment 0.219 0.005 0.098 -0.09 .385* .382* 
N 
 
46 45 44 44 35 36 
Relationships tend to be 
unstable, chaotic, and rapidly 
changing 
Chaotic 
lifestyle -.313* -0.202 -.344* -0.02 0.068 0.065 
N 
 
46 45 44 44 35 36 
Struggles with genuine wishes 
to kill him/herself Self-harm -0.075 -0.099 -0.158 -0.091 -0.219 -.345* 
N  46 45 44 44 35 36 
LTPP 
Tends to stir up conflict or 
animosity between other 
people Splitting 0.153 0.222 0.042 0.214 .363* .418** 
 N  51 46 51 46 42 42 
**. Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed). 
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Table 11b 
Borderline-dysregulated Items’ Change Scores Correlations with the HDRS-17, GAF and CORE-OM  
Allocation 
group 
SWAP-II Item Item type 
HDRS-17 
Change Score 
at 18 months 
HDRS-17 
Change Score 
at 42 months 
GAF Change 
Score at 18 
months 
GAF Change 
Score at 42 
months 
CORE 
Change 
Score at 18 
months 
CORE 
Change 
Score at 42 
months 
TAU 
Emotions tend to spiral out of 
control, leading to extremes of 
anxiety, sadness, rage, etc. 
Affect 
dysregulation 0.091 .386* 0.186 0.302 0.182 0.157 
N  39 39 38 39 31 35 
Tends to feel misunderstood, 
mistreated or victimized 
Insecure 
attachment 0.253 .385* 0.142 0.26 0.208 0.202 
N  39 39 38 39 31 35 
Relationships tend to be 
unstable, chaotic, and rapidly 
changing 
Chaotic 
lifestyle -0.307 -.480** -0.176 -0.232 -0.091 -0.19 
N  39 39 38 39 31 35 
Is prone to intense anger, out of 
proportion with the situation at 
hand 
Affect 
dysregulation -0.02 0.147 0.093 .317* 0.063 0.181 
N  39 39 38 39 31 35 
Emotions tend to change rapidly 
and unpredictably 
Affect 
dysregulation -0.088 0.137 0.102 .445** 0.142 0.059 
N  36 36 35 36 29 32 
LTPP 
Tends to stir up conflict or 
animosity between other people Splitting 0.096 0.276 0.018 0.158 0.163 .350* 
N  44 41 44 41 37 38 
Tends to feel misunderstood, 
mistreated or victimized 
Insecure 
attachment 0.241 0.077 .358* 0.068 0.114 0.163 
N  44 41 44 41 37 38 
Tend to become irrational when 
strong emotions are stirred up 
Affect 
dysregulation 0.11 .327* -0.013 0.253 -0.028 0.144 
N  44 41 44 41 37 38 
**. Correlation is significant at the 0.01 level (2-tailed), * Correlation is significant at the 0.05 level (2-tailed).  
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3.5.6. Regression Analysis 
A regression analysis was finally carried out, in order to test whether participants’ SWAP-II 
borderline-dysregulated score at baseline predicts their HDRS-17, GAF and CORE-OM change 
scores at 18 and 42 months. 
The full regression statistics are presented in Appendix U. None of the regression models 
reached a significance level of p < .05. 
The regression analysis results also indicated that very little of the variation in any of the three 
outcome measures’ change scores could be accounted for by the borderline-dysregulated SWAP-
II score at baseline. Given that most of the participants had a borderline-dysregulated baseline 
score below 55, these regression results give little information about the impact that borderline-
dysregulated features or disorder have on treatment outcome. This question was partially 
addressed earlier in this chapter, where the analysis results for those who met the SWAP-II 
criteria for borderline features or disorder were presented. The small number of those 
participants did not allow for further statistical analyses to be carried out, however. 
The results presented in this chapter will be further interpreted in the final, discussion chapter of 
this thesis next.
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4. Discussion and Conclusion 
The introduction chapter presented the concepts of treatment resistant depression and borderline 
personality disorder, as understood through the medical and psychoanalytic models.  
In reviewing the literature to date, it became apparent that theoretical differences aside, most 
researchers and clinicians agree that personality plays at least some role in the course and 
treatment of depression. This is evidenced by the high rates of psychiatric comorbidity between 
depression and personality disorders, as well as by the number of research studies investigating 
the link between personality disorder and/or personality traits and depression. Borderline 
personality disorder, in particular, has been the subject of many such investigations. Yet, no 
study to date has addressed the link between borderline personality disorder, treatment resistant 
depression and treatment outcome, particularly in the course of psychodynamic psychotherapy.  
Moreover, most studies of personality disorder and depression have used a categorical approach 
to personality, where the presence/absence of a disorder is considered. The role of personality 
disorder features, in the absence of a formal diagnosis has been so far generally neglected in the 
literature. Of note, what is meant by “features” in the current study is the degree of resemblance 
to borderline personality disorder in individuals, who do not present with the full features of the 
disorder and are therefore not diagnosed with BPD. 
The current study has attempted to address this gap in the literature, which is of both theoretical 
and clinical relevance. The borderline-dysregulated personality prototype, as measured by the 
SWAP-II, was used in studying borderline personality both as a dimensional, as well as a 
categorical variable. Its relationship to the three TADS outcome measures – the HDRS-17, the 
CORE-OM and the GAF was explored in both the treatment as usual (TAU) and in the long-term 
psychotherapy (LTPP) group. A summary of these findings, together with their interpretation, is 
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presented in this final chapter. The chapter finishes with a discussion of the limitations of this 
study, as well as some suggestions for future research and clinical practice directions. 
4.1. Interpretation of Results 
4.1.1. Borderline-dysregulated personality  
4.1.1.1. Borderline-dysregulated features and disorder 
The borderline-dysregulated score at baseline did not correlate significantly with any of the 
outcome measures in either group. This result should not be confused with borderline personality 
disorder not being related to or predictive of treatment outcome, however, as none of the TAU 
patients, and only two (3%) of the LTPP patients met criteria for BPD at baseline, as measured 
by the SWAP-II. Thus, the results only indicate that whether patients scored higher or lower on 
the borderline-dysregulated scale at baseline, did not have a significant link to their depression, 
general functioning and psychological distress at the end of treatment and follow-up.  
A small number of patients in each group - 5 (8%) in TAU and 11 (16%) in LTPP - met SWAP-
II criteria for having significant borderline-dysregulated features or disorder (although there 
were only two people who scored above cut-off for disorder and they were both in the LTPP 
group). These figures are somewhat in line with epidemiological statistics of 6% BPD 
prevalence in primary care settings, and 10% in outpatient clinical settings (APA, 2013).  
A correlational analysis explored the link between the borderline-dysregulated prototype, as a 
continuous variable, and the number of Axis I disorders at baseline, end of treatment, and end of 
follow-up. Interestingly, the borderline score did not correlate significantly with Axis I disorders 
at baseline in either group, but higher scores on the prototype at baseline were significantly 
linked to a higher number of Axis I disorders at 18- and 42-months in the LTPP group. In this 
group the higher number of Axis I disorders at the end of treatment and follow-up was also 
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linked to poorer general functioning, and to less improvement in depression (at the end of 
follow-up only). The number of Axis I disorders at 18- and 42-months in the TAU group was 
related only to smaller changes in depression scores at these two time points, but not to the 
borderline prototype, or to general functioning.  
The interpretation of these results is difficult, when based only on correlation statistics. One 
possible way of understanding the data is that in the LTPP group the more patients resembled the 
borderline-dysregulated prototype, the more likely they were to meet criteria for multiple Axis I 
disorders at the end of treatment and follow-up, which in turn is associated with poorer treatment 
outcome, as measured by the GAF (at 18 months) and the HDRS-17 and GAF (at 42 months). It 
is not possible to establish a causal relationship between any of the variables. Is seems plausible 
to argue, however, that in the LTPP group higher borderline-dysregulated scores were linked to 
greater clinical complexity, expressed in the multiple Axis I diagnoses at the end of treatment. A 
patient who presents with multiple difficulties, is therefore less likely to benefit significantly 
from a single intervention (Levy, 2016). The same results were not observed in the TAU group, 
where a correlation statistic of r = 0 indicated a non-linear relationship between the borderline 
score at baseline and the number of Axis I disorders at the end of treatment and follow-up.  
Finally, the results chapter offered a closer look at the full personality profiles of those patients 
who scored above 55 on the borderline-dysregulated SWAP-II scale, and therefore presented 
with significant features or with borderline-dysregulated disorder. Shedler (2016) warns against 
interpreting T-scores too rigidly, however, as the SWAP-II cut-off scores are provided as a 
guideline, as well as to ensure some “backward compatibility” with previous classification tools, 
such as the DSM, which presents personality disorders in categorical terms. Thus, the selection 
of those who had a borderline-dysregulated score ≥55 might not be the most clinically 
meaningful way to look at a sub-sample of patients. Yet, it is one way of choosing some cases 
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where borderline personality appears to be partially expressed, in order to investigate the 
implications it has for the treatment of depression. 
All patients who met criteria for borderline features or disorder either at baseline or at the end of 
treatment (or both) were presented, in terms of their borderline-dysregulated scores and outcome 
measures scores at the three time-points, together with the corresponding change scores. The 
borderline-dysregulated change score for most patients with borderline features/disorder was ≥5 
points, and for four patients it was ≥10 points. The reader is reminded that the SWAP-II 
prototype scales are standardised, with 10 points representing one standard deviation. A change 
in score equal to or larger than 10 points is considered both statistically, as well as clinically 
significant. Shedler (2016) further argues that a change of .5 standard deviations has clinical 
significance too, comparing this to recent NICE guidelines on clinically significant change in the 
use of anti-depressants. It can therefore be concluded that, for the majority of patients with 
borderline features or disorder in both TAU and LTPP groups, the treatment appeared to 
exacerbate their personality difficulties, rather than to alleviate them. This conclusion was 
statistically supported for the TAU group, where the post-treatment borderline-dysregulated 
mean score was significantly higher than the baseline one. 
Furthermore, these patients’ improvement in depression, general functioning and psychological 
distress was also questionable. In the TAU group only three people had a positive HDRS change 
score (indicating decrease in depression) at 42 months, and none of the patients reached full or 
partial remission of depression (HDRS ≤8, and ≤12, respectively). In the LTPP group there was 
a significant improvement on the GAF measure at 18 months, but no significant improvement of 
depression or psychological distress. A further look into the individual data showed that in the 
LTPP group 7 people had a positive HDRS change score at 42 months, but only one of them 
reached full remission (HDRS=4) and one – partial remission (HDRS=12).  
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A categorical distribution of the patients in terms of their depression score revealed no shifts at 
the end of treatment and follow-up, in comparison to baseline, for those who presented with 
borderline features/disorder at the end of treatment. On the contrary, having borderline features 
or disorder in the LTPP group at 18 months appeared to make it more likely that the patient also 
scored as severely or very severely depressed on the HDRS.  
These results are based on a very small sample, and should therefore be interpreted with caution. 
Yet, they pose some very important clinical and research questions. The first one is – can 
patients who present with borderline personality features or disorder, and depression, improve in 
terms of their depression? Previous RCTs, which looked at the effectiveness of treatments for 
BPD, suggest that they can. For example, five RCTs comparing the effectiveness of 
Mentalization Based Treatment (MBT) for BPD to other treatments, all reported a significant 
decrease in depressive symptoms, based on scores on the Beck Depression Inventory (Bateman 
& Fonagy, 2001; Bateman & Fonagy, 1999, 2009; Jørgensen et al., 2013) and the Mood and 
Feelings Questionnaire (Rossouw & Fonagy, 2012). In these studies a decrease in depression 
was also reported to be significantly greater for those in the MBT groups, compared to the other 
treatments. Another study, comparing Manualised Cognitive Behavioural Therapy to Treatment 
as Usual for BPD, also reported a significant decrease in depression, as measured by the HDRS, 
although the between-group differences were not statistically significant (Tyrer et al., 2004). It is 
thus important to consider why, in the TADS patient group, neither borderline features, nor 
depression appear to improve in the course of either of the treatments offered, for those who 
presented with borderline features/disorder. 
A recent, yet unpublished meta-analysis on the treatment of BPD, presented in the 22
nd
 Annual 
BACP Conference by Prof Kenneth Levy, might give some possible answers to this question 
(Levy, 2016). More specifically, Levy argued that borderline personality disorder is often not 
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recognised in outpatient clinical settings, and treatments are offered for other presenting 
difficulties, such as major depression. He considered this to have detrimental consequences for 
treatment outcome, as borderline personality disorder affects both the course and outcome of 
depression treatments, but not the other way around (an argument substantiated by the BPD RCT 
results reported above). He therefore warned against “privileging” the interventions for 
depression and linked this to research indicating that having even one BPD symptom increases 
the likelihood of suicide in patients being treated for mood disorders (e.g. Zimmerman et al., 
2014). Levy therefore stressed the importance of assessing patients who present with difficulties 
such as depression and anxiety, for underlying borderline personality symptoms, and stated that 
for many patients, borderline personality features remain undiagnosed for an average of 6-10 
years, which leads to under-treatment or mistreatment. He then presented the results of a meta-
analysis (in press), which included 73 studies on the treatment of BPD, and identified a number 
of common treatment factors, all believed to contribute to treatment effect sizes. These included 
the structured nature of BPD treatments, and the more active, engaged stance of the therapist, 
where particular attention is being paid to the therapeutic frame and relationship. In addition, 
therapists’ supervision was also reported to be an important therapeutic factor. 
This gives rise to the second question, namely: if depression can be treated in the context of 
borderline personality disorder (or features) what adjustments need to be made to treatment and 
how relevant is this to the outcomes of the TADS study? 
The first chapter of this thesis introduced some of the existing theories on borderline personality 
disorder. Relevant to this part of this discussion appears to be what mentalization theories 
suggest to be a main difficulty for patients diagnosed with BPD – namely to conceive, process 
and think about their own affective and mental states, as well as those of other people (Bateman 
& Fonagy, 2016). Target (2016) states: 
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“In infancy and psychotherapy, before affects can be symbolized and regulated, they need 
to be located in the inner world. Gradually the action they demand becomes metaphorical 
– lived out only in the embodied mental activity of unconscious phantasy.” (p.208) 
Fonagy & Luyten (2016) provide further rationale for adapting interventions for patients who 
present with borderline personality features. More specifically the authors point at the anxious-
preoccupied attachment strategies, characteristic of these patients. They put forward the 
argument that, in order to survive in context of early life adversity and trauma, individuals with 
BPD have lower threshold for attachment system activation – they are more sensitive to 
interpersonal stress, which in turn activates the amygdala system in the brain and leads to 
proximity seeking; this is, at the same time, associated with a deactivation of the “neural systems 
associated with controlled social cognition, including systems involved in judging the 
trustworthiness of others” (p.747), and leads to a “vicious interpersonal cycle” marked by high 
levels of both anxiety and avoidance. Fonagy & Luyten (ibid) further emphasise the adaptive 
function of anxious-preoccupied strategies in early life for individuals who were deprived of a 
stable and supportive environment, where emotional states have been recognised and thought 
about by the care-giver, fostering the development of mentalizing capacities and the ability to 
self-sooth and self-regulate. These strategies become, however, maladaptive, in different social 
context and further feed into chronic feelings of hopelessness and helplessness, which are 
expressed through negative affect, such as depression. 
The process of the therapist recognising affective states (including feelings of depression) and 
reflecting them back to the patient, was compared by Target (2016) to the process of “marked 
mirroring”, which leads to the individual beginning to first own, and then make sense of their 
emotional experiences. Only when this capacity is developed enough, she argued, can the patient 
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hear, understand and make use of the therapist’s other interventions, such as interpretations in a 
psychoanalytic treatment, for example.  
Bateman & Fonagy (2016) present further ideas about treatment modifications required for 
patiens who presenting with both depression and features of BPD. They argue that treatments for 
depression are bound to be unsuccessful, unless BPD is taken into account. This is due to 
limitations in these patients’ capacity for reflective functioning – namely, when strong emotions 
are experienced, the individual manages them through action (e.g. self-harming behaviours) 
rather than through thinking about their mental representaions of self- and others. High levels of 
arousal and anxiety are futher thought to be triggered by long silences in therapy, or focus on 
interpreations of the patient-therapist relationship; this is considered to be unhelpful, and on 
occasions even harmful to the patient. Bateman & Fonagy (ibid) therefore suggest that 
treatments for BPD and depression adopt and active, validating and supportive stance, where the 
initial focus is on recovering the capacity to mentalize, as suggested by Taget (2016), too. 
Implicit marked mirroring in both the TAU and LTPP might therefore be considered insufficient 
for those patients who present with borderline features or disorder. The lack of improvement in 
these patients’ personality presentation and depression suggests that more active adaptation of 
their treatment, and a more explicit consideration of their personality profiles might need to take 
place, if treatment is to be of significant and lasting benefit. 
Some important limitations are worth noting here, too. The first one is that the above-presented 
arguments are only partially based on statistical analysis of the data, which was carried out for 
the small number of TADS patients who met criteria for borderline features or disorder. This 
limits the findings’ reliability and generisability. 
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Second, most of these patients met criteria for at least one more personality disorder, as well as 
in many of the cases – for multiple personality features. Taylor (2003) pointed to the constant 
interaction between different aspects of the personality, as well as between personality and the 
environment. He stated that object relations, personality structure and the experience of 
symptoms are all “dimensional rather than categorical, and dynamic rather than static in nature” 
(Taylor, 2003, p. 28). Focusing on borderline personality features and depression alone, without 
examining the contribution of other personality features and wider environmental factors is 
bound to be a limited way of approaching patients’ presentation and treatment outcome. Yet, it is 
one step further in the direction of understanding the complex nature of these patients’ 
difficulties and the support needs they might have. 
Third, it is hard to ascertain the degree of clinical significance these personality changes hold. As 
noted already, Shedler (2016) suggested that a change score of more than 5 points on a scale 
level denotes a clinically significant change, whilst also stressing the importance of evaluating 
clinical significance on an individual, case-by-case basis, too. Furthermore, the DSM-5 advises 
against giving a BPD diagnosis to individuals diagnosed with depression, when only cross-
sectional information is available (APA, 2013). The Manual stresses the importance of 
ascertaining the longitudinal and enduring nature of personality pathology, as well as its onset in 
adolescence/early adulthood, which is one of the main criteria for PD diagnosis in the DSM. The 
same longitudinal approach would need to be taken when assessing personality changes. This 
was unfortunately not within the remit of the current project. 
Given the small number of patients who actually met criteria for borderline features or disorder, 
the author decided not to carry out any higher order analyses, such as analysis of variance, but 
rather to explore how changes in the borderline dysregulated score in the course of treatment 
related to treatment outcome. 
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4.1.1.2. Borderline-dysregulated personality change score 
A borderline-dysregulated personality change score was calculated in order to test whether 
changes in patients’ degree of resemblance of the borderline personality disorder prototype were 
significantly linked to changes in any of the outcome variables at the end of treatment and 
follow-up. Furthermore, as the borderline-dysregulated prototype is one of eleven Q-factor 
prototypes, change scores were also calculated for the remaining ten prototypes and correlations 
were calculated for all of them with each other.  
Presented below is the summary and interpretation of this set of analyses for each of the 
treatment groups. 
4.1.1.2.1. The LTPP group 
Four of the eleven SWAP-II personality prototypes’ change scores were significantly related to 
changes in one or more of the outcome measures. These were the depressive, anxious-avoidant, 
borderline-dysregulated and hysteric-histrionic scales.  
A decrease on the depressive and anxious-avoidant prototype score at the end of treatment was 
significantly linked to a decrease in the symptoms of depression both at 18- and 42-months, as 
well as to a decrease in psychological distress and increase in general functioning. Moreover, 
changes in the two personality prototypes were also significantly related to one another.  
A decrease in the hysteric-histrionic score, on the other hand, was only associated with an 
increase of the patient’s general functioning at the end of the follow-up period. Interestingly, this 
prototype was negatively correlated with the anxious-avoidant one.  
Lower scores on the borderline-dysregulated prototype were related to a decrease in depressive 
symptomatology at the end of the follow-up period, as well as with increase on the personality 
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health prototype. Increased personality health, in turn, was significantly related to a decrease in 
depressive symptoms, psychological distress, fewer Axis I disorders, and to an increase in 
general functioning, all at the end of the follow-up period. Furthermore, better personality 
functioning was also significantly related to lower scores on the anxious-avoidant and paranoid 
prototypes. Finally, the borderline-dysregulated prototype was significantly associated with the 
paranoid and the dependent-victimised prototypes (decrease in one leading to decrease in the 
other). 
Whilst it is hard to offer the reader a comprehensive interpretation of these results, which will 
account for all changes in the personality prototype scores in relation to the three outcome 
measures, the finding suggest that in the LTPP group changes in the different personality 
disorder features in the course of treatment and follow-up, was related to improvement in 
depression and general functioning. This appears in line with previous literature, where 
personality difficulties, in general, were linked to poor outcome in treatment-resistant depression 
(e.g. Petersen et al., 2002).  
What is more difficult to establish is whether there is a causal relationship – namely, whether a 
decrease in personality difficulties in general, and borderline personality disorder/features in 
particular, accounts for better treatment outcome for depression. Moreover, it could be argued 
that personality health is the product of, rather than the cause for, a decrease in depression, and 
the reduction in personality difficulties is also a consequence of individuals being less depressed, 
and therefore abler to function in the world. If this were indeed the case, however, one might 
expect that an increase in personality health and decrease in personality difficulties, as measured 
by higher change scores on the SWAP-II prototypes listed above, would be significantly related 
to lower depression scores, less psychological distress and better general functioning at the end 
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of treatment. This was indeed the case for the depressive and anxious-avoidant prototypes, but 
not for the borderline-dysregulated one, which is the main subject of this thesis. 
The statistically significant relationship between the borderline-dysregulated and personality 
health prototypes, on the one hand, and the outcome measures on the other hand at the end of the 
follow-up period, but not at the end of treatment, supports the hypothesis that personality 
difficulties and depression interact, rather than one leading to the other in a straight-forward 
manner (e.g. Howland & Thase, 2005; Kay, Garside, Beamish, & Roy, 1969; Scott, 1988). 
Furthermore, the link between changes in the borderline score and improvement in depression 
could also be accounted for by the so-called “sleeper effect” of psychodynamic psychotherapy 
(Fonagy et al., 2015). This refers to the observed increase in patients’ improvement in the LTPP 
group in the course of the two-year follow-up, which was argued to explain the bigger effect 
sizes of the difference between the LTPP and TAU groups, in relation to the main outcome data 
(ibid). In other words, patients’ functioning (personality as well as their experiences of 
depression) continued to improve in the follow-up period. 
Returning to the SWAP-II literature, the reader is also reminded that apart from the eleven 
personality prototypes, the SWAP developers also derived (through factor analysis) three 
overarching personality spectra: internalising, externalising and borderline, as well as a separate 
cluster of neurotic styles (Westen et al., 2012). These were presented in more detail in the 
methods chapter of this thesis, but Figure 5 overleaf reminds the reader of the spectra, and the 
specific PDs that fall under each of them. 
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Figure 5 
Hierarchical Structure of Personality Diagnoses (adapted from Westen et al., 2012)
 
It appears that the TADS patient group fell mostly in the internalising spectrum (particularly as 
the anxious-avoidant, depressive and schizoid-schizotypal disorders were also highly prevalent 
in the LTPP and TAU groups). Given the relatively low prevalence of borderline disorder and 
features, it seems unusual that this prototype, which also forms a separate personality spectrum 
(ibid) correlates with changes in the treatment outcome measures’ scores. The following 
definition by Shedler (2015) might be relevant to the interpretation of these results: 
“Individuals in the borderline-dysregulated spectrum are qualitatively distinct from stable 
internalizers or stable externalizers. Their perceptions of self and others are unstable and 
changeable, and they show impaired ability to regulate emotion. As a result, they tend to 
oscillate between emotions characteristic of both internalizing and externalizing spectrum 
pathology (e.g., depression, anxiety, rage). They may best be described as “stably 
unstable” (Schmideberg, 1959).” (Shedler, 2015, p. 241) 
This conceptualisation of the borderline presentation might make more meaningful the 
correlations between the borderline change score on the one hand, and both the dependent-
victimised and the paranoid prototype change scores. In other words, a decrease in borderline 
presentation is linked to a decrease in feelings of depression, as well as to other personality 
dysfunctions which fall under both the internalizing and externalizing spectra, but are not best 
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captured by either.  
Interestingly, higher scores on the hysteric-histrionic prototype were linked to better general 
functioning at the end of the follow-up period. Whilst this might be a counter-intuitive result at 
first (as it suggests more pathology being linked to better functioning), Westen et al. (2012) 
actually argue that the neurotic styles (one of which the hysteric-histrionic prototype is) are 
characterized by less impairment than the other personality syndromes and “may therefore be 
considered character styles rather than disorders” (p.282).  
Similarly to Westen et al. (2012) , Kernberg & Caligor (2005) conceptualised personality 
disorders across three levels: borderline, neurotic and psychotic. The neurotic level of 
organisation, they argued, is characterised by more integrated self- and others- representations, 
than the borderline and psychotic one, as well as by the use of more “mature” defences and a 
better reality-testing. Obsessive-compulsive, hysterical and depressive-masochistic personality 
disorders were considered to fall under this category. 
4.1.1.2.2. The TAU group 
In the TAU group only the borderline-dysregulated prototype change score was significantly 
related to the HDRS-17 at the end of treatment. Furthermore, a decrease in the prototype score 
was associated with an increase in global functioning (GAF) at the end of treatment and at 
follow-up, and a decrease in psychological distress (CORE-OM) at the end of treatment.  
Interestingly, an increase in the dependent-victimised and obsessional scores was significantly 
linked to an increase in global functioning at 42-months.  
Like in the LTPP group, a decrease in the borderline-dysregulated score was associated with a 
decrease in the paranoid score. A negative correlation was observed with the obsessional 
prototype score, however – the lower the borderline-dysregulated score, the higher the 
obsessional one.  
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One way of interpreting the results in the TAU group is to again refer to the factor model by 
Westen et al. (2012). It can then be argued that in the TAU group improvements in general 
functioning were linked to a decrease in a more borderline-type functioning and a shift towards 
internalizing (dependent-victimised) and neurotic presentation (obsessional personality). At the 
same time such an interpretation does not account for the categorical shifts in the borderline 
prototype, observed in this group: whilst only five people scored above cut-off for borderline-
dysregulated features and none for disorder at baseline, at the end of treatment eight people met 
criteria for features and one for disorder. It is also interesting to notice that in the TAU group 
anxious-avoidant and depressive PD were also highly prevalent at baseline and end of treatment, 
and yet these prototypes’ change scores did not correlate significantly to treatment outcome.  
4.1.1.2.3. Differences between the two groups 
The first difference between LTPP and TAU is that changes in score on the borderline-
dysregulated prototype in the former were significantly related to a decrease in depression at the 
end of follow up only, whereas in the TAU group this link was statistically significant only at the 
end of treatment. This might be accounted for by the “sleeper effect” in the LTPP group, as 
described earlier.  It could also be argued that in the LTPP group treatment outcome, as 
measured by the HDRS, CORE-OM and GAF, appeared to be related to changes in a number of 
the personality prototypes, which was less so in the TAU group.  
Another interesting difference is that in the LTPP group the borderline-dysregulated prototype 
was related to personality health, which in turn was also significantly linked to treatment 
outcome. This was not the case in the TAU group. This, as argued earlier, might be linked to the 
different aims of the LTPP and TAU treatments – the former focusing more intently on leading 
to changes at the level of personality organisation, and the latter, generally speaking, targeting 
symptoms of depression alone.  
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It remains unclear, however, why the borderline-dysregulated personality prototype was 
significantly related to treatment outcome in both groups, despite the low number of people who 
met criteria for features or disorder. In the following section the author presents a discussion of 
the analysis of specific borderline-dysregulated characteristics and their link to treatment 
outcome in the two TADS treatment groups. 
4.1.1.3. Borderline-dysregulated items and their link to treatment outcome 
The introduction chapter summarised different conceptualisations of borderline personality 
disorder, as well as the diagnostic descriptions provided by the DSM-5 and by psychoanalytic 
authors. Regardless of the theoretical model used, borderline personality has been described in 
the literature as a constellation of different characteristics, encompassing different domains of 
functioning (e.g. affect regulation; interpersonal relationships etc.). Some authors have further 
attempted to refine the borderline construct by identifying aspects of it that are most 
characteristic and distinctive of borderline personality disorder. 
Westen & Shedler (2007), for example, referred to an unpublished examination (Bradley, 
Shedler, & Westen, 2006) of the highest-ranking SWAP borderline-dysregulated items, which 
led to a narrowing down to 15 “core” items, considered to be both characteristic and distinctive 
of BPD (e.g., “Emotions tend to spiral out of control, leading to extremes of anxiety, sadness, 
rage, etc.”), as well as to a “stable core of items” which were characteristic but not distinctive – 
mainly thought to indicate negative affectivity, observable in other personality disorders, too. In 
addition, the same item analysis identified features that are “highly distinctive” of BPD, but only 
observable under extreme stress (e.g., “Tends to engage in self-mutilating behavior”). The 
distinction of those features of the disorder which are stable over time, from those which “wax 
and wane” is considered important (Westen & Shedler, 2007), as a focus on the latter more than 
the former, can lead to the wrong impression that borderline personality disorder is unstable over 
time (Shedler, 2016). Yet, some of the more stable features are at the same time argued to be less 
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distinctive of BPD (e.g. negative affectivity). Shedler (2016) indeed proposed that the 
borderline-dysregulated prototype item “Tends to feel unhappy, depressed or despondent” is not 
a BPD-specific item, as it indicates depression, but argued that all other 23 prototype items are 
specific, albeit still a combination of “stable” and “unstable” ones (e.g. the items relating to self-
harming behavior). 
Clarkin, Fonagy, Levy, & Bateman (2015), argued that impulsivity is most characteristic of the 
disorder, but warned that the concept of impulsivity overlaps with other concepts such as 
“sensation-seeking, risk-taking, lack of planning, inability to delay gratification, insensitivity to 
consequences of action, and alteration in the perception of time” (p.355). In addition, the authors 
noted that negative affect is also a characteristic feature of BPD, but is found in other disorders. 
According to Clarkin et al. (ibid), however, negative affect in borderline patients is distinct by its 
transiency and fluctuations, as well as by being triggered by environmental stimuli. 
In a nutshell, it appears that some of the characteristics of BPD are more distinctive of the 
disorder than others, and that certain expressions of it, like self-harming behaviours, might be 
only observable under stress, but not at all times. The analysis of each borderline-dysregulated 
item aimed, therefore, to examine which of the borderline-dysregulated items had specific 
relevance for treatment outcome, as measured by the HDRS, CORE-OM and GAF scales.  
4.1.1.3.1. Borderline-dysregulated items at baseline  
Only two items at baseline correlated negatively with treatment outcome in the TAU group. 
These represented chaotic lifestyle, which predicted poorer outcome on the measure of 
depression at the end of treatment, and self-harm which predicted less improvement in 
psychological distress at the end of the follow-up period. Interestingly, one of the items 
indicating insecure attachment, correlated significantly with the psychological distress change 
score, suggesting that the more insecurely attached patients were at the beginning of the trial, the 
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higher they scored on their 18- and 42-months CORE-OM compared to their baseline score on 
the measure. 
The reader is reminded that out of the three outcome measures, the CORE-OM is the only self-
rated one. One hypothesis about the above-reported results could be that the more insecurely-
attached patients sought the therapist’s/researcher’s approval more and their higher CORE-OM 
scores at the end of treatment and end of follow-up in the TAU group were an expression of a 
tendency to please the other.  
It is important to note here that attachment styles classifications go beyond a “secure-insecure” 
distinction, however, but attachment neuances were not captured by the current study. This is a 
limitation of this study, for, as presented earlier, research has found anxious-preoccupied 
attachment strategies to be of a particular relevance to BPD, and to the way in which individuals 
make use of therapeutic interventions (Bateman & Fonagy, 2016; Fonagy & Luyten, 2016). 
In the LTPP group a similar positive correlation was observed between one of the items 
measuring splitting and the CORE-OM change score at 18 and 42 months. This result is even 
more bewildering and hence difficult to interpret. One way of making sense of it could be that 
the CORE-OM scores for patients more prone to splitting, were not reflecting as accurately their 
state of mind, but rather only the more positive (split-off) aspects of their experiences. It is 
unclear why this trend was observed in the LTPP but not in the TAU group. 
4.1.1.3.2. Borderline-dysregulated item change scores 
Patients who experienced less improvement in affect instability and insecure attachment (feeling 
victimised and mistreated, in particular) in the course of treatment in the TAU group, also 
experienced less improvement in depression at 42 months. Smaller change scores on two further 
affect dysregulation items were also associated with less improvement in general functioning at 
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the end of follow-up in this group. Interestingly, an increase in relationship instability was linked 
to improvement in depression at 42 months.  
This latter finding is also bewildering. A possible explanation could take into account the 
prevalence of dependent and avoidant PDs in the TADS sample, which might suggest that 
patients overall were more likely to avoid interpersonal conflict and multiple break-ups and 
separations. An increased relationship instability score might thus reflect a decrease in 
interpersonal dependency and subjugation, which for some patients might have been a 
contributing factor to their depression. This hypothesis remains speculative and would need to be 
tested further, however. 
In the LTPP group lower change score on one of the affect dysregulation items alone (becoming 
irrational when strong feelings were stirred up) was related to less improvement in depression. 
Better general functioning at 18 months was linked to feeling less victimised and misunderstood, 
whereas a decrease in splitting was associated with less psychological distress at the end of the 
follow-up period. 
A big limitation of this part of the analysis needs to be noted here, however. More specifically, 
only 12 out of the 24 items that describe the borderline-dysregulated prototype had a fair to 
excellent inter-rater reliability correlations, as reported earlier in the results chapter. This led to 
the other half of the items being omitted from the analysis due to poor reliability. These included 
the four items describing processes of projective identification and identity diffusion, as well as 
one of the two items describing splitting, and two of the items describing self-harm. Instability 
and lack of cohesiveness in one’s internal representations of self and others, together with the 
use of more primitive defences such as splitting and projective identification, have been 
considered by a number of authors to be central characteristics of BPD (e.g. Green, 1977; 
Kernberg, 1978; Winnicott, 1969). Repeated suicidal and self-harm threats and gestures are also 
highly characteristics of the disorder (APA, 2013; Clarkin et al., 2015), despite the more 
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fluctuating nature of this particular trait (Westen & Shedler, 2007). Not being able to test how 
these items relate to treatment outcome is a drawback of the current study. The limitation of the 
poor reliability of certain items will be returned to later in this chapter. 
The borderline-dysregulated items which were included in the analysis thus encompassed mainly 
affect dysregulation, insecure attachment and chaotic lifestyle. It is therefore not surprising that 
predominantly improvements in the patient’s ability to regulate emotions (affect), as well as a 
change in their attachment patterns were linked to improvements in depression, general 
functioning and psychological distress.  
As noted previously, a number of publications have explored the link between attachment and 
the capacity to mentalise (e.g. Fonagy & Luyten, 2016). One’s capacity to regulate affect, 
develops in the context of one’s relational capacities (secure attachment to others). When one’s 
way of relating to others is marked by insecurity and instability, deficits in affect regulation 
ensue. Mentalization theory suggests that when one’s emotions cannot be represented and 
regulated internally (be given meaning to, in the context of the individual thinking about their 
own and others’ minds), three modes of less adaptive functioning take over: psychic equivalence 
(inner states being experienced as equivalent to external facts), teleological mode (inner 
experiences being regulated only by action), and pretend mode (thoughts and feelings can be 
thought about and described but get dissociated from the person’s actual lived experience).  
Splitting, projective-identification and self-harm can be seen as expressions of these three modes 
of responding to and regulating intense affect, characteristic of borderline personality disorder. 
Insecure attachment and affect dysregulation alone, however, are not exclusively characteristic 
to BPD, but can encompass a wider spectrum of personality difficulties. More specifically, it 
appears that affect dysregulation and insecure attachment in the TADS patient group, both at the 
beginning, as well as at the end of treatment, were linked to experiences of psychological 
distress in general, and depression in particular. Improvement in the course of treatment on the 
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three outcome measures is associated with improvements in affect regulation and attachment 
style. This is despite the fact that only two people in the whole patient group met criteria for 
borderline-dysregulated disorder, and a small proportion (8% in TAU, and 13% in LTPP) scored 
above the SWAP-II cut-off for borderline features. 
The Psychodynamic Diagnostic Manual (PDM Task Force, 2006) considers borderline 
personality as a level of organisation subsuming other personality disorders and hence an 
expression of a personality difficulties more generally. Whether borderline personality disorder 
is a separate, albeit heterogeneous construct, akin to other personality constructs in terms of its 
distinct structure and manifestation, or a higher level personality organisation, which includes 
different personality disorders, including BPD, appears to remain an on-going debate in the 
literature (Meehan & Levy, 2015). The results from both the TAU and the LTPP groups provide 
some evidence in support of the more encompassing nature of certain borderline features, such 
as insecure attachment and affect dysregulation, and their relationship with depression and 
general distress and functioning. Due to poor item reliability, however, other aspects of the 
borderline prototype, which might be particularly distinctive of it (e.g. self-destructive 
behaviours and identity diffusion) could not be entered into the analysis. 
4.1.2. Personality disorders frequency and comorbidity 
Another very striking finding presented in the Results chapter of this thesis, was that the majority 
of the TADS participants (over 90%) met SWAP-II criteria for at least one personality disorder. 
Moreover, the average number of personality disorders per patient were approximately 2 at 
baseline and 2 at the end of treatment for both groups, when the SWAP-II measure was used. 
The three most prevalent personality disorders both in the LTPP and TAU group were 
depressive, anxious-avoidant and schizoid-schizotypal. 
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The author also calculated the average number of personality disorders as measured by the 
SCID-II-PQ. Based on this measure, patients in the TAU group met criteria for an average of 
4.2, 3.4 and 3.5 personality disorders at baseline, end of treatment and end of follow-up 
respectively, and patients in the LTPP group met criteria for an average of 4.6, 3.6, and 2.9 
personality disorders at the three time points, respectively. The SCID-II-PQ thus points to a 
larger personality disorder comorbidity than the SWAP-II.  
These results need to be interpreted with a lot of caution. As noted in the introduction chapter, 
the SCID-II-PQ is a screening tool, which is to be used in combination with the SCID-II semi-
structured interview, where the interviewing clinician asks further and more detailed questions, 
before arriving at a personality disorder diagnosis. It is therefore likely that the SCID-II-PQ, 
when used on its own, over-estimates the prevalence of personality disorder. Furthermore, it is a 
self-rating tool, which makes it less reliable (when compared to a clinician- or multiple-
informant based diagnosis). The SCID-II-PQ will therefore not be considered in any further 
detail in the rest of this chapter. 
The differences in the average number of PD diagnoses as measured by the SWAP-II and SCID-
II-PQ are generally in line with what was reported by Lewis (2008), who used an earlier version 
of the SWAP – the SWAP-200 – to look at a sub-sample (N=25) of TADS participants and 
found an average PD prevalence of 1.2 SWAP-200 Q-factor diagnoses, and 4.6 SCID-II-PQ 
diagnoses. Another recent study by Marin-Avellan, McGauley, Campbell, & Fonagy (2014) also 
demonstrated that when the SWAP is used as a measure of personality disorders, there is 50% 
less PD comorbidity,  compared to using the SCID-II. At the same time, the current project 
found an average of roughly 2 SWAP-II personality disorders per participant, both at the 
beginning and end of treatment, which is twice as high as the one PD diagnosis in a “typical 
patient”, reported by Westen & Shedler (1999).  
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One possible interpretation of the high number of personality disorder prevalence and 
comorbidity in the TADS patient group could be that it is a reflection of the high complexity of 
the TADS patients’ presentation and difficulties. As reported in the method chapter, the majority 
of participants met criteria for “severe” to “very severe” depression, as measured by the HDRS 
at baseline, and had experienced re-current depression for many years with a number of 
treatments (approximately four on average) offered to them, which had led to little or no 
improvement.  
Furthermore, a high proportion of the patients in both groups (over 70% in both groups) met 
criteria for anxiety disorder, and had an average of over 3 Axis I disorders at baseline. Although 
the data collected on abusive and traumatic experiences was incomplete and therefore not 
officially reported in the main outcome journal article (Fonagy et al., 2015), a large number of 
patients also appear to have experienced one or more traumatic events at different stages of their 
life. It could therefore be hypothesised that the high personality disorder prevalence is an 
expression of the enduring difficulties of these patients, which go far beyond problems with 
mood alone and spread across different areas of their lives in a complex and incapacitating 
manner. 
A more detailed interpretation of the personality disorders prevalence and comorbidity also goes 
beyond the aims and scope of the current thesis, and will hopefully be addressed in a separate 
future publication by the TADS research team. The issues of complexity, in general, and trauma, 
in particular, are addressed next.  
4.2. The Role of Trauma and Victimisation 
The Introduction chapter of this thesis presented some theoretical and clinical ideas about the 
link between attachment difficulties and the experience of trauma and victimisation. Insecure 
attachment was in turn linked to personality development, as expressed through stable 
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representations of self- and others, the ability to regulate emotions, and the capacity to mentalize. 
Despite the different views on what constitutes “trauma” and which types of trauma are 
particularly predictive of borderline pathology, there seems to be a unanimous agreement 
amongst authors that most borderline patients have experienced some form of early life 
adversity. Bateman & Fonagy (2016) draw attention to the overlap between BPD and “complex 
traumatic stress disorder”. The British Psychological Society has further suggested that the term 
“psronality disorder” is replaced by “complex trauma” or “complex trauma reaction” (Division 
of Clinical Psychology Beyond Functional Psychiatric Diagnosis Committee, 2015). 
The SWAP-II borderline prototype item “Tends to feel misunderstood, mistreated or victimised” 
was linked to a few of the outcome measures. For example, decrease of score on this item was 
associated with lower depression scores in the TAU group at 42 months, and improved general 
functioning in the LTPP at the end of treatment.  
A significant proportion of the TADS patients had reported experiences of loss, physical and 
sexual violence, and bullying. The exact statistics of this have not been yet published, as the 
analysis of this part of the data set is not complete, but a summary was presented by the TADS 
research team during the 45
th
 SPR International Annual Meeting (Booker, 2014). Some patients 
had experienced a combination of adverse events, on a number of occasions throughout their life, 
prior to taking part in the TADS. In addition, 18% of participants had reported being in an 
abusive relationship at the beginning of treatment. This calls for a discussion of patients’ 
experiences of feeling mistreated and victimized, as measured by the SWAP-II, and the link with 
actual experiences of trauma and abuse, as well as the implications this has for the treatment of 
depression. 
André Green argues that identity fragmentation, deficits in thinking, and the use of splitting and 
projection are all unconsciously resorted to by patients with BPD, in order to defend the ego 
against getting in touch with complex underlying traumatic “constellations”, which threaten to 
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cause a “psychic catastrophe” (Green, 2000). Attachment theorists take a different view, in 
arguing that fragmentation and difficulties in metalizing are caused by disrupted early 
attachments (as summarised above), rather than by repression or the overreliance on certain 
unconscious defences. Clearly more patients in the TADS group had reported traumatic 
experiences than those who could be considered to present with borderline features or disorder. 
The link between insecure attachment, affect dysregulation and treatment outcome might, 
however, also be further understood in relation to such experiences. It is therefore interesting that 
this has not been addressed in the main TADS outcome paper (Fonagy et al., 2015), and that the 
data on adverse experiences is incomplete, and thus not suitable for being entered into the 
analysis of the current thesis, either. 
Herman (1997) draws attention to trauma victims often not being believed in society and states 
that silencing and denial are common social processes. She argues that both social and political 
contexts need to allow for the holding of traumatic realities into consciousness. “Repression, 
dissociation and denial are phenomena of social as well as individual consciousness” (p.9).  
Alessandra Lemma presents a similar argument, although with more general reference: “What 
we see and hear in the clinical situation tells the story of an individual, couple, or family and 
their relationships, but it is also a current, running commentary on the society we live in” 
(Lemma, 2012, p. 67). She insists that it is the mental health professionals’ moral obligation to 
use their ideas and understanding of the mind in impacting what happens on a social level, 
outside of the consulting room. 
Both Herman and Lemma’s arguments call for researchers and clinicians to be more daring in 
asking questions about social processes, including injustice and adversity, and in inviting their 
contemporaries to know and think about these wider issues. The TADS patients’ experiences of 
often multiple loss and violence should not, therefore, be left out of sight and out of mind. This 
thesis did not succeed in factoring such experiences in an organised and systematic way into the 
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data analysis, but the author certainly invites the reader to think about the implications this might 
have on the results in particular, and on the approach to understanding and treating “treatment-
resistant depression”, more generally. 
4.3. Further Limitations of the Current Study 
4.3.1. The SWAP-II 
4.3.1.1. The use of the SWAP-II Borderline-Dysregulated Q-sort as a measure of 
borderline personality disorder 
One of the main limitations of the current study is linked to the use of the borderline-
dysregulated T-score as a single measure of BPD. To the best of the author’s knowledge, no 
previous project has used the SWAP-II in this way. Moreover, the personality profiles of those 
who met criteria for borderline features or disorder demonstrated that personality is a 
constellation of different features. The description of a patient only in terms of their borderline 
characteristics, as well as the manipulation in statistical analysis of the borderline prototype as a 
separate variable, is bound to carry some artificiality. At the same time, this study demonstrated 
how the SWAP-II produces personality profiles marked by less personality disorder comorbidity, 
as compared to the SCID-II-PQ. The alleged advantages of the SWAP over the more traditional, 
DSM-informed categorical approach to personality disorder, were presented in the previous 
chapters of this thesis. It thus appears that, despite the limitations, the SWAP-II might be a better 
approach to capturing personality and describing it, both categorically, as well as dimensionally, 
through the use of the tool’s narrative descriptions. 
4.3.1.2. Differences between SWAP-II completers and non-completers 
One of the findings presented in the previous chapters was that those who were rated on SWAP-
II at the end of treatment had a significantly higher average depressive PD score than those who 
were not rated (for reasons listed in the methods chapter). This means that the SWAP data 
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available at 18 months was representing the patients with a higher degree of difficulties, at leased 
based on their depressive PD score at baseline. It is difficult to know whether the rest of the 
results would have been different, if all data were available. 
4.3.1.3.On scoring the SWAP-II using the TADS clinical material  
A further limitation is related to the type of information used for the scoring of the SWAP-II. 
Shedler & Westen (2007) advised that the SWAP is scored after the completion of the Clinical 
Diagnostic Interview (CDI) (Westen & Muderrisoglu, 2003), developed particularly for this 
purpose. When the CDI cannot be completed, it is recommended that the SWAP-II is scored 
after a minimum of 6 psychotherapy sessions, in order to allow a good-enough knowledge of the 
patient and their presentation. 
As already discussed in the method chapter, Lewis (2008) compared the CDI to the Tavistock 
Psychodynamic Interview (TPI) and concluded that the latter can be used as a replacement of the 
former, despite some of the differences between the two interviews. It is worth noting some of 
these differences again and the limitations they carry. The four main areas, which are attended to 
in the CDI interview, but not explicitly asked about in the TPI, concern the patient’s sexual life 
and experiences, their experiences of and feelings about themselves as an individual, the way 
they manage difficult emotions, and any recent difficulties they might have encountered.  
The TPI does not contain a question about sexuality or the patient’s current sexual relationships 
(although it does ask about past and current intimate relationships). This led to the lack of 
sufficient information required to score any of the SWAP-II items linked to sexual identify, 
sexual perversions or the patient’s attitude towards sexual experiences more generally (e.g. 
“Appears to associate sex with danger”). This omission is a significant one, as it has led to these 
items being scored as “0” (i.e. not at all descriptive of the patient), when this information, if 
available, might have been central to both the clinical formulation, as well as to the patient’s 
personality profile.  
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A similar argument can be made about the CDI asking in a more detailed manner about the 
patient’s self-image (e.g. “Do your feelings about yourself change a lot? Do you ever feel like 
you don’t know who you are, or like the different sides of you don’t fit together?” (Lewis, 2008, 
p. 110)). As already pointed out throughout this thesis, a lack of stable sense of self is one of the 
central borderline personality disorder features. The same is true about affect dysregulation, 
which is more thoroughly investigated during the CDI interview. It is thus unclear whether the 
TADS patients’ score on the borderline-dysregulated porotype would have been different, had 
this information been available. 
At the same time the TPI asks some questions, which are not included in the CDI, but 
nonetheless provide valuable information about the patient’s functioning and personality. These 
include questions about the patient’s early life-, as well as more recent experiences of separation 
and loss, and questions about current social support and about the patient’s understanding of 
their depression. These questions provided the SWAP-II raters with some insight about the 
patient’s relationships with others, including how others are perceived and described by the 
patient, as well as with information about the patient’s capacity to think about their own minds 
and the minds of others (or in other words “mentalize”). The importance of early experiences of 
loss and adversity has been referred to in this thesis already. The TPI asked the patients 
questions which allowed for the exploration of such experiences. 
4.3.1.4. On the importance of well-informed clinical formulation in making accurate and 
valid personality assessments 
Shedler (2009) stated the the SWAP “relies on clinicians to do what they do best: provide 
psychologically rich descriptions of the individual patients they know and treat” (p.3). He further 
recommended that additional sources of information, such as patient records and other 
psychological tests, should also be used when the SWAP is scored. A wide range of information 
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was available in the TADS, but it was not possible to fully follow this recommendation for 
pragmatic reasons (i.e. limitations in time and resources).  
Furthermore, the TADS was a pragmatic randomised trial, which means that it tested the 
effectiveness of interventions already delivered as part of the National Health Service (NHS) in 
the UK. Clinicians in current NHS settings rarely have enough time to get to know the patient 
very well, especially in the context of time-limited therapies, which might last 6 sessions in total 
(e.g. in the case of CBT interventions in primary care). Assessments are usually carried out in no 
more than one session and if an intervention is offered, it is not unusual that this is delivered by a 
different clinician. Some patients might have prolonged and multiple contacts with health-care 
services, but brief treatments provided by different clinicians are more the rule than the 
exception. This way of working places significant limitations on the clinicians’ ability to arrive 
at a detailed clinical formulation of the patient’s difficulties, which includes not only the 
presenting problem (e.g. symptoms of depression) but also the individual’s overall way of 
functioning and personality organisation. The access to 2-4 hours of recorded assessment 
material for the purposes of completing the SWAP-II can therefore be regarded as unusual, 
compared to the limited information and contact time clinicians have before drawing an initial 
formulation and making treatment recommendations. 
Finally, Westen & Shedler (2007) pointed out that the SWAP-II has mainly been used for 
research purposes. The tool’s use in clinical settings and clinical trials has not been thoroughly 
evaluated (ibid), particularly when the SWAP-II was used by a team of (five) researchers, who 
completed the assessments. It can be argued that the personality profiles might have been more 
clinically accurate if they were completed by the assessing clinician, who had direct contact with 
the patient, instead. This is another limitation of the study, and one which was the product of 
pragmatic restrictions. 
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4.3.2. Outcome measures’ limitations  
The TADS used the HDRS-17 as a main treatment outcome measure. Secondary measures 
included the CORE-OM and GAF. Each of these scales and its psychometric properties was 
presented in the methods chapter. It is important to also note some further limitations, too. 
4.3.2.1. The HDRS-17 
A main critique of the HDRS-17, presented earlier in this thesis, has been the lack of an updated 
version, which reflects developments in the conceptualisation of depression (Bagby et al., 2004; 
Gibbons, Clark, & Kupfer, 1993). Yet, no convincing successor of the HDRS seems to have 
been identified and adopted in the study of depression and its treatments to date. 
Furthermore, Bagby et al. (2004) highlighted that the HDRS was developed with the primary 
aim of measuring the treatment effects of anti-depressants in the late 1950s/early 1960s. This 
point is important to consider, as depression can be conceptualised in different ways, as 
demonstrated in the introduction chapter, with different treatments having very distinctive 
therapeutic aims. For example, anti-depressants’ main objective is to reduce the observable, 
behavioural symptoms of depression, such as sleep disturbance and anxiety. Psychodynamic 
psychotherapy, on the other hand, aims primarily to achieve greater personal integration, by 
changing the way the person functions as a whole (Taylor, 2015). Symptom reduction, in that 
sense, remains a secondary aim, or even a by-product of the main treatment aim. It can thus be 
argued that the HDRS-17 does not capture optimally changes in the TADS patients’ experiences 
of depression. This hypothesis is further supported by the lack of significant change in the 
depressive PD scores pre- and post-treatment in either of the groups. Depressive PD, as 
measured by the SWAP-II, was highly prevalent amongst the TADS patients (66.1% and 70.1% 
in TAU and LTPP, respectively). Furthremore, high scores on the depressive PD scale in the 
TAU group were also linked to pooer general functioning at the end of follow-up. The lack of 
change in the pateints’ depressive PD presentation might suggest that any therapeutic gains 
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remained on the level of symptom reduction, rather than impacting the patients’ personality 
functioning.  
4.3.2.2. The GAF 
The General Assessment of Functioning (GAF) measure also has important limitations, which 
are relevant to the current study. More specifically, different authors have questioned the 
measure’s reliability in capturing clinical improvement.  
Moos, Nichol, & Moos (2002), for example, assessed the GAF’s value in guiding clinical 
decision making and predicting treatment outcome, among nearly 10 000 patients with 
psychiatric and substance misuse diagnoses. The authors used a range of clinician- and self-rated 
measures and analysed the data they yielded in relation to the GAF scores. They concluded that 
there was little or no relationship between GAF ratings and symptoms, social and occupational 
treatment outcome, and hence stated that “these findings cast doubt on the value of including 
GAF ratings as predictors of treatment outcome”. The prognostic accuracy of the GAF has been 
questioned by subsequent authors too, who have argued that other measures predict prognosis 
and treatment outcome better (e.g. Aas, 2010). The DSM (APA, 2013) has indeed removed the 
GAF in its latest 5
th
 edition, stating that the measure has been criticised for its “conceptual lack 
of clarity” and “questionable psychometrics in routine practice” (p.16). The APA (2013) has 
replaced the GAF with the WHO Disability Assessment Schedule (ibid). 
These limitations need to be born in mind when thinking about the changes of the TADS 
participants’ general functioning, as reported in this study. It can be argued that these changes 
reflect more shifts in symptomatology, than an actual change in the patients’ day-to-day 
experiences across different domains of their lives.  
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4.3.2.3. The validity of the “outcome measures” in measuring treatment outcome  
Another important consideration concerns the extent to which the HDRS, GAF and CORE-OM 
measure actual treatment outcome. In a recent conference presentation Truijens (2016) addressed 
the issue of epistemic validity in psychotherapy research, or, in other words: how valid are 
different measures in assessing the treatment outcome of psychotherapy interventions. She gave 
an example with the Beck Depression Inventory, which has good test validity – the scale 
captures adequately the patient’s experiences of depression. Figure 6 summarises problems 
arising when using the BDI or similar measures, like the HDRS, to test not depression, but 
treatment success. 
Figure 6 
Test vs. Epistemic Validity (Adapted from Truijens, 2016) 
 
 
 
 
 
 
 
Truijens argueed that the test validity of a measure could not and does not cover the whole 
epistemic process, which is lodged into the context within which it takes place – social research, 
and individual. This issue is very relevant to the TADS study, in general, and the current project 
in particular. More specifically, the main research question concerned the impact of borderline 
personality features/disorder on treatment outcome for patients presenting with treatment-
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resistant depression. Treatmenet outcome was measured only in terms of the HDRS, CORE-OM 
and GAF change scores. The TADS also collected qualitative information, however, in the form 
of interviews with patients and therapists. This information has not been yet fully analysed and 
published, but it poses the question of what is considered an “outcome” – a change on a 
depression rating scale or the individual’s experience of having received some support and how 
this support has impacted on their subjective experiences of depression, as well as on their way 
of relating to themselves and the world aorund them, more generally. Truijens (ibid) refered to a 
recent study by Cornelis et al. (2016) which indeed demostrated how different treatment 
outcome results might change, based on the type of measurement tool used (in that example - the 
BDI score, as compared to the patient’s cortisol levels and their use of anti-depressant 
medication). 
Out of the three “outcome measures” used in the current study, the CORE-OM was the only one 
which was developed with the particular aim of measuring the effectiveness of different types of 
psychotherapy. Even still, its developers also advised against using the CORE-OM as a stand-
alone measure of clinical change and effectiveness, and noted that each service needs to choose 
other supplementary measures, based on the type of intervention it is delivering (Evans et al., 
2000). 
4.4. Summary of Clinical Implications and Suggestions for Further Research  
The results of this thesis pointed at the complex personality presentation of the TADS patients, 
who were being treated in the trial for “treatment-resistant depression”, either through long-term 
(18-month) psychodynamic psychotherapy, or through treatment as usual.  The length and 
severity of these patients’ depression were much higher than those of other depressed patient 
groups, on which recommendations such as the NICE guidelines have been based (Fonagy et al., 
2015). Axis I comorbidity, and the presence of significant and often multiple personality 
difficulties were the rule, more than the exception for the TADS participants. A retrospective 
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measure of personality pathology – the SWAP-II – further pointed at the high prevalence of PDs 
in the TADS population. 
The current study did not find a significant link between borderline personality disorder or 
features at the beginning of treatment, and treatment outcome, as measured by changes in 
patients’ HDRS, CORE-OM and GAF scores. Very few patients met criteria for borderline-
dysregulated disorder or features, although this number increased in the TAU group by the end 
of treatment, compared to baseline. Those who did meet these criteria, appeared to experience 
little benefit from the the treatment offered in both the TAU and LTPP groups, with the 
exception of significant improvement in general functioning, as measured by the GAF, in the 
LTPP group.  The TAU patients in this subgroup generally deteriorated in their borderline 
presentation in the course of treatment.  
These findings have important clinical implications. First, they demonstrate that not all patients 
benefit from the interventions offered, even when they present (at least at face value) with the 
same symptoms – for example, of major depression. The study’s results appear in support of the 
psychoanalytic view of mental health difficulties being lodged in the development of the 
personality, particularly for individuals whose depression is “resisting” first-line forms of 
treatment (e.g. anti-depressants or brief psychological therapies). Fast-tracking patients to and 
through treatments, only on the basis of meeting a set of psychiatric diagnostic criteria is, 
therefore, not sufficient in accurately predict the effectiveness of interventions. A thorough 
assessment of the person’s presentation, including any possible personality difficulties, seems 
very much needed for patients presenting with more complex and enduring difficulties. Only 
then can a better-informed decision be made about treatment suitability. 
Whist this study did not look into other personality disorders in detail, a significant finding 
appeared to be the overall lack of improvement of most of the PD scores, as measured by the 
SWAP-II, and the increased scores on some of the PD scales by the end of the treatment. The 
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possible harm inflicted by inappropriate interventions has been highlighted by some authors 
(e.g.Fonagy & Bateman, 2006), although this seems to remain an issue, which is generally not 
openly discussed in RCTs. The thesis discussed different treatment adaptations suggested in the 
literature, such as considering the patient’s capacity to “mentalize”, where a more borderline 
presentation is apparent, and adapting the therapeutic stance in order to meet the individual 
idiosyncratic treatment needs. Such an approach to treatment calls for on-going reformulation of 
the patient’s difficulties, in addition to a thorough assessment. 
This is, however, made difficult by the limited access to resources in contemporary public health 
care services. Diagnoses and treatment guidelines are one way of organising the immense mass 
of human complexity and experiences and responding to it in treatment. Diagnostic labels 
arrived at through assessment might serve as a shortcut to deciding what interventions to use, 
and how to adapt them, but they are always bound to simplify what a whole living person brings 
into the consulting room - namely their histories, their past and current relationships, the myriad 
of their conscious and unconscious experiences, and of course – the reflection of the society they 
live in. 
The TADS patients with borderline features or disorder, all seemed to fit many diagnostic boxes, 
with no one intervention or theory being able to fully capture their complexity. Further research 
therefore needs to continue examining the links between chronic and difficult-to-treat 
depression, and personality disorder (including borderline personality). 
Shedler (2009) gives some further guidance on how these issues need to be addressed clinically: 
“Although acute Axis I symptoms may prompt the patient to seek treatment, underlying 
personality patterns must be addressed to achieve lasting treatment gains. The therapist 
should identify and explore self-defeating patterns in the patient’s thinking, behavior, 
and relationships, including the relationship with the therapist, and help the patient gain 
insight into the ways in which he discounts or repudiates his own emotional needs or 
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inhibits his capacity to fulfil them.” (p.11) 
Future research needs to also consider using a wider range of measures, which are not 
predominantly focused on symptoms and illness (like the HDRS and GAF), but more accurately 
reflect the individuals functioning and lived experiences across different areas of their lives. The 
same is true for personality disorder measures. The SWAP-II assessments in this study had a 
number of limitations, and future research should seek to improve the methodology, by, for 
example, recruiting the treating clinicians into rating the SWAP-II. 
Finally, further refinement of both the theoretical and clinical understanding of what works for 
whom in treating TRD is needed. Blatt (2015) highlights the “Dodo bird effect” in treatment 
outcome for bona fide therapies for depression, where roughly half of the patients in RCT’s 
benefit from the intervention offered, whilst the other half do not. The current study identified 
that improvements in affect regulation and insecure attachment are associated to improvements 
in depression, general functioning and psychological distress. More research is needed to 
identify the specific processes that account for such changes and whether and how they depend 
on the patient’s personality, their history and the type of treatment offered. 
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Appendices 
Appendix A – SWAP-II Description of Borderline-dysregulated Personality  
Affect dysregulation 
Emotions tend to change rapidly and unpredictably. 
Emotions tend to spiral out of control, leading to extremes of anxiety, sadness, rage, etc. 
Tends to become irrational when strong emotions are stirred up; may show a significant decline 
from customary level of functioning. 
Is prone to intense anger, out of proportion to the situation at hand (e.g., has episodes of rage). 
Is unable to soothe or comfort him/herself without the help of another person (i.e., has 
difficulty regulating own emotions). 
Tends to “catastrophize”; is prone to see problems as disastrous, unsolvable, etc. 
Tends to feel unhappy, depressed, or despondent. 
 
Splitting 
When upset, has trouble perceiving both positive and negative qualities in the same person at 
the same time; sees others in black or white terms (e.g., may swing from seeing someone as 
caring to seeing him/her as malevolent and intentionally hurtful). 
Tends to stir up conflict or animosity between other people (e.g., may portray a situation 
differently to different people, leading them to form contradictory views or work at cross 
purposes). 
 
Projective identification 
Manages to elicit in others feelings similar to those she/he is experiencing (e.g., when angry, 
acts in such a way as to provoke anger in others; when anxious, acts in such a way as to 
induce anxiety in others). 
Tends to draw others into scenarios, or pull them into roles, that feel alien or unfamiliar (e.g., 
being uncharacteristically insensitive or cruel, feeling like the only person in the world who 
can help). 
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Identity diffusion 
Lacks a stable sense of who she/he is (e.g., attitudes, values, goals, and feelings about self, 
seem unstable or ever-changing). 
Is prone to painful feelings of emptiness (e.g., may feel lost, bereft, abjectly alone even in the 
presence of others). 
 
Insecure attachment 
Tends to be needy or dependent. 
Appears to fear being alone; may go to great lengths to avoid being alone. 
Tends to fear she/he will be rejected or abandoned. 
Tends to become attached quickly or intensely; develops feelings, expectations, etc. that are 
not warranted by the history or context of the relationship. 
Tends to feel misunderstood, mistreated, or victimized. 
 
Self-harm (desperate efforts to self-regulate) 
Tends to engage in self-mutilating behavior (e.g., self-cutting, self-burning). 
Tends to make repeated suicidal threats or gestures, either as a “cry for help” or as an effort to 
manipulate others. 
Struggles with genuine wishes to kill him/herself. 
 
Chaotic lifestyle 
Relationships tend to be unstable, chaotic, and rapidly changing. 
Work life and/or living arrangements tend to be chaotic or unstable (e.g., job or housing 
situation seems always temporary, transitional, or ill-defined). 
Tends to be impulsive. 
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Appendix B - Narrative Description of the Borderline-dysregulated Personality 
Summary Statement: Individuals with Borderline-Dysregulated Personality have impaired 
ability to regulate their emotions, have unstable perceptions of self and others that lead to 
intense and chaotic relationships, and are prone to act on impulses, including self-
destructive impulses. 
Individuals who match this prototype have emotions that can change rapidly and spiral out 
of control, leading to extremes of sadness, anxiety, and rage. They tend to “catastrophize,” 
seeing problems as disastrous or unsolvable, and are often unable to soothe or comfort 
themselves without the help of another person. They tend to become irrational when strong 
emotions are stirred up, showing a significant decline from their usual level of functioning. 
Individuals who match this prototype lack a stable sense of self: Their attitudes, values, 
goals, and feelings about themselves may seem unstable or ever-changing, and they are 
prone to painful feelings of emptiness. They similarly have difficulty maintaining stable, 
balanced views of others: When upset, they have trouble perceiving positive and negative 
qualities in the same person at the same time, seeing others in extreme, black-or-white 
terms. Consequently, their relationships tend to be unstable, chaotic, and rapidly changing. 
They fear rejection and abandonment, fear being alone, and tend to become attached 
quickly and intensely. They are prone to feeling misunderstood, mistreated, or victimized. 
They often elicit intense emotions in other people and may draw them into roles or 
“scripts” that feel alien and unfamiliar (e.g., being uncharacteristically cruel, or making 
“heroic” efforts to rescue them). They may likewise stir up conflict or animosity between 
other people. Individuals who match this prototype tend to act impulsively. Their work life 
or living arrangements may be chaotic and unstable. They may act on self-destructive 
impulses, including self-mutilating behavior, suicidal threats or gestures, and genuine 
suicidality, especially when an attachment relationship is disrupted or threatened. 
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Appendix C – Tavistock Adult Depression Study Ethics Approval 
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Appendix D – University of Essex Ethics Approval 
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Appendix E – Tavistock Adult Depression Study Participant Consent Form 
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Appendix F - TADS Honorary Contract 
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Appendix G – The Shedler-Westen Personality Assessment Profile – II (SWAP-II) 
Score  
Desired 
No
w  SWAP-II Data Entry 
7             8  0 Instructions 
6           10  0 
 ● Select the ID cell and enter patient identifying information (e.g., patient ID number or 
initials). 
5           12  0 
 ● Enter a score for each SWAP item (0=least descriptive, 7=most descriptive). Press the 
Enter key after each entry. 
4           14  0 
 ● Click Sort by score to arrange the items in descending order by score (you will do this 
repeatedly as you work). 
3           16  0 
 ● The blue table to the left shows the Desired score distribution and the score distribution 
Now. 
2           18  0  ● Working from 7 to 0, adjust the scores until you have the correct distribution. 
1           22  0  ● When the score distribution is correct, the numbers in the Now column turn green. 
0          100 0  ● When finished, click Save to database. 
      
ID ►   
To obtain an authorized copy of this software or learn more about the 
SWAP family of assessment instruments, visit 
www.SWAPassessment.com. Clinical interpretive reports are coming 
soon! 
  
Sco
re  
1   
1. Tends to feel guilty (e.g., may blame self or feel responsible for bad 
things that happen). 
2   
2. Is able to use his/her talents, abilities, and energy effectively and 
productively. 
3   
3. Takes advantage of others; has little investment in moral values (e.g., 
puts own needs first, uses or exploits people with little regard for their 
feelings or welfare, etc.). 
4   
4. Has an exaggerated sense of self-importance (e.g., feels special, superior, 
grand, or envied). 
5   
5.Tends to be emotionally intrusive (e.g., may not respect other people’s 
needs for autonomy, privacy, etc.). 
6   
6. Is troubled by recurrent obsessional thoughts that s/he experiences as 
intrusive. 
7   
7. Appears conflicted about his/her racial or ethnic identity (e.g., 
undervalues and rejects, or overvalues and is preoccupied with, own 
cultural heritage). 
8   8. Tends to get into power struggles. 
9   
9. When upset, has trouble perceiving both positive and negative qualities 
in the same person at the same time (e.g., may see others in black or white 
terms, shift suddenly from seeing someone as caring to seeing him/her as 
malevolent and intentionally hurtful, etc.). 
10   
10. Believes that some important other has a special, seemingly magical 
ability to know his/her innermost thoughts or feelings (e.g., imagines 
rapport is so perfect that ordinary communication is superfluous). 
11   
11. Tends to become attached quickly or intensely; develops feelings, 
expectations, etc. that are not warranted by the history or context of the 
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relationship. 
12   
12. Emotions tend to spiral out of control, leading to extremes of anxiety, 
sadness, rage, etc. 
13   
13. Tends to use his/her psychological or medical problems to avoid work 
or responsibility (whether consciously or unconsciously). 
14   
14. Tends to blame own failures or shortcomings on other people or 
circumstances; attributes his/her difficulties to external factors rather than 
accepting responsibility for own conduct or choices. 
15   
15. Lacks a stable sense of who s/he is (e.g., attitudes, values, goals, and 
feelings about self seem unstable or ever-changing). 
16   16. Tends to be angry or hostile (whether consciously or unconsciously). 
17   
17. Tends to be ingratiating or submissive (e.g., consents to things s/he does 
not want to do, in the hope of getting support or approval). 
18   
18. Tends to stir up conflict or animosity between other people (e.g., may 
portray a situation differently to different people, leading them to form 
contradictory views or work at cross purposes). 
19   19. Enjoys challenges; takes pleasure in accomplishing things. 
20   20. Tends to be deceitful; tends to lie or mislead. 
21   
21. Tends to be hostile toward members of the opposite sex, whether 
consciously or unconsciously (e.g., may be disparaging or competitive). 
22   
22. Tends to develop somatic symptoms in response to stress or conflict 
(e.g., headache, backache, abdominal pain, asthma, etc.). 
23   
23. Tends to become involved in romantic or sexual “triangles” (e.g., is 
drawn to people who are already attached, sought by someone else, etc.). 
24   
24. Tends to be unreliable and irresponsible (e.g., may fail to meet work 
obligations or honor financial commitments). 
25   25. Has difficulty acknowledging or expressing anger. 
26   
26. Tends to get drawn into or remain in relationships in which s/he is 
emotionally or physically abused, or needlessly puts self in dangerous 
situations (e.g., walking alone or agreeing to meet strangers in unsafe 
places). 
27   
27. Has panic attacks (i.e., episodes of acute anxiety accompanied by strong 
physiological responses). 
28   
28. Tends to be preoccupied with concerns about dirt, cleanliness, 
contamination, etc. (e.g., drinking from another person’s glass, sitting on 
public toilet seats, etc.). 
29   
29. Has difficulty making sense of other people’s behavior; tends to 
misunderstand, misinterpret, or be confused by others’ actions and 
reactions. 
30   30. Tends to feel listless, fatigued, or lacking in energy. 
31   
31. Tends to show reckless disregard for the rights, property, or safety of 
others. 
32   
32. Is capable of sustaining meaningful relationships characterized by 
genuine intimacy and caring. 
33   
33. Is conflicted or inhibited about achievement or success (e.g., 
achievements may be below potential, may sabotage self just before 
attaining important goals, etc.). 
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34   
34. Tends to be sexually seductive or provocative (e.g., may be 
inappropriately flirtatious, preoccupied with sexual conquest, prone to “lead 
people on,” etc.). 
35   35. Tends to feel anxious. 
36   
36. Tends to feel helpless, powerless, or at the mercy of forces outside 
his/her control. 
37   
37. Finds meaning in belonging and contributing to a larger community 
(e.g., organization, neighborhood, church). 
38   
38. Tends to feel s/he is not his/her true self with others; may feel false or 
fraudulent. 
39   
39. Appears to gain pleasure or satisfaction by being sadistic or aggressive 
toward others (whether consciously or unconsciously). 
40   40. Tends to engage in unlawful or criminal behavior. 
41   
41. Appears unable to describe important others in a way that conveys a 
sense of who they are as people; descriptions of others come across as two-
dimensional and lacking in richness. 
42   42. Tends to feel envious. 
43   
43. Tends to seek power or influence over others (whether in beneficial or 
destructive ways). 
44   
44. When distressed, perception of reality can become grossly impaired 
(e.g., thinking may seem delusional). 
45   
45. Is prone to idealizing people; may see admired others as perfect, larger 
than life, all wise, etc. 
46   46. Tends to be suggestible or easily influenced. 
47   
47. Attempts to avoid or flee depressive feelings through excessive 
optimism, activity, energy, etc. 
48   48. Seeks to be the center of attention. 
49   49. Has fantasies of unlimited success, power, beauty, talent, brilliance, etc. 
50   50. Tends to feel life has no meaning. 
51   51. Tends to be liked by other people. 
52   
52. Has little empathy; seems unable or unwilling to understand or respond 
to others’ needs or feelings. 
53   
53. Seems to treat others primarily as an audience to witness own 
importance, brilliance, beauty, etc. 
54   54. Tends to feel s/he is inadequate, inferior, or a failure. 
55   
55. Finds meaning and fulfillment in guiding, mentoring, or nurturing 
others. 
56   
56. Appears to find little or no pleasure, satisfaction, or enjoyment in life’s 
activities. 
57   
57. Religious or spiritual beliefs are central to his/her identity and 
experience. 
58   58. Has little or no interest in sex. 
59   
59. Is empathic; is sensitive and responsive to other peoples’ needs and 
feelings. 
60   60. Tends to be shy or self-conscious in social situations. 
61   
61. Tends to disparage qualities traditionally associated with own gender 
(e.g., a woman who disdains nurturance and overvalues power; a man who 
disdains power and overvalues emotional sensitivity). 
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62   62. Tends to be preoccupied with food, diet, or eating. 
63   
63. Is able to assert him/herself effectively and appropriately when 
necessary. 
64   
64. Mood tends to cycle over intervals of weeks or months between excited 
and depressed states (high placement implies bipolar mood disorder). 
65   
65. Attempts to dominate a significant other (e.g., spouse, lover, family 
member) through violence or intimidation. 
66   
66. Is excessively devoted to work and productivity to the detriment of 
leisure and relationships. 
67   
67. Tends to be stingy and withholding (e.g., of time, money, affection, 
ideas). 
68   68. Has a good sense of humor. 
69   
69. Decisions and actions are unduly influenced by efforts to avoid 
perceived dangers; is more concerned with avoiding harm than pursuing 
desires. 
70   
70. Has uncontrolled eating binges followed by “purges” (e.g., makes self 
vomit, abuses laxatives, fasts, etc.); has bulimic episodes. 
71   
71. Tends to seek thrills, novelty, excitement, etc.; appears to require a high 
level of stimulation. 
72   
72. Tends to perceive things in global and impressionistic ways (e.g., 
misses details, glosses over inconsistencies, mispronounces names). 
73   
73. Tends to “catastrophize”; is prone to see problems as disastrous, 
unsolvable, etc. 
74   74. Expresses emotion in exaggerated and theatrical ways. 
75   
75. Tends to think in concrete terms and interpret things in overly literal 
ways; has limited ability to appreciate metaphor, analogy, or nuance. 
76   
76. Manages to elicit in others feelings similar to those s/he is experiencing 
(e.g., when angry, acts in such a way as to provoke anger in others; when 
anxious, acts in such a way as to induce anxiety in others). 
77   77. Tends to be needy or dependent. 
78   
78. Tends to express anger in passive and indirect ways (e.g., may make 
mistakes, procrastinate, forget, become sulky, etc.). 
79   
79. Attempts to deny or “override” fear or anxiety by rushing headlong into 
feared situations, taking unnecessary risks, etc. 
80   
80. Tends to be sexually possessive or jealous; is preoccupied with 
concerns about real or imagined infidelity. 
81   
81. Repeatedly re-experiences or re-lives a past traumatic event (e.g., has 
intrusive memories or recurring dreams of the event; is startled or terrified 
by present events that resemble or symbolize the past event). 
82   
82. Is capable of hearing information that is emotionally threatening (i.e., 
that challenges cherished beliefs, perceptions, and self-perceptions) and can 
use and benefit from it. 
83   
83. Beliefs and expectations seem cliché or stereotypical, as if taken from 
storybooks or movies. 
84   
84. Tends to be competitive with others (whether consciously or 
unconsciously). 
85   85. Sexual orientation is central to his/her identity or sense of self. 
86   86. Tends to feel ashamed or embarrassed. 
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87   
87.Sense of identity revolves around a “cause,” movement, or label (e.g., 
adult child of alcoholic, adult survivor, environmentalist, born-again 
Christian, etc.); may be drawn to extreme or all-encompassing belief 
systems. 
88   
88. Tends to be insufficiently concerned with meeting own needs; appears 
not to feel entitled to get or ask for things s/he deserves. 
89   
89. Appears to have come to terms with painful experiences from the past; 
has found meaning in, and grown from such experiences. 
90   
90. Is prone to painful feelings of emptiness (e.g., may feel lost, bereft, 
abjectly alone even in the presence of others, etc.). 
91   
91. Is self-critical; sets unrealistically high standards for self and is 
intolerant of own human defects. 
92   92. Is articulate; can express self well in words.  
93   
93. Seems naïve or innocent; appears to know less about the ways of the 
world than might be expected given his/her intelligence or background. 
94   94. Has an active and satisfying sex life. 
95   95. Appears comfortable and at ease in social situations.  
96   96. Tends to elicit dislike or animosity in others. 
97   
97. Tends to use his/her physical attractiveness to an excessive degree to 
gain attention or notice. 
98   98. Tends to fear s/he will be rejected or abandoned. 
99   
99. Appears to associate sex with danger (e.g., injury, punishment, 
contamination), whether consciously or unconsciously. 
100   
100. Tends to think in abstract and intellectualized terms, even in matters of 
personal import. 
101   101. Generally finds contentment and happiness in life’s activities. 
102   
102. Has a deep sense of inner badness; sees self as damaged, evil, or rotten 
to the core (whether consciously or unconsciously).  
103   
103. Tends to have extreme reactions to perceived slights or criticism (e.g., 
may react with rage, humiliation, etc.). 
104   
104. Appears to have little need for human company or contact; is 
emotionally detached or indifferent. 
105   
105. Is suspicious; tends to assume others will harm, deceive, conspire 
against, or betray him/her. 
106   
106. Tends to express emotion appropriate in quality and intensity to the 
situation at hand. 
107   
107. Tends to express qualities or mannerisms traditionally associated with 
own gender to an exaggerated or stereotypical degree (i.e., a hyper-
feminine woman; a hyper-masculine, “macho” man). 
108   
108. Tends to restrict food intake to the point of being underweight and 
malnourished. 
109   
109. Tends to engage in self-mutilating behavior (e.g., self-cutting, self-
burning, etc.). 
110   
110. Tends to become attached to, or romantically interested in, people who 
are emotionally unavailable. 
111   
111. Has the capacity to recognize alternative viewpoints, even in matters 
that stir up strong feelings. 
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112   
112. Appears impervious to consequences; seems unable or unwilling to 
modify behavior in response to threats or negative consequences. 
113   113. Experiences little or no remorse for harm or injury caused to others. 
114   114. Tends to be critical of others. 
115   
115. Is prone to violence (e.g., may break things or become physically 
assaultive). 
116   
116. Tends to see own unacceptable feelings or impulses in other people 
instead of in him/herself. 
117   
117. Is unable to soothe or comfort him/herself without the help of another 
person (i.e., has difficulty regulating own emotions). 
118   
118. Has difficulty maintaining attention and focus on tasks; is easily 
distracted by sights, sounds, unrelated thoughts, or other competing stimuli.   
119   
119. Tends to be inhibited or constricted; has difficulty allowing self to 
acknowledge or express wishes and impulses. 
120   120. Has moral and ethical standards and strives to live up to them. 
121   121. Is creative; is able to see things or approach problems in novel ways. 
122   
122. Attempts to avoid feeling helpless or depressed by becoming angry 
instead. 
123   
123. Tends to adhere rigidly to daily routines and become anxious or 
uncomfortable when they are altered. 
124   
124. Tends to avoid social situations because of fear of embarrassment or 
humiliation. 
125   
125. Appearance or manner seems odd or peculiar (e.g., grooming, hygiene, 
posture, eye contact, speech rhythms, etc. seem somehow strange or “off”). 
126   126. Appears to have a limited or constricted range of emotions. 
127   127. Tends to feel misunderstood, mistreated, or victimized. 
128   128. Fantasizes about ideal, perfect love. 
129   
129. Tends to be conflicted about authority (e.g., may feel s/he must 
submit, rebel against, win over, defeat, etc.). 
130   
130. Reasoning processes or perceptual experiences seem odd and 
idiosyncratic (e.g., may make seemingly arbitrary inferences; may see 
hidden messages or special meanings in ordinary events). 
131   
131. Appears conflicted about experiencing pleasurable emotions; tends to 
inhibit excitement, joy, pride, etc. 
132   132. Tends to have numerous sexual involvements; is promiscuous. 
133   133. Tends to be dismissive, haughty, or arrogant. 
134   
134. Tends to act impulsively (e.g., acts without forethought or concern for 
consequences). 
135   
135. Is hypochondriacal; has exaggerated fears of contracting medical 
illness (e.g., worries excessively about normal aches and pains). 
136   
136. Tends to believe in supernatural, paranormal, or superstitious 
phenomena or to be drawn to “alternative” belief systems (e.g., astrology, 
tarot, crystals, psychics, auras). 
137   
137. Is confused, conflicted, or uncertain about his/her sexual orientation 
(e.g., may struggle to keep homosexual feelings out of awareness, have an 
exaggerated fear of homosexuality, etc.). 
138   
138. Tends to enter altered, dissociated states when distressed (e.g., the self 
or world feels strange, unreal, or unfamiliar). 
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139   
139. Tends to hold grudges; may dwell on insults or slights for long 
periods. 
140   
140. Sexual fantasies or activities are unusual, idiosyncratic, or rigidly 
scripted (e.g., dominance, submission, voyeurism, fetishes, etc.). 
141   
141. Is invested in seeing and portraying self as emotionally strong, 
untroubled, and emotionally in control, despite clear evidence of underlying 
insecurity, anxiety, or distress. 
142   
142. Tends to make repeated suicidal threats or gestures, either as a “cry for 
help” or as an effort to manipulate others. 
143   
143. Tends to believe s/he can only be appreciated by, or should only 
associate with, people who are high-status, superior, or otherwise “special.” 
144   
144. Tends to see self as logical and rational, uninfluenced by emotion; 
prefers to operate as if emotions were irrelevant or inconsequential. 
145   
145. Thought processes or speech tend to be circumstantial, vague, 
rambling, digressive, etc. (e.g., may be unclear whether s/he is being 
metaphorical or whether thinking is confused or peculiar). 
146   
146. Tends to elicit boredom in others (e.g., may talk incessantly, without 
feeling, or about inconsequential matters). 
147   147. Tends to abuse drugs or alcohol. 
148   148. Has little psychological insight into own motives, behavior, etc. 
149   149. Tends to feel like an outcast or outsider. 
150   
150. Tends to identify with admired others to an exaggerated degree, taking 
on their attitudes, mannerisms, etc. (e.g., may be drawn into the “orbit” of a 
strong or charismatic personality). 
151   
151. Appears to experience the past as a series of disjointed or disconnected 
events; has difficulty giving a coherent account of his/her life story. 
152   
152. Tends to repress or “forget” distressing events, or distort memories of 
distressing events beyond recognition. 
153   153. Relationships tend to be unstable, chaotic, and rapidly changing. 
154   
154. Tends to draw others into scenarios, or “pull” them into roles, that feel 
alien or unfamiliar (e.g., being uncharacteristically insensitive or cruel, 
feeling like the only person in the world who can help, etc.). 
155   
155. Tends to describe experiences in generalities; is reluctant to provide 
details, examples, or supporting narrative. 
156   
156. Has a disturbed or distorted body-image (e.g., may see self as 
unattractive, grotesque, disgusting, etc.). 
157   
157. Tends to become irrational when strong emotions are stirred up; may 
show a significant decline from customary level of functioning. 
158   158. Appears afraid of commitment to a long-term love relationship. 
159   
159. Tends to deny or disavow own need for nurturance, caring, comfort, 
etc. (e.g., may regard such needs as weakness, avoid depending on others or 
asking for help, etc.) 
160   160. Lacks close friendships and relationships. 
161   
161. Tends to deny, disavow, or squelch his/her own realistic hopes, 
dreams, or desires to protect against anticipated disappointment (whether 
consciously or unconsciously). 
162   
162. Expresses contradictory feelings or beliefs without being disturbed by 
the inconsistency; has little need to reconcile or resolve contradictory ideas. 
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163   
163. Appears to want to “punish” self; creates situations that lead to 
unhappiness, or actively avoids opportunities for pleasure and gratification. 
164   164. Tends to be self-righteous or moralistic. 
165   
165. Tends to distort unacceptable wishes or feelings by transforming them 
into their opposite (e.g., may express excessive concern while showing 
signs of unacknowledged hostility, disgust about sexual matters while 
showing signs of unacknowledged excitement, etc.). 
166   
166. Tends to alternate between undercontrol and overcontrol of needs and 
impulses (e.g., sometimes acts on desires impulsively while at other times 
denying them entirely). 
167   
167. Is simultaneously needy of, and rejecting toward, others (e.g., craves 
intimacy and caring, but tends to reject it when offered). 
168   168. Struggles with genuine wishes to kill him/herself. 
169   
169. Is afraid or conflicted about becoming like a parent (or parent figure) 
about whom s/he has strong negative feelings (e.g., may go to lengths to 
avoid or reject attitudes or behaviors associated with that person). 
170   170. Tends to be oppositional, contrary, or quick to disagree. 
171   
171. Appears to fear being alone; may go to great lengths to avoid being 
alone. 
172   
172. Seems unable to settle into, or sustain commitment to, identity-
defining life roles (e.g., career, occupation, lifestyle, etc.). 
173   
173. Tends to become absorbed in details, often to the point that s/he 
misses what is significant. 
174   
174. Expects self to be “perfect” (e.g., in appearance, achievements, 
performance, etc.). 
175   175. Tends to be conscientious and responsible. 
176   
176. Tends to confuse own thoughts, feelings, or personality traits with 
those of others (e.g., may use the same words to describe him/herself and 
another person, believe the two share identical thoughts and feelings, etc.). 
177   
177. Repeatedly convinces others of his/her commitment to change but then 
reverts to previous maladaptive behavior; tends to convince others that “this 
time is really different.” 
178   
178. Has a pervasive sense that someone or something necessary for 
happiness has been lost forever, whether consciously or unconsciously 
(e.g., a relationship, youth, beauty, success). 
179   179. Tends to be energetic and outgoing. 
180   
180. Has trouble making decisions; tends to be indecisive or to vacillate 
when faced with choices. 
181   
181. Tends to choose sexual or romantic partners who seem inappropriate 
in terms of age, status (e.g., social, economic, intellectual), etc. 
182   182. Tends to be controlling. 
183   
183. Is psychologically insightful; is able to understand self and others in 
subtle and sophisticated ways. 
184   
184. Verbal statements seem incongruous with accompanying affect, or 
incongruous with accompanying non-verbal messages. 
185   
185. Is prone to intense anger, out of proportion to the situation at hand 
(e.g., has rage episodes). 
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186   
186. Has difficulty directing both tender feelings and sexual feelings 
toward the same person (e.g., sees others as nurturing and virtuous or sexy 
and exciting, but not both). 
187   
187. Tends to feel guilty or ashamed about his/her sexual interests or 
activities (whether consciously or unconsciously). 
188   
188. Work-life and/or living arrangements tend to be chaotic or unstable 
(e.g., job or housing situation seems always temporary, transitional, or ill-
defined). 
189   189. Tends to feel unhappy, depressed, or despondent. 
190   190. Appears to feel privileged and entitled; expects preferential treatment. 
191   191. Emotions tend to change rapidly and unpredictably. 
192   
192. Tends to be overly concerned with rules, procedures, order, 
organization, schedules, etc. 
193   193. Lacks social skills; tends to be socially awkward or inappropriate. 
194   194. Tends to be manipulative. 
195   195. Tends to be preoccupied with death and dying. 
196   
196. Finds meaning and satisfaction in the pursuit of long-term goals and 
ambitions. 
197   
197. Tends to seek out or create interpersonal relationships in which s/he is 
in the role of caring for, rescuing, or protecting the other. 
198   
198. Has trouble acknowledging or expressing anger toward others, and 
instead becomes depressed, self-critical, self-punitive, etc. (i.e., turns anger 
against self). 
199   199. Tends to be passive and unassertive. 
200   
200. Tends to ruminate; may dwell on problems, replay conversations in 
his/her mind, become preoccupied with thoughts about what could have 
been, etc. 
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Appendix H – The  SWAP –II Personality Health Syndrome (adapted from Westen et al., 
2012) 
 
Personality Health 
This prototype represents optimal personality health. Degree of match with this prototype 
provides a measure of adaptive psychological strengths. The more individuals match this 
prototype, the more they are able to engage in meaningful and mature relationships, find 
meaning and satisfaction in life’s pursuits, and make effective use of their talents and 
abilities. 
Individuals who match this prototype are capable of sustaining meaningful relationships 
characterized by genuine intimacy and caring. They are empathic and responsive to others’ 
needs and feelings and have the capacity to recognize alternative viewpoints, even when 
emotions are strong. They have moral and ethical standards, strive to live up to them, and 
tend to be conscientious and responsible. They appear comfortable in social situations, are 
able to assert themselves effectively and appropriately when necessary, tend to be energetic 
and outgoing, and tend to be liked by others. They tend to have satisfying sex lives. They 
are psychologically insightful and able to understand themselves and others in nuanced 
ways. They are capable of hearing and making effective use of information that is 
emotionally threatening, and have generally come to terms with painful experiences from 
the past, finding meaning in the experiences and growing from them. Individuals who 
match this prototype tend to express emotion appropriate in quality and intensity to the 
situation at hand. They generally find contentment and happiness in life’s activities. They 
find meaning and fulfillment in guiding or nurturing others, in belonging and contributing 
to a larger community, and in the pursuit of long-term goals and ambitions. Individuals 
who match this prototype are able to use their talents, abilities, and energy effectively and 
productively. They enjoy challenges and take pleasure in accomplishing things. They are 
able to express themselves verbally, have a sense of humor, and tend to see things and 
approach problems in creative ways. 
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Appendix I - Hamilton Depression Rating Scale (HDRS)  
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Appendix J - Hamilton Depression Rating Scale (HDRS) – TADS Scoring Sheet 
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Appendix K – Clinical Outcome in Routine Evaluation (CORE-OM) 
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Appendix L – Global Assessment of Functioning (GAF) 
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Appendix Ma. SWAP-II Correlations at baseline 
Patient ID ICC ICC Correction Correlation Correlation correction Rates used 
 102 0.83 0.91 0.71 0.83   
106 0.83 0.91 0.71 0.83   
108 0.69 0.82 0.53 0.69   
109 0.97 0.98 0.94 0.97   
117 0.76 0.87 0.62 0.76   
119 0.76 0.86 0.61 0.76   
126 0.61 0.76 0.44 0.61   
128 0.73 0.84 0.58 0.73   
130 0.64 0.78 0.47 0.64   
133 0.93 0.96 0.87 0.93   
134 0.79 0.88 0.65 0.79   
140 0.59 0.74 0.42 0.59   
154 0.79 0.88 0.65 0.79   
155 0.85 0.92 0.74 0.85   
157 0.74 0.85 0.59 0.74   
159 0.80 0.89 0.67 0.80   
161 0.56 0.72 0.39 0.56   
164 0.74 0.85 0.58 0.73   
169 0.73 0.84 0.58 0.73   
171 0.74 0.85 0.59 0.74   
172 0.50 0.67 0.34 0.50 R3 & R1 
176 0.76 0.86 0.62 0.76   
180 0.75 0.86 0.60 0.75   
183 0.59 0.74 0.42 0.59   
184 0.59 0.74 0.42 0.59   
188 0.63 0.78 0.46 0.63   
194 0.64 0.78 0.47 0.64   
199 0.66 0.79 0.49 0.66   
201 0.61 0.76 0.44 0.61   
208 0.58 0.73 0.41 0.58 R3 & R1 
209 0.70 0.82 0.53 0.69   
217 0.61 0.76 0.44 0.61 R3 & R1 
223 0.54 0.70 0.37 0.54   
237 0.78 0.88 0.65 0.78   
251 0.72 0.84 0.57 0.72   
255 0.84 0.92 0.73 0.84   
261 0.56 0.71 0.39 0.56   
265 0.96 0.98 0.93 0.96   
266 0.68 0.81 0.51 0.68   
272 0.73 0.84 0.57 0.73   
276 0.83 0.91 0.71 0.83   
289 0.72 0.84 0.56 0.72 R3 & R2 
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291 0.76 0.86 0.61 0.76   
296 0.60 0.75 0.43 0.60   
299 0.73 0.84 0.57 0.73   
301 0.78 0.88 0.64 0.78   
302 0.71 0.83 0.55 0.71   
308 0.77 0.87 0.63 0.77   
315 0.70 0.82 0.54 0.70   
321 0.62 0.76 0.45 0.62   
323 0.79 0.88 0.65 0.79   
324 0.75 0.86 0.60 0.75   
326 0.77 0.87 0.63 0.77 R3 & R2 
329 0.71 0.83 0.55 0.71 R3 & R1 
334 0.61 0.76 0.44 0.61   
345 0.70 0.82 0.53 0.69   
351 0.66 0.79 0.49 0.66   
354 0.74 0.85 0.59 0.74   
367 0.73 0.85 0.58 0.73   
374 0.56 0.72 0.39 0.56   
380 0.68 0.81 0.51 0.68   
402 0.70 0.82 0.53 0.70   
407 0.80 0.89 0.67 0.80   
Average 0.80 0.89 0.67 0.80   
 
  
Borderline-dysregulated personality and Treatment -resistant Depression  
 
207 
Appendix Mb. SWAP-II Correlations at the end of treatment 
Patient ID ICC ICC Correction Correlation Correlation correction Rates used 
119 0.884 0.792 0.938 0.884   
180 0.806 0.674 0.893 0.805   
343 0.803 0.671 0.891 0.803   
147 0.802 0.699 0.890 0.823   
218 0.792 0.655 0.884 0.792   
301 0.786 0.648 0.880 0.786   
308 0.786 0.648 0.880 0.786   
325 0.786 0.648 0.880 0.786   
350 0.784 0.645 0.879 0.784 R2 & R3 
159 0.778 0.636 0.875 0.778   
181 0.767 0.622 0.868 0.767   
265 0.766 0.621 0.867 0.766   
131 0.765 0.619 0.867 0.765   
161 0.763 0.687 0.866 0.814   
188 0.755 0.606 0.860 0.755   
209 0.755 0.606 0.860 0.755   
262 0.754 0.605 0.860 0.754   
402 0.754 0.605 0.860 0.754   
109 0.753 0.604 0.859 0.753   
143 0.753 0.603 0.859 0.752   
348 0.75 0.6 0.857 0.750   
389 0.749 0.599 0.856 0.749   
242 0.746 0.595 0.855 0.746   
282 0.742 0.59 0.852 0.742   
317 0.738 0.584 0.849 0.737   
133 0.737 0.583 0.849 0.737   
126 0.736 0.582 0.848 0.736   
314 0.735 0.581 0.847 0.735   
155 0.726 0.57 0.841 0.726   
128 0.725 0.568 0.841 0.724   
127 0.724 0.567 0.840 0.724   
199 0.724 0.567 0.840 0.724 R2 & R3 
208 0.713 0.553 0.832 0.712   
169 0.709 0.549 0.830 0.709   
326 0.701 0.54 0.824 0.701 R2 & R3 
102 0.698 0.536 0.822 0.698   
104 0.697 0.535 0.821 0.697   
223 0.697 0.534 0.821 0.696   
274 0.697 0.535 0.821 0.697   
340 0.682 0.517 0.811 0.682   
352 0.679 0.514 0.809 0.679   
175 0.669 0.503 0.802 0.669   
217 0.669 0.503 0.802 0.669   
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154 0.666 0.559 0.800 0.717   
195 0.664 0.497 0.798 0.664 R2 & R3 
331 0.662 0.495 0.797 0.662   
172 0.655 0.487 0.792 0.655   
407 0.653 0.485 0.790 0.653   
353 0.638 0.469 0.779 0.639   
114 0.632 0.462 0.775 0.632 R1 & R3 
184 0.628 0.458 0.771 0.628   
259 0.626 0.456 0.770 0.626   
140 0.624 0.454 0.768 0.624 R1 & R3 
289 0.618 0.447 0.764 0.618   
164 0.612 0.441 0.759 0.612 R2 & R3 
241 0.611 0.44 0.759 0.611   
384 0.61 0.439 0.758 0.610 R1 & R3 
108 0.609 0.438 0.757 0.609   
203 0.602 0.43 0.752 0.601   
600 0.59 0.42 0.742 0.592   
380 0.574 0.403 0.729 0.574 R1 & R2 
227 0.573 0.402 0.729 0.573 R2 & R3 
251 0.571 0.4 0.727 0.571 R1 & R2 
Average 0.706 0.552 0.825 0.708   
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Appendix N – ICC and inter-rater correlations for the borderline-dysregulated items 
SWAP-II item number Correlation coefficient Correlation correction ICC ICC  correction 
9 0.132 0.23 0.227 0.37 
11 0.518 0.68 0.588* 0.74 
12 0.537 0.70 0.698* 0.82 
15 -0.027 -0.06 -0.054 -0.11 
18 0.615 0.76 0.752** 0.86 
73 -0.197 -0.49 -0.445 -1.60 
76 -0.255 -0.68 -0.486 -1.89 
77 0.376 0.55 0.543* 0.70 
90 0.208 0.34 0.344 0.51 
98 0.312 0.48 0.468* 0.64 
109 1 1.00 0 0.00 
117 -0.002 0.00 -0.003 -0.01 
127 0.432 0.60 0.601* 0.75 
134 0.02 0.04 0.038 0.07 
142 CANNOT BE COMPUTED  0 variance 0 variance 
153 0.325 0.49 0.487* 0.66 
154 -0.149 -0.35 -0.291 -0.82 
157 0.282 0.44 0.427* 0.60 
168 0.38 0.55 0.548* 0.71 
171 0.008 0.02 0.016 0.03 
185 0.296 0.46 0.438* 0.61 
188 0.836 0.91 0.91** 0.95 
191 0.49 0.66 0.63 0.77 
* Coefficient indicating “fair” inter-rater agreement; ** Coefficient indicating “excellent” inter-rater agreement 
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Appendix P. SWAP-II baseline independent T-test results 
Group Statistics 
 
Allocation 
group 
N Mean Std. 
Deviation 
Std. Error 
Mean 
SWAP-II Depressive Qfactor prototype BL 
TAU 62 61.87 6.615 .840 
Treatment 66 62.47 6.090 .750 
SWAP-II Anxious-Avoidant Qfactor prototype BL 
TAU 62 57.53 6.498 .825 
Treatment 66 54.98 6.865 .845 
SWAP-II Dependent-Victimized Qfactor prototype 
BL 
TAU 62 51.13 6.669 .847 
Treatment 66 53.71 6.516 .802 
SWAP-II Schizoid-Schizotypal Qfactor prototype 
BL 
TAU 62 58.26 6.324 .803 
Treatment 66 57.76 6.448 .794 
SWAP-II Antisocial-Psychopathic Qfactor prototype 
BL 
TAU 62 47.27 5.701 .724 
Treatment 66 47.67 5.330 .656 
SWAP-II Paranoid Qfactor prototype BL 
TAU 62 51.32 6.233 .792 
Treatment 66 50.83 6.025 .742 
SWAP-II Narcissistic Qfactor prototype BL 
TAU 62 46.58 7.482 .950 
Treatment 66 49.71 6.809 .838 
SWAP-II Borderline-Dysregulated Qfactor prototype 
BL 
TAU 62 48.24 4.430 .563 
Treatment 66 48.56 5.959 .734 
SWAP-II Obsessional Qfactor prototype BL 
TAU 62 50.63 5.806 .737 
Treatment 66 51.20 7.019 .864 
SWAP-II Hysteric-Histrionic Qfactor prototype BL 
TAU 62 39.61 6.492 .824 
Treatment 66 41.97 7.160 .881 
SWAP-II Personality Health Qfactor prototypeBL 
TAU 62 46.52 7.511 .954 
Treatment 66 46.30 5.781 .712 
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Independent Samples Test 
 
Levene's Test 
for Equality 
of Variances 
t-test for Equality of Means 
F Sig. t df Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
SWAP-II 
Depressive 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
1.661 .200 -.533 126 .595 -.599 1.123 -2.821 1.624 
Equal 
variances 
not 
assumed 
  
-.532 123.395 .596 -.599 1.126 -2.827 1.630 
SWAP-II 
Anxious-
Avoidant 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
.385 .536 2.153 126 .033 2.547 1.183 .206 4.889 
Equal 
variances 
not 
assumed 
  
2.157 125.992 .033 2.547 1.181 .210 4.885 
SWAP-II 
Dependent-
Victimized 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
.344 .558 -
2.216 
126 .028 -2.583 1.166 -4.890 -.276 
Equal 
variances 
not 
assumed 
  
-
2.215 
125.070 .029 -2.583 1.166 -4.892 -.275 
SWAP-II 
Schizoid-
Schizotypal 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
.004 .947 .443 126 .659 .500 1.130 -1.735 2.736 
Equal 
variances 
not 
assumed 
  
.443 125.759 .658 .500 1.129 -1.734 2.735 
SWAP-II 
Antisocial-
Psychopathic 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
1.284 .259 -.403 126 .688 -.392 .975 -2.322 1.537 
Equal 
variances 
not 
assumed 
  
-.402 123.907 .689 -.392 .977 -2.326 1.541 
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SWAP-II 
Paranoid Qfactor 
prototype BL 
Equal 
variances 
assumed 
.394 .531 .452 126 .652 .489 1.083 -1.655 2.633 
Equal 
variances 
not 
assumed 
  
.451 124.828 .653 .489 1.085 -1.657 2.636 
SWAP-II 
Narcissistic 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
.099 .754 -
2.479 
126 .015 -3.131 1.263 -5.632 -.631 
Equal 
variances 
not 
assumed 
  
-
2.471 
122.979 .015 -3.131 1.267 -5.640 -.623 
SWAP-II 
Borderline-
Dysregulated 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
3.604 .060 -.342 126 .733 -.319 .933 -2.165 1.528 
Equal 
variances 
not 
assumed 
  
-.345 119.800 .731 -.319 .924 -2.149 1.512 
SWAP-II 
Obsessional 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
2.327 .130 -.497 126 .620 -.568 1.143 -2.829 1.693 
Equal 
variances 
not 
assumed 
  
-.500 124.048 .618 -.568 1.136 -2.816 1.680 
SWAP-II 
Hysteric-
Histrionic 
Qfactor 
prototype BL 
Equal 
variances 
assumed 
.001 .973 -
1.947 
126 .054 -2.357 1.211 -4.752 .039 
Equal 
variances 
not 
assumed 
  
-
1.953 
125.847 .053 -2.357 1.207 -4.745 .031 
SWAP-II 
Personality 
Health Qfactor 
prototypeBL 
Equal 
variances 
assumed 
4.564 .035 .181 126 .857 .213 1.180 -2.123 2.549 
Equal 
variances 
not 
assumed 
  
.179 114.498 .858 .213 1.190 -2.144 2.570 
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Appendix Q. SWAP-II end of treatment independent T-test results 
Group Statistics 
 
Allocation 
group 
N Mean Std. 
Deviation 
Std. Error 
Mean 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Depressive End 
TAU 55 63.73 7.194 .970 
Treatment 55 61.47 8.397 1.132 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Anxious-Avoidant End 
TAU 55 57.60 6.364 .858 
Treatment 55 56.80 7.090 .956 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Dependent-Victimized End 
TAU 55 52.00 7.850 1.059 
Treatment 55 51.29 6.391 .862 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Schizoid-Schizotypal End 
TAU 55 58.65 6.818 .919 
Treatment 55 56.87 6.950 .937 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Antisocial-Psychopathic End 
TAU 55 47.71 5.520 .744 
Treatment 55 47.44 6.253 .843 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Paranoid End 
TAU 55 53.38 6.026 .813 
Treatment 55 51.29 6.425 .866 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Narcissistic End 
TAU 55 49.53 6.170 .832 
Treatment 55 49.98 8.449 1.139 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Borderline-Dysregulated End 
TAU 55 49.67 4.647 .627 
Treatment 55 47.05 7.230 .975 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Obsessional End 
TAU 55 53.27 6.892 .929 
Treatment 55 55.40 6.525 .880 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Hysteric-Histrionic End 
TAU 55 37.13 6.110 .824 
Treatment 55 39.22 6.288 .848 
Normalized T-score - SWAP-II Qfactor prototype scale - 
Personality Health End 
TAU 55 43.00 6.681 .901 
Treatment 
55 46.00 7.510 1.013 
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Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Depressive End 
Equal 
variances 
assumed 
1.693 .196 1.512 108 .133 2.255 1.491 -.701 5.210 
Equal 
variances not 
assumed 
  
1.512 105.517 .133 2.255 1.491 -.702 5.211 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Anxious-Avoidant 
End 
Equal 
variances 
assumed 
1.235 .269 .623 108 .535 .800 1.285 -1.747 3.347 
Equal 
variances not 
assumed 
  
.623 106.763 .535 .800 1.285 -1.747 3.347 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Dependent-
Victimized End 
Equal 
variances 
assumed 
1.449 .231 .520 108 .604 .709 1.365 -1.996 3.415 
Equal 
variances not 
assumed 
  
.520 103.730 .605 .709 1.365 -1.998 3.416 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Schizoid-
Schizotypal End 
Equal 
variances 
assumed 
.006 .938 1.357 108 .178 1.782 1.313 -.820 4.384 
Equal 
variances not 
assumed 
  
1.357 107.961 .178 1.782 1.313 -.820 4.384 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Antisocial-
Psychopathic End 
Equal 
variances 
assumed 
.527 .469 .242 108 .809 .273 1.125 -1.957 2.502 
Equal 
variances not 
assumed 
  
.242 106.362 .809 .273 1.125 -1.957 2.502 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Equal 
variances 
assumed 
.005 .946 1.760 108 .081 2.091 1.188 -.264 4.445 
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Paranoid End Equal 
variances not 
assumed 
  
1.760 107.559 .081 2.091 1.188 -.264 4.445 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Narcissistic End 
Equal 
variances 
assumed 
3.931 .050 -.322 108 .748 -.455 1.411 -3.251 2.342 
Equal 
variances not 
assumed 
  
-.322 98.841 .748 -.455 1.411 -3.254 2.345 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Borderline-
Dysregulated End 
Equal 
variances 
assumed 
9.472 .003 2.259 108 .026 2.618 1.159 .321 4.915 
Equal 
variances not 
assumed 
  
2.259 92.111 .026 2.618 1.159 .317 4.920 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Obsessional End 
Equal 
variances 
assumed 
.143 .706 -
1.662 
108 .099 -2.127 1.280 -4.664 .409 
Equal 
variances not 
assumed 
  
-
1.662 
107.679 .099 -2.127 1.280 -4.664 .409 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Hysteric-Histrionic 
End 
Equal 
variances 
assumed 
.000 .984 -
1.769 
108 .080 -2.091 1.182 -4.434 .253 
Equal 
variances not 
assumed 
  
-
1.769 
107.911 .080 -2.091 1.182 -4.434 .253 
Normalized T-score 
- SWAP-II Qfactor 
prototype scale - 
Personality Health 
End 
Equal 
variances 
assumed 
.720 .398 -
2.213 
108 .029 -3.000 1.355 -5.687 -.313 
Equal 
variances not 
assumed 
  
-
2.213 
106.552 .029 -3.000 1.355 -5.687 -.313 
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Appendix Qa. Patient borderline-dysregulated scores at baseline and end-of-treatment – TAU group 
 TAU 
Patient ID 101 102 184 195 208 227 259 261 291 297 323 397 
Borderline-dysregulated baseline 
score 
53 55* 49 59* 46 51 50 43 55* 59* 49 55* 
Borderline-dysregulated end-of-
treatment score 
56*† 48† 56*† 57* 56*† 57*† 56*† 57*† 45† 60**† 55*† 53† 
Borderline-dysregulated Change 
score 
-3 7 -7 2 -10 -6 -6 -14 10 -1 -6 3 
HDRS baseline score 28 17 21 26 23 15 18 12 23 22 18 23 
HDRS end-of-treatment score 30 13 20 n/a n/a 16 17 21 16 n/a 25 24 
HDSR 18m change score -2 4 1 n/a n/a -1 1 -9 7 n/a -7 -1 
HDRS end-of-follow-up score 26 20 24 30 30 24 18 20 18 n/a n/a 20 
HDSR 42m change score 2 -3 -3 -4 -7 -9 0 -8 5 n/a n/a 3 
*Score indicates “features” ** Score indicates “disorder” † Categorical change, compared to the baseline profile 
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Appendix Qb. Patient borderline-dysregulated scores at baseline and end-of-treatment – LTPP group 
*Score indicates “features” ** Score indicates “disorder” † Categorical change, compared to the baseline profile 
  
 LTPP 
Patient ID 114 131 154 171 178 183 198 199 255 301 305 314 319 324 351 370 
Borderline-dysregulated baseline score 
64** 40 52 47 51 55* 55* 56* 64** 55* 57* 54 40 58* 55* 56* 
Borderline-dysregulated end-of-treatment score 58*† 57*† 57*† 56*† 56*† n/a 46† 63**† 60** 49† 55* 58*† 57*† n/a 52† 44† 
Borderline-dysregulated end-of-treatment change 
score 
12 -17 -5 -9 -5 n/a 9 -7 4 6 2 -4 -14 n/a 3 12 
HDRS baseline score 29 19 24 21 21 17 16 17 21 18 12 17 22 21 24 14 
HDRS end-of-treatment score 20 18 22 26 20 n/a 12 21 12 16 n/a 21 14 n/a 29 12 
HDSR 18m change score 9 1 2 -5 1 n/a 4 -4 9 2 n/a -4 7 n/a -5 2 
HDRS end-of-follow-up score 25 16 30 28 27 n/a 4 23 14 n/a n/a 12 17 n/a 22 16 
HDSR 42m change score 4 3 -6 -7 -6 n/a 12 -6 7 n/a n/a 5 5 n/a 2 -2 
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Appendix R. Borderline-dysregulated personality disorder patients’ full SWAP-II 
personality profiles 
Patient 297 (TAU) 
 
Patient 199 (LTPP) 
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Appendix S – Correlation coefficients between the SWAP-II Q-factor personality change scores and the HDRS-17, GAF and CORE-OM 
change scores 
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Appendix Ta.  Borderline-dysregulated baseline item correlation with the HDRS-17, 
CORE-OM and GAF change scores at 18- and 42-months 
Allocatio
n group 
  
HDRS-
17 
Change 
Score at 
18 
months 
HDRS-
17 
Change 
Score at 
42 
months 
GAF 
Change 
Score at 
18 
months 
GAF 
Change 
Score at 
42 
months 
CORE 
Change 
Score at 
18 
months 
CORE 
Change 
Score at 
42 
months 
TAU 
Tends to become 
attached quickly or 
intensely 
Pearson 
Correlatio
n -0.013 -0.047 0.065 0.005 0.157 0.087 
  
N 46 45 44 44 35 36 
 
Emotions tend to 
spiral out of control, 
leading to extremes 
of anxiety, sadness, 
rage, etc. 
Pearson 
Correlatio
n 0.161 0.192 0.196 0.087 0.067 -0.082 
  
N 46 45 44 44 35 36 
 
Tends to stir up 
conflict or animosity 
between other people 
Pearson 
Correlatio
n 0.177 0.175 0.048 0.055 0.099 0.003 
  
N 46 45 44 44 35 36 
 
Tends to be needy or 
dependent 
Pearson 
Correlatio
n 0.008 -0.029 -0.014 0.099 0.088 -0.101 
  
N 46 45 44 44 35 36 
 
Tends to fear she/he 
will be rejected or 
abandoned 
Pearson 
Correlatio
n 0.219 0.005 0.098 -0.09 .385* .382* 
  
N 46 45 44 44 35 36 
 
Tends to feel 
misunderstood, 
mistreated or 
victimized 
Pearson 
Correlatio
n 0.025 0.071 -0.092 -0.007 0.045 0.062 
  
N 46 45 44 44 35 36 
 
Relationships tend to 
be unstable, chaotic, 
and rapidly changing 
Pearson 
Correlatio
n -.313* -0.202 -.344* -0.02 0.068 0.065 
  
N 46 45 44 44 35 36 
 
Tend to become 
irrational when 
strong emotions are 
stirred up 
Pearson 
Correlatio
n 0.153 0.003 0.171 -0.157 0.05 -0.171 
  
N 46 45 44 44 35 36 
 
Struggles with 
genuine wishes to 
kill him/herself 
Pearson 
Correlatio
n -0.075 -0.099 -0.158 -0.091 -0.219 -.345* 
  
N 46 45 44 44 35 36 
 
Is prone to intense 
anger, out of 
proportion with the 
situation at hand 
Pearson 
Correlatio
n 0.025 -0.045 0.138 0.108 0.103 -0.049 
  
N 46 45 44 44 35 36 
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Work life and/or 
living arrangements 
tend to be chaotic or 
unstable 
Pearson 
Correlatio
n 0.12 -0.044 0 -0.065 0.136 -0.234 
  
N 46 45 44 44 35 36 
 
Tends to feel 
unhappy, depressed 
or despondent 
Pearson 
Correlatio
n 0.027 0.151 -0.114 0.124 0.1 0.006 
  
N 46 45 44 44 35 36 
 
Emotions tend to 
change rapidly and 
unpredictably 
Pearson 
Correlatio
n 0.146 0.164 0.129 0.235 0.169 -0.035 
  
N 46 45 44 44 35 36 
LTPP 
Tends to become 
attached quickly or 
intensely 
Pearson 
Correlatio
n -0.045 -0.058 0.24 -0.116 -0.077 -0.304 
  
N 51 46 51 46 42 42 
 
Emotions tend to 
spiral out of control, 
leading to extremes 
of anxiety, sadness, 
rage, etc. 
Pearson 
Correlatio
n -0.172 0.018 0.056 0.202 -0.12 -0.112 
  
N 51 46 51 46 42 42 
 
Tends to stir up 
conflict or animosity 
between other people 
Pearson 
Correlatio
n 0.153 0.222 0.042 0.214 .363* .418** 
  
N 51 46 51 46 42 42 
 
Tends to be needy or 
dependent 
Pearson 
Correlatio
n 0.046 0.134 -0.113 0.122 -0.17 -0.211 
  
N 51 46 51 46 42 42 
 
Tends to fear she/he 
will be rejected or 
abandoned 
Pearson 
Correlatio
n 0.089 0.122 0.037 0.156 0.069 0.075 
  
N 51 46 51 46 42 42 
 
Tends to feel 
misunderstood, 
mistreated or 
victimized 
Pearson 
Correlatio
n 0.078 0.003 0.2 -0.003 0.087 0.104 
  
N 51 46 51 46 42 42 
 
Relationships tend to 
be unstable, chaotic, 
and rapidly changing 
Pearson 
Correlatio
n 0.117 0.016 -0.025 -0.053 -0.202 -0.173 
  
N 51 46 51 46 42 42 
 
Tend to become 
irrational when 
strong emotions are 
stirred up 
Pearson 
Correlatio
n -0.14 0.181 -0.029 0.29 -0.089 0.138 
  
N 51 46 51 46 42 42 
 
Struggles with 
genuine wishes to 
kill him/herself 
Pearson 
Correlatio
n 0.06 0.205 0.014 0.026 -0.104 0.108 
  
N 51 46 51 46 42 42 
 
Is prone to intense 
anger, out of 
proportion with the 
Pearson 
Correlatio
n -0.033 -0.133 -0.019 -0.088 -0.176 -0.254 
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situation at hand 
  
N 51 46 51 46 42 42 
 
Work life and/or 
living arrangements 
tend to be chaotic or 
unstable 
Pearson 
Correlatio
n 0.112 -0.007 0.186 -0.067 0.068 -0.076 
  
N 51 46 51 46 42 42 
 
Tends to feel 
unhappy, depressed 
or despondent 
Pearson 
Correlatio
n -0.097 -0.235 0.035 -0.023 -0.034 -0.157 
  
N 51 46 51 46 42 42 
 
Emotions tend to 
change rapidly and 
unpredictably 
Pearson 
Correlatio
n -0.063 -0.017 0.132 0.036 -0.109 -0.185 
  
N 51 46 51 46 42 42 
** Correlation is significant at the 0.01 level (2-tailed); * Correlation is significant at the 0.05 level (2-tailed). 
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Appendix Tb Borderline-dysregulated items change score correlation with the HDRS-17, 
CORE-OM and GAF change scores at 18- and 42-months 
Allocation 
group 
  
HDRS 
Change 
Score 
18m 
HDRS 
Change 
Score 
42m 
GAF 
Change 
Score 
18m 
GAF 
Change 
Score 
42m 
CORE 
Change 
Score 
18m 
CORE 
Change 
Score 
42m 
TAU 
Tends to become 
attached quickly or 
intensely 
Pearson 
Correlation -0.024 -0.141 -0.034 -0.192 0.065 -0.009 
  
N 39 39 38 39 31 35 
 
Emotions tend to spiral 
out of control, leading to 
extremes of anxiety, 
sadness, rage, etc. 
Pearson 
Correlation 0.091 .386* 0.186 0.302 0.182 0.157 
  
N 39 39 38 39 31 35 
 
Tends to stir up conflict 
or animosity between 
other people 
Pearson 
Correlation -0.012 0.055 0.091 0.162 0.06 0.312 
  
N 39 39 38 39 31 35 
 
Tends to be needy or 
dependent 
Pearson 
Correlation -0.14 -0.121 0.022 0.155 -0.085 -0.111 
  
N 39 39 38 39 31 35 
 
Tends to fear she/he will 
be rejected or abandoned 
Pearson 
Correlation 0.246 0.034 0.013 -0.029 0.239 0.197 
  
N 39 39 38 39 31 35 
 
Tends to feel 
misunderstood, 
mistreated or victimized 
Pearson 
Correlation 0.253 .385* 0.142 0.26 0.208 0.202 
  
N 39 39 38 39 31 35 
 
Relationships tend to be 
unstable, chaotic, and 
rapidly changing 
Pearson 
Correlation -0.307 
-
.480** -0.176 -0.232 -0.091 -0.19 
  
N 39 39 38 39 31 35 
 
Tend to become 
irrational when strong 
emotions are stirred up 
Pearson 
Correlation -0.022 0.069 -0.056 -0.001 0.338 0.161 
  
N 39 39 38 39 31 35 
 
Struggles with genuine 
wishes to kill him/herself 
Pearson 
Correlation -0.08 -0.051 -0.016 0.133 -0.078 -0.196 
  
N 39 39 38 39 31 35 
 
Is prone to intense anger, 
out of proportion with 
the situation at hand 
Pearson 
Correlation -0.02 0.147 0.093 .317* 0.063 0.181 
  
N 39 39 38 39 31 35 
 
Work life and/or living 
arrangements tend to be 
chaotic or unstable 
Pearson 
Correlation 0.177 -0.169 0.129 -0.237 0.139 -0.301 
  
N 39 39 38 39 31 35 
 
Tends to feel unhappy, 
depressed or despondent 
Pearson 
Correlation 0.262 0.093 0.21 0.115 0.04 -0.228 
  
N 39 39 38 39 31 35 
 
Emotions tend to change 
rapidly and 
unpredictably 
Pearson 
Correlation -0.088 0.137 0.102 .445** 0.142 0.059 
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N 36 36 35 36 29 32 
LTPP 
Tends to become 
attached quickly or 
intensely 
Pearson 
Correlation -0.051 -0.039 0.191 -0.077 -0.122 -0.261 
  
N 44 41 44 41 37 38 
 
Emotions tend to spiral 
out of control, leading to 
extremes of anxiety, 
sadness, rage, etc. 
Pearson 
Correlation -0.087 0.183 -0.06 0.203 -0.104 -0.016 
  
N 44 41 44 41 37 38 
 
Tends to stir up conflict 
or animosity between 
other people 
Pearson 
Correlation 0.096 0.276 0.018 0.158 0.163 .350* 
  
N 44 41 44 41 37 38 
 
Tends to be needy or 
dependent 
Pearson 
Correlation -0.083 0.009 -0.085 0.148 -0.213 -0.062 
  
N 44 41 44 41 37 38 
 
Tends to fear she/he will 
be rejected or abandoned 
Pearson 
Correlation 0.033 -0.027 0.133 0.016 0.05 0.03 
  
N 44 41 44 41 37 38 
 
Tends to feel 
misunderstood, 
mistreated or victimized 
Pearson 
Correlation 0.241 0.077 .358* 0.068 0.114 0.163 
  
N 44 41 44 41 37 38 
 
Relationships tend to be 
unstable, chaotic, and 
rapidly changing 
Pearson 
Correlation 0.114 0.142 -0.04 0.076 -0.019 0.049 
  
N 44 41 44 41 37 38 
 
Tend to become 
irrational when strong 
emotions are stirred up 
Pearson 
Correlation 0.11 .327* -0.013 0.253 -0.028 0.144 
  
N 44 41 44 41 37 38 
 
Struggles with genuine 
wishes to kill him/herself 
Pearson 
Correlation 0.094 0.213 -0.034 0.168 -0.031 0.095 
  
N 44 41 44 41 37 38 
 
Is prone to intense anger, 
out of proportion with 
the situation at hand 
Pearson 
Correlation 0.103 -0.049 -0.121 -0.141 -0.05 -0.22 
  
N 44 41 44 41 37 38 
 
Work life and/or living 
arrangements tend to be 
chaotic or unstable 
Pearson 
Correlation -0.048 -0.065 0.02 -0.046 0.05 -0.091 
  
N 44 41 44 41 37 38 
 
Tends to feel unhappy, 
depressed or despondent 
Pearson 
Correlation 0.052 0.058 0.252 .318* 0.006 -0.025 
  
N 44 41 44 41 37 38 
 
Emotions tend to change 
rapidly and 
unpredictably 
Pearson 
Correlation 0.09 0.216 -0.06 0.043 -0.14 -0.047 
  
N 44 41 44 41 37 38 
** Correlation is significant at the 0.01 level (2-tailed); * Correlation is significant at the 0.05 level (2-tailed). 
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Appendix U. Regression Analysis 
Regression statistics on the SWAP-II borderline-dysregulated score at baseline as a 
predictor of the HDRS-17 change scores at 18- and 42 months  
Model Summary 
Allocation group Model R R Square Adjusted R Square Std. Error of the 
Estimate 
TAU 1 .324
a
 .105 .084 5.666 
LTPP 1 .224
a
 .050 .030 7.028 
a. Predictors: (Constant), Hamilton Change Score at 18 months 
 
 
ANOVA
a
 
Allocation group Model Sum of 
Squares 
df Mean Square F Sig. 
TAU 1 
Regression .297 1 .297 .006 .936
b
 
Residual 2013.442 44 45.760 
  
Total 2013.739 45 
   
LTPP 1 
Regression 4.387 1 4.387 .157 .694
b
 
Residual 1372.437 49 28.009 
  
Total 1376.824 50 
   
a. Dependent Variable: Hamilton Change Score at 18 months 
b. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
Coefficients
a
 
Allocation 
group 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
TAU 1 
(Constant) 3.736 12.963 
 
.288 .775 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
-.021 .266 -.012 -.081 .936 
LTPP 1 
(Constant) 6.560 6.658 
 
.985 .329 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
-.053 .135 -.056 -.396 .694 
a. Dependent Variable: Hamilton Change Score at 18 months 
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Model Summary 
Allocation group Model R R Square Adjusted R Square Std. Error of the 
Estimate 
TAU 1 .007
a
 .000 -.023 5.79943 
Treatment 1 .054
a
 .003 -.020 6.71059 
a. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
 
ANOVA
a
 
Allocation group Model Sum of Squares df Mean Square F Sig. 
TAU 1 
Regression .075 1 .075 .002 .962
b
 
Residual 1446.236 43 33.633 
  
Total 1446.311 44 
   
LTPP 1 
Regression 5.807 1 5.807 .129 .721
b
 
Residual 1981.410 44 45.032 
  
Total 1987.217 45 
   
a. Dependent Variable: Hamilton Change Score at 42 months 
b. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
 
 
Coefficients
a
 
Allocation 
group 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
TAU 1 
(Constant) .164 10.196 
 
.016 .987 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.010 .211 .007 .047 .962 
Treatment 1 
(Constant) .897 8.338 
 
.108 .915 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.061 .171 .054 .359 .721 
a. Dependent Variable: Hamilton Change Score at 42 months 
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Regression statistics on the SWAP-II borderline-dysregulated score at baseline as a 
predictor of the GAF change scores at 18- and 42 months 
Model Summary 
Allocation group Model R R Square Adjusted R Square Std. Error of the 
Estimate 
TAU 1 .189
a
 .036 .013 8.58311 
LTPP 1 .079
a
 .006 -.014 8.06620 
a. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
ANOVA
a
 
Allocation group Model Sum of Squares df Mean Square F Sig. 
TAU 1 
Regression 114.119 1 114.119 1.549 .220
b
 
Residual 3094.131 42 73.670 
  
Total 3208.250 43 
   
LTPP 1 
Regression 19.920 1 19.920 .306 .583
b
 
Residual 3188.119 49 65.064 
  
Total 3208.039 50 
   
a. Dependent Variable: GAF Change Score at 18 months 
b. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
Coefficients
a
 
Allocation 
group 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
TAU 1 
(Constant) -16.480 16.706 
 
-.986 .330 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.425 .341 .189 1.245 .220 
LTPP 1 
(Constant) 13.717 10.147 
 
1.352 .183 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
-.114 .206 -.079 -.553 .583 
a. Dependent Variable: GAF Change Score at 18 months 
 
 
Model Summary 
Allocation group Model R R Square Adjusted R Square Std. Error of the 
Estimate 
TAU 1 .210
a
 .044 .021 8.28995 
LTPP 1 .135
a
 .018 -.004 10.96153 
a. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
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ANOVA
a
 
Allocation group Model Sum of Squares df Mean Square F Sig. 
TAU 1 
Regression 133.508 1 133.508 1.943 .171
b
 
Residual 2886.379 42 68.723 
  
Total 3019.886 43 
   
LTPP 1 
Regression 97.780 1 97.780 .814 .372
b
 
Residual 5286.829 44 120.155 
  
Total 5384.609 45 
   
a. Dependent Variable: GAF Change Score at 42 months 
b. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
 
Coefficients
a
 
Allocation 
group 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
TAU 1 
(Constant) -16.614 14.599 
 
-1.138 .262 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.420 .301 .210 1.394 .171 
LTPP 1 
(Constant) -1.005 13.597 
 
-.074 .941 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.252 .279 .135 .902 .372 
a. Dependent Variable: GAF Change Score at 42 months 
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Regression statistics on the SWAP-II borderline-dysregulated score at baseline as a 
predictor of the CORE-OM change scores at 18- and 42 months 
Model Summary 
Allocation group Model R R Square Adjusted R Square Std. Error of the 
Estimate 
TAU 1 .005
a
 .000 -.030 .70649 
LTPP 1 .086
a
 .007 -.017 .72929 
a. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
ANOVA
a
 
Allocation group Model Sum of Squares df Mean Square F Sig. 
TAU 1 
Regression .000 1 .000 .001 .976
b
 
Residual 16.471 33 .499 
  
Total 16.472 34 
   
LTPP 1 
Regression .158 1 .158 .297 .589
b
 
Residual 21.275 40 .532 
  
Total 21.433 41 
   
a. Dependent Variable: CORE Change Score at 18 months 
b. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
Coefficients
a
 
Allocation 
group 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
TAU 1 
(Constant) -.006 1.385 
 
-.004 .996 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.001 .029 .005 .031 .976 
LTPP 1 
(Constant) -.161 1.024 
 
-.157 .876 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.011 .021 .086 .545 .589 
a. Dependent Variable: CORE Change Score at 18 months 
 
 
Model Summary 
Allocation group Model R R Square Adjusted R Square Std. Error of the 
Estimate 
TAU 1 .048
a
 .002 -.027 .85757 
LTPP 1 .084
a
 .007 -.018 .76618 
a. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
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ANOVA
a
 
Allocation group Model Sum of Squares df Mean Square F Sig. 
TAU 1 
Regression .059 1 .059 .080 .779
b
 
Residual 25.005 34 .735 
  
Total 25.064 35 
   
LTPP 1 
Regression .168 1 .168 .287 .595
b
 
Residual 23.481 40 .587 
  
Total 23.650 41 
   
a. Dependent Variable: CORE Change Score at 42 months 
b. Predictors: (Constant), SWAP-II Borderline-Dysregulated Q-factor prototype BL 
 
Coefficients
a
 
Allocation 
group 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
TAU 1 
(Constant) .435 1.720 
 
.253 .802 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
-.010 .036 -.048 -.283 .779 
Treatment 1 
(Constant) .044 .965 
 
.046 .964 
SWAP-II Borderline-
Dysregulated Q-factor 
prototype BL 
.011 .020 .084 .536 .595 
a. Dependent Variable: CORE Change Score at 42 months 
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Regression statistics for the HDRS-17, GAF and CORE-OM change scores regressed on 
the borderline-dysregulated baseline score 
Allocation Group Measure F Sig. 
TAU 
HDRS-17 Change Score 18m .006 .936 
HDRS-17 Change Score 42m .002 .962 
GAF Change Score 18m 1.549 .220 
GAF Change Score 42m 1.943 .171 
CORE-OM Change Score 18m .001 .976 
CORE-OM Change Score 42m .080 .779 
LTPP 
HDRS-17 Change Score 18m .157 .694 
HDRS-17 Change Score 42m .129 .721 
GAF Change Score 18m .306 .583 
GAF Change Score 42m .814 .372 
CORE-OM Change Score 18m .297 .589 
CORE-OM Change Score 42m .287 .595 
 
